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Abstract 
 
Human endometrial stromal cells (HESCs) undergo cyclic differentiation, termed decidualisation, 
into highly specialised cells, which prepares them to respond appropriately to embryonic signals 
and this is critical to facilitate successful implantation. Human chorionic gonadotrophin (hCG) is 
secreted by the embryo and is known classically to maintain progesterone production from the 
corpus luteum during early pregnancy yet emerging evidence reports that it signals in a paracrine 
manner at the embryo-endometrial interface. Its cognate receptor, the LH/CGR, is a G-protein 
coupled receptor (GPCR) that is expressed in the endometrium but the role of hCG and its 
underlying signalling mechanisms here are largely unknown. I show that in HESCs hCG acts via 
a non-classical Gαi pathway and that signalling via this pathway can negatively regulate 
important decidua-specific genes. Furthermore, the LH/CGR undergoes ‘reprogramming’ during 
decidualisation, which changes both its trafficking and MAPK signalling profiles, where only a 
subset of pathways are activated by hCG upon decidualisation. I further show that the majority of 
the LH/CGR localises to an endocytic compartment which is distinct from the early endosome, 
termed the very early endosome (VEE) and that this is dependent on the C-terminal tail of the 
receptor. Moreover, cellular depletion of an essential VEE component, GIPC, can cause hCG-
induced modulation of downstream decidual genes to be reversed. Importantly, in HESCs from 
recurrent miscarriage (RM) patients, hCG-induced signalling opposes that of signalling in control 
patients and in addition, LH/CGR trafficking and recycling may be disordered. Together, these 
findings provide novel insights of the mode of action of hCG and the LH/CGR in the 
endometrium and highlight how perturbation of their signalling and trafficking profiles may 
contribute to pregnancy loss.  
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PDZ Postsynaptic density 95/disc large/zonula occludens-1 
PFA Paraformaldehyde 
PGE2 Prostaglandin E2 
PI3K Phosphatidylinositol 3-kinase 
PKA Protein kinase A 
PKC Protein kinase C 
PLD Phospholipase D 
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PMSF Phenylmethylsulfonyl fluoride 
PR Progesterone receptor 
PRL Prolactin 
PROK1 Prokineticin-1 
Ptx Pertussis toxin 
RGS Regulator of G-protein signalling 
RLX Relaxin 
RM Recurrent Miscarriage 
RNA Ribonucleic acid 
ROS Reactive oxygen species 
RPM Revolution per minute 
RSK Ribosomal S6 Kinase 
RT Room temperature 
RT-PCR Reverse transcription PCR 
RTQ-PCR Real time quantitative-PCR 
SDS Sodium dodecylsulphate 
SDS-PAGE SDS-polyacrylamide gel electrophoresis 
SEM Standard error of the mean 
SEP Superecliptic pHluorin 
siRNA Small interfering RNA 
SOD2 Superoxide dismutase-2 
STAT5 Signal Transducer and Activator of Transcription 5 
SUMO Small ubiquitin-like modifier 
TBS Tris buffered saline 
TBS-T TBS-Tween 
TE Tris-borate-EDTA 
TEMED N, N, N, N’-Tetramethylethylenediamine 
TGFβ Transforming growth factor beta 
TIMPs Tissue inhibitors of metalloproteinases 
TIRF-M Total Internal Reflection Fluorescence Microscopy 
TM Transmembrane 
TOR Target of rapamycin 
TSH Thyroid Stimulating Hormone 
U Units 
uNK Uterine natural killer  
V Volts 
% v/v Volume/volume 
VEE Very Early Endosome 
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VEGF Vascular Endothelial Growth Factor 
% w/v Weight/volume 
WB Western blot 
wt Wild type 
YFP Yellow Fluorescent Protein 
β2AR β2-Adrenergic receptor 
βARR β-arrestin 
μg Microgram 
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 The Human Endometrium 1.1
The endometrium is the mucosal lining of the inner wall of the uterus and is adjacent to the 
myometrium. The endometrium comprises of two main layers: a basal layer (basalis) and a 
functional layer (functionalis). The functionalis is highly receptive and sensitive, and is under 
tight control by circulating steroid hormones [1]. This layer undergoes cyclical changes broadly 
divided into stages of proliferation, receptivity, differentiation and, in the absence of pregnancy, 
shedding during menstruation. This menstrual cycle lasts approximately 28 days and women have 
on average 400 menstrual cycles in their lifetime, with on average 2 of these resulting in 
pregnancy [2]. The basal layer, directly next to the myometrium, does not exhibit cyclical 
changes but forms the basis on which the functional layer regenerates. The main role of the 
endometrium is to facilitate a successful pregnancy by allowing appropriate and timely 
implantation of an embryo and providing an optimal environment which favours growth and 
development of that embryo [1].  
 
 Structure of the endometrium 1.2
The human uterus consists of an outer serosal surface, the fibromuscular myometrium and an 
inner multilayered tissue which lines the inside of the uterine cavity known as the endometrium 
[3] (Fig. 1.1). The lining of the endometrium is made up of a single layer of columnar epithelium 
which overlays a network of connective tissue and a multicellular stromal compartment [4]. 
Uterine glands form cavities from within the mucosal surface into the stromal layer. Endometrial 
blood supply enters through radial arteries arising from the myometrium, which then split to form 
the smaller basal arteries and the spiral arterioles to supply the basal layer and functional layer 
respectively [5]. The spiral arterioles have a distinct coiled morphology and capillaries branch 
from these in order to supply the stromal compartment and adjacent networks. The vasculature of 
the basal compartment does not undergo significant changes throughout the menstrual cycle, 
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whereas the blood supply for the functional layer is under the control of steroid hormones and is 
therefore constantly changing [5].  
The basal layer which persists from cycle to cycle, harbours glands, stroma, supportive 
vasculature, lymphoid aggregates and, more recently known, epithelial progenitor cells [6, 7]. 
Also identified in the endometrium are mesenchymal stem cells and endothelial progenitor cells, 
which, together with the epithelial progenitor cells, have highly proliferative and self-renewal 
capacities, as well as the ability to differentiate into mature progeny [7]. As described, the 
functional layer undergoes cyclical changes of regeneration and degeneration and this stem cell 
population is critical to maintain this part of the endometrium during these cycles. In the presence 
of an implanting embryo however, the functional layer does not degenerate and remains intact 
becoming the maternal component of the placenta together with the myometrial junctional zone.  
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Figure 1.1. The structure of the human endometrium. A schematic illustrating the multi-layered 
structure of the endometrium, which forms the inner lining of the uterus. The functional layer is 
composed of endometrial epithelial and stromal cells and undergoes cyclical changes under the 
control of steroid hormones. The basal layer serves as a source of stem and progenitor cells for 
regeneration following menstruation.  
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 Cyclical changes of the endometrium 1.3
During female reproduction the endometrium undergoes phases of cell proliferation, 
differentiation, inflammatory cell recruitment, apoptosis and tissue degeneration and 
regeneration, with a normal cycle lasting 28 days [8]. These modifications are implemented by 
changes in the ovarian cycle and influenced considerably by alterations in steroid hormone levels. 
The ovarian cycle consists of the follicular and luteal phases and coincides with the proliferative 
and secretory endometrial phases (Fig. 1.2). During days 1-5 the majority of the endometrial 
functional layer of the endometrium is lost, accompanied by bleeding, which occurs following the 
drop of estrogen, progesterone and inhibin A levels at the end of each cycle; this is known as 
menstruation. Inhibin A and progesterone act as negative regulators of the gonadotrophin 
hormones luteinising hormone (LH) and follicle stimulating hormone (FSH) as well as further 
reducing the positive feedback estrogen can have on these hormones [1]. When this negative 
feedback is abolished at the end of the cycle, the anterior pituitary can resume LH and FSH 
secretion. Consequently, the presence of these hormones allows follicular growth and granulosa 
cells within the follicles can then secrete estrogen as a result of their acquired aromatase activity. 
There is then a temporary plateauing of LH and FSH levels due to the negative feedback of 
estrogen, however, a dominant follicle then leads to an increase of estrogen [1]. The result of the 
increasing estrogen levels also causes growth of the endometrial functional layer and rapid 
epithelial and stromal cell proliferation which lasts from days 5-13 and is termed the proliferative 
phase [9]. This occurs in concert with vascular growth and lengthening of the spiral arteries 
which serves to nourish the expanding endometrial layer [10]. During this proliferative and pre-
ovulatory follicular phase, the endometrium will grow up to 5-7mm [5]. A surge in estrogen at 
about day 12 resulting from the dominant follicle then triggers a concomitant surge (day 14) in 
levels of LH and FSH and this time, due to the high levels, estrogen is acting as a positive 
feedback mechanism [1]. Ovulation then follows and the resultant corpus luteum begins to 
produce progesterone. Additionally, due to follicular collapse after ovulation, levels of estrogen 
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fall and thereafter, the high levels of both LH and FSH also fall. This marks the end of the 
follicular and proliferative phases. The secretory phase begins following the onset of 
progesterone production from the corpus luteum. Days 15-19 are considered the pre-receptive 
period of the endometrium and at the mid-secretory phase, spanning days 20-23, the endometrium 
becomes receptive [1]. With rising levels of progesterone, proliferation of the endometrium 
ceases and it causes endometrial stromal cell differentiation, commonly referred to as 
decidualisation, a period lasting approximately 4 days between days 24-28 [8, 10]. The secretory 
phase is accompanied by transformation of the glands as well as other extensive functional and 
morphological changes. The pre-decidual reaction begins at the lower part of spiral arteries and 
they expand and become increasingly coiled. There is also an influx of uterine natural killer cells 
(uNKs) after ovulation, and these can make up a considerable portion of the cells in the stromal 
compartment (30-40%) [11]. The stromal compartment also undergoes profound changes in the 
extracellular matrix (ECM) simultaneous to stromal decidualisation.  
In all, these pronounced changes in the endometrial functional layer are absolutely 
indispensable in order to provide a suitable and favourable environment for embryo implantation 
and future development. When conception has not occurred, the corpus luteum collapses resulting 
in a drop in levels of progesterone and estrogen that leads to apoptosis and break down of the 
functional layer then the cycle restarts again with menstruation. If a conceptus is present 
however, it secretes human chorionic gonadotrophin (hCG) which rescues the corpus luteum and 
allows it to sustain progesterone production, thus the functional layer of the endometrium is 
maintained and decidualisation can progress further. 
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Figure 1.2. The menstrual cycle and decidualisation. The menstrual cycle is series of degenerative 
and regenerative endometrial changes that occurs on a monthly basis in response to altering levels of 
ovarian hormones. The cyclical changes involve transformation of the endometrium into a state where 
it is most receptive to the implanting embryo 7 days following ovulation. Following ovulation, the 
elevated progesterone levels during the mid-secretory phase triggers decidualisation (days 23-27). 
Decidualisation can be recapitulated in vitro by treating primary endometrial stromal cells with cAMP 
and progesterone analogues. Adapted from [12]. 
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 Decidualisation 1.4
Three processes are orchestrated together to allow a successful pregnancy: embryo development, 
placental growth and stromal cell decidualisation. The process of decidualisation is marked by the 
transformation of stromal fibroblastic cells into secretory decidual cells and is of vital importance 
in species with invasive embryos [10]. As described previously, decidualisation occurs after 
ovulation in the mid-luteal phase of the cycle occurring even when an embryo is not present 
being therefore regarded as a maternally driven phenomenon. It encompasses both morphological 
and biochemical changes of the endometrium and, although it is sometimes referred to as 
‘spontaneous’ decidualisation, in fact tight temporal, spatial and physiological cues are 
paramount in this process. It is a progressive event starting in the mid-late secretory phase and 
during pregnancy it essentially takes over the entire endometrium. The extent of decidualisation 
is also thought to correspond with the extent of trophoblast invasion [13] and it is known to 
incorporate a wide variety of components within the uterine cavity, including the endometrial 
epithelial cells as well as stromal cells, immune and myometrial cells, and components of the 
vasculature such as the spiral arteries. Unsurprisingly, involved with these changes is a diverse 
set of signalling pathways and gene expression changes. All of these events must be initiated at a 
timely interval, specifically at the end of the receptive time of the cycle which is now known as 
the window of implantation.  
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 Decidualisation cues 1.5
1.5.1 Endocrine cues 
As described in section 1.3, uterine physiology is primarily under control by the steroid hormones 
estrogen and progesterone. Prior to ovulation, the endometrial stromal cells are primed by 
estrogens and can therefore mount a decidual response following the post-ovulatory rise in 
progesterone. However, the morphological signs of decidualisation are not seen until 
approximately 9 days following ovulation, illustrating that other factors are necessary to initiate 
this process [14]. In vitro experiments in primary endometrial stromal cell cultures are consistent 
with this; induction of decidual markers takes 7-10 days of exposure to a progesterone analogue 
which can be accelerated by other factors [15, 16]. This indicates that progesterone, although 
important for progression and maintenance of the decidual stroma, is not the primary initiating 
force behind this differentiation [8]. 
Relaxin is another factor which rises after the LH surge at about 6-9 days and is known to 
promote the decidualisation of cells in culture. However, this increase after the LH surge is fairly 
moderate [17]. The gonadotrophins, LH, FSH and hCG have also been implicated in the decidual 
process, although this subject still remains a topic of debate [18-20]. It is now known that the 
expression of local environmental factors including relaxin and prostaglandins all contribute to 
the elevated levels of cAMP in endometrial stromal cells in culture and lead towards 
decidualisation [8].  
1.5.2 Paracrine and autocrine cues 
In addition to endocrine cues, following the onset of decidualisation endometrial stromal cells 
secrete a number of factors which contribute to their own decidualisation. These include growth 
factors, cytokines, peptides and lipids. The importance of these factors has been shown in mouse 
models as well as in HESCs. One example includes the heparin-binding epidermal growth factor 
(HB-EGF) and its cognate receptors EGFR and ErbB4 (HER4) which are known to be 
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upregulated during the mid-secretory phase and at decidualisation HESCs [21]. Blockade of 
signalling by using neutralising antibodies or inhibitors of HB-EGF during decidualisation causes 
reduced expression of decidual markers in HESCs and sensitises cells to pro-inflammatory 
factors resulting in shorter cell survival [22]. HB-EGF has also been shown to enhance the 
migration ability of HESCs [23] and at implantation, promote trophoblast invasion [24]. The 
transforming growth factor β (TGFβ) family is also known to play a pivotal role during 
decidualisation. Activin A, a member of the TGFβ family, increases following cAMP addition in 
HESCs and additionally activin A itself is known to act as a deciduogenic cue [25]. Growth factor 
secretion by endometrial epithelial cells can also impact on the stromal cell population, for 
example TGFβ1 which activates the Smad signalling pathway in the endometrium [26].  
Another paracrine factor involved in decidualisation is the interleukin family of 
cytokines, such as interleukin-11 (IL-11), which is known to be upregulated during 
decidualisation and additionally is required for full expression of the classic decidual markers 
prolactin and IGFBP-1 [27, 28]. Lack of the IL-11 receptor in genetically modified mice is 
known to cause infertility due to lack of sustained decidualisation and therefore an impaired 
response to implantation [29]. Other interleukins important for decidualisation include IL-1β, 
which is an embryo-derived factor and is known to be important for complete decidualisation, as 
well as embryo implantation [30, 31]. Leukaemia inhibitory factor (LIF), a member of the IL-6-
type family of cytokines, is present during the early stages of pregnancy; this indispensable for 
embryo implantation in mice [32] and has been shown to also play a critical role in implantation 
in women [33]. This could be due to the recognised role LIF has in decidualisation in mice and 
humans [34].  
The Notch signalling pathway, considered to be initiated by a juxtacrine mechanism 
where neighbouring cells expressing the ligand and receptor interact, is known to be important in 
a wide range of systems for cell communication, gene transcriptional responses and 
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differentiation [35]. It is also involved in decidualisation and decreased Notch signalling has been 
purported to impair decidualisation in women with endometriosis [36, 37]. Likewise, lipid 
signalling pathways also play a part in decidualisation, such as pathways triggered by the 
prostaglandins, endocannabinoids or phosphatidic acid [8].  
There are a multitude of other factors involved in the paracrine and autocrine control of 
decidualisation. These will not be explored in the scope of this introduction, but examples include 
somatostatin signalling [38], peptide signalling [39], parathyroid hormone like hormone (PTH-
LH) signalling [40] and mechanical stretch [41]. These and the other endocrine, paracrine and 
autocrine factors described are all responsible for orchestrating a decidual response in an 
appropriate spatial and temporal manner, and the involvement of intricate positive and negative 
regulatory systems ensures that correct implantation and placentation can occur [8].  
 
1.5.3 Progesterone signalling  
Primary HESCs can be isolated from other endometrial components and can grow in culture 
independently. They have proved to be an important informative model system and have led to 
many of the discoveries outlined above. The process of in vivo decidualisation can be 
recapitulated using these cultures in vitro by treating cells with a combination of cAMP and 
progesterone analogues (8-Bromo-cAMP and medroxyprogesterone acetate, MPA) [42] (Fig. 
1.2). The expression of the progesterone receptors is driven by estrogens acting on the estrogen 
receptor-α (ERα) and therefore in the follicular phase, estrogen primes endometrial progesterone 
responsiveness in preparation for the luteal phase where progesterone levels rise and 
decidualisation takes place [43]. It is therefore essential when culturing HESCs to have estrogen 
present not only to promote growth but to ensure progesterone receptor expression is maintained. 
Progesterone signals largely through its nuclear receptor isoforms progesterone receptor-A and 
progesterone receptor-B (PR-A and PR-B) to induce or repress gene expression [44]. These 
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receptor isoforms display differential expression depending on cell type as well as phase of the 
cycle. PR-A, the dominant form in stromal cells, is known to be highly expressed in the stromal 
compartment throughout the menstrual cycle, whereas expression of PR-B is at the highest during 
the mid-proliferative phase and there is a steady decline in its expression levels thereafter [45]. 
Sustaining the spatiotemporal and relative expression levels of PR-A and PR-B has been shown 
to be essential as an incorrect ratio is connected to endometrial neoplasia [46]. The importance of 
these receptors has been demonstrated using mice knockout models and in mice lacking both 
receptors, the decidual response is absent and implantation is impaired [47]. Chaperones such as 
heat-shock proteins and immunophilins are responsible for maintaining the unliganded PR in a 
conformational state, which allows progesterone binding and to mobilise the receptor between the 
nucleus and the cytoplasm. When the PR binds progesterone, it undergoes a conformational 
change which gives rise to its phosphorylation and releases the associated chaperones and the PR 
is free to dimerise and bind to promoter and enhancer elements of specific target genes [43]. PRs 
can also indirectly modify gene expression by acting in an extranuclear manner to activate 
cytoplasmic Src tyrosine kinases which act on the mitogen activated protein kinase (MAPK) 
signalling cascade, which in turn then affect transcriptional outputs [48]. The activity of PRs is 
greatly modulated by post-translational modifications such as serine phosphorylation, 
ubiquitination and sumoylation and these can govern hormone responsiveness by altering PR 
expression, stability, trafficking and promoter selectivity [49]. Primary HESCs in culture harbour 
all of the components in order to allow progesterone mediated signalling, however, only a limited 
number of genes are acutely activated in response to progesterone and addition of cAMP is 
required for the PR to trigger expression of the full array of decidual genes.  
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1.5.4 cAMP signalling  
Cyclic adenosine monophosphate (cAMP) is a second messenger produced by activated (ligand-
bound) Gαs-coupled G-protein coupled receptors (GPCRs, discussed later in section 1.8). In the 
endometrium, Gαs-coupled receptors elevating cAMP include the relaxin, prostaglandin E2 
(PGE2) and corticotrophin releasing hormone (CRH) receptors [50, 51]. It is produced when 
GPCRs activate adenylate cyclase which catalyses the formation of cAMP from adenosine 
triphosphate (ATP). cAMP predominantly activates the enzyme protein kinase A (PKA) by 
binding to its two regulatory (R) subunits leading to a conformational change and the release of 
its two catalytic subunits (C); in turn these go on to regulate several different target proteins 
located in the cytoplasm [52]. When in the nucleus of stromal cells, the C subunits also 
phosphorylate a number of target proteins which modulate gene expression such as cAMP 
response element binding protein (CREB) and cAMP response element modulating protein 
(CREM). These both belong to the family of basic region/leucine zipper (bZIP) transcriptional 
regulators and function as homodimers which bind to the response element CRE found on gene 
promoters [53]. Other target proteins of PKA include signal transducer and activator of 
transcription 5 (STAT5), Forkhead box protein O1 (FOXO1) and CCAAT-enhancer binding 
protein (C/EBPβ). These all contribute to the induction of a myriad of decidual genes such as 
prolactin and IGFBP-1. The significance of cAMP signalling during decidualisation is 
highlighted by studies which have used a PKA inhibitor and demonstrated dramatic attenuation of 
decidual gene expression in HESCs in culture [54, 55]. Another lesser studied target of cAMP is 
exchange protein directly activated by cAMP (EPAC), of which there are two isoforms and 
siRNA knockdown of either of these prevents decidualisation in HESCs [56]. Given the 
importance of cAMP in decidualisation, unsurprisingly adenylate cyclase activity as well as 
cAMP levels are both higher in the secretory phase of the cycle in vivo and is higher in the 
endometrium compared to the myometrium, fallopian tubes or corpus luteum [57].  
 
Chapter 1: Introduction 
 
34 
 
1.5.5 Merging of cAMP and progesterone signalling  
Treating HESCs with progesterone alone provokes only a slow and marginal decidual response 
and this is only following 7-10 days of treatment [16] yet treating cells with 8-Bromo-cAMP 
alone results in a relatively rapid (1-3 days) onset of decidual gene transcription [58]. However, 
this response is short-term and not maintained in culture for extended periods [42]. It has now 
become apparent that while progesterone does not trigger the decidual response it is required to 
maintain it and cAMP, via activation of PKA, is the initiating factor sensitising the stromal cells 
to progesterone. A number of mechanisms are known which results in convergence of these two 
pathways; a schematic of the most well-established is shown in Figure 1.3. One way is that 
cAMP signalling activates or causes the expression of a number of transcription factors such as 
SV40 promoter binding protein 1 (SP1), STAT3 and STAT5, FOXO1 and C/EBP-β [59-61] 
which all have the ability to bind in a complex to the PR. These transcription complexes permit 
the PR to modulate genes without the need for a progesterone response element [14]. Another 
way in which convergence of the cAMP and progesterone pathways is evident is by the fact that 
progesterone-dependent HESC decidualisation occurs simultaneously with intracellular cAMP 
elevation and is abolished in the presence of a PKA inhibitor [54]. Furthermore, cAMP is known 
to attenuate repressive post-translational modifications of PR-A, namely sumoylation, thereby 
contributing to the sensitisation of cells to progesterone [62].  
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Figure 1.3. Merging of cAMP and progesterone signalling. The activation of G-protein coupled 
receptors (GPCRs) by ligands such as relaxin (RLX), prostaglandin E2 (PGE2) and corticotrophin 
releasing hormone (CRH) causes an increase in levels of cellular cAMP. Consequently, there is an 
accumulation of transcription factors within the nuclei of stromal cells which form a complex with the 
activated progesterone receptor (PR-A), resulting in activation of a number of decidua-specific genes 
such as prolactin (PRL) and prokineticin 1 (PROK1). Adapted from [14]. 
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 The Importance of Decidualisation in Embryo Implantation 1.6
1.6.1 The window of implantation 
It is now well-established that for a successful pregnancy the endometrium must first acquire a 
temporary and receptive phenotype so that the blastocyst implants in a favourable uterine 
environment. This period is known as the window of implantation and usually occurs at around 
days 19-24 of the menstrual cycle [63] coinciding with the mid-luteal phase and 6-10 days after 
the LH surge [64]. The failure to acquire this transient receptive state can result in infertility and 
equally there is a strong correlation between implantation which occurs beyond the normal period 
of receptivity and early pregnancy loss [65]. There have been many attempts to establish 
biomarkers which signify endometrial receptivity including histological dating, high-throughput 
immunohistochemistry, proteomic approaches and microarray analysis. Several candidate genes 
have been found using these methods but the number of common genes that were identified was 
minimal [66]. However, it was shown that local factors produced during the receptive period 
included cytokines, growth factors, transcription factors and morphogens which serve to specify 
endometrial receptivity.  
1.6.2 Embryo invasion 
Embryo implantation involves embryo apposition and adhesion to the endometrial surface 
epithelium, breaching of the luminal epithelium and encapsulation and invasion into the 
endometrial stromal cells [67]. For both ethical and practical reasons, our understanding of this 
process is restricted to the use of animal models and in vitro co-culture systems, being therefore 
relatively limited. What does seem to be apparent is that both the encapsulation capacity of 
maternal cells in addition to the invasive phenotype of the trophoblast leads to effective 
implantation. The decidualised endometrial stromal cell population secrete a number of matrix 
metalloproteases (MMPs) [68], display motile abilities and are invasive in nature [69]. They are 
able to promote embryo invasion due to the chemoattractant ability of their secreted leukocytes 
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[70]. Additionally, the expansion of trophoblast spheroids cultured with decidualised HESCs is 
increased compared to those cultured with undifferentiated HESCs, which is thought to be due to 
the secretion of epidermal growth factors and interleukins [71]. Decidualised HESCs are also able 
to distinguish a low-quality embryo from a high-quality embryo and will migrate more towards 
high-quality embryos [72]. It is also apparent that the implantation process is a highly regulated 
process as it does not appear to cause any damage or cell death to surrounding decidual cells [73]. 
Together, it is becoming clear that the decidual cells are not merely subjected to an invading 
blastocyst but that they actively take part in the process of its engulfment and encapsulation [8, 
74, 75].  
1.6.3 Embryo selection and immunomodulation  
In vitro models have shown the capabilities of decidualised stromal cells in detecting incompetent 
embryos at the point of implantation. It has been shown that the expression profiles of cytokines, 
chemokines, and growth factors from supernatants of decidualised HESCs co-cultured with 
blastocysts, are altered if the blastocyst displays signs of developmental arrest, and secretion of 
interleukins and growth factors are inhibited [76]. Time-lapse microscopy of migrating 
decidualised HESCs have shown that they migrate less in the presence of low-quality embryos 
compared to high-quality embryos [72]. Gathering evidence suggests that, amongst other 
pathways, the Wnt signalling pathway is also involved in implantation. Co-culture systems have 
demonstrated that endometrial cells, when in the presence of a trophoblast, upregulate genes 
involved in this pathway including dickkopf 1 (DKK1) and Wnt-inducible protein (WISP) 
although it has not yet been determined how this contributes to discrimination between high- and 
low-quality embryos [77, 78]. Decidualised HESCs are also known to mount an ER stress 
response when cultured with supernatants from developmentally incompetent blastocysts. This 
stress response was shown in vivo when conditioned media from these embryos were exposed to 
mouse uteri [79]. 
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Serine proteases have been implicated as a factor secreted by embryos which may act as a 
sign for embryo quality. These enzymes act through cleavage and activation of endometrial 
epithelial cell Na+ channels leading to an influx of Ca2+ through L-type Ca2+ channels and 
ultimately triggers CREB activation and PGE2 release [80]. Developmentally competent embryos 
triggered transient influxes of Ca2+, and in contrast embryos deemed to be incompetent exhibited 
Ca2+ influxes which were heightened and abnormally long-lasting [79]. This evidence suggests 
that the endometrial epithelium plays an important part in the initial signal transduction of 
implanting embryos. However, the decidualised stromal compartment is considered to be the 
main ‘biosensor’ which limits the implantation and encapsulation of developmentally 
incompetent embryos [8, 76].  
Decidualised stromal cells are also known to act in a manner which modulates the 
immune responses at the fetal-maternal interface. Since the embryo has half paternal and half 
maternal genetic components, it is therefore considered to be a ‘semi-allograft’ and would 
normally be rejected by the maternal cells. Decidualised cells however ensure that there is a 
sufficient balance of specialised macrophages and uNKs helping to prevent the priming of 
maternal T cells to paternal antiallogens which are expressed by the embryo. uNKs are unlike 
peripheral NKs in that they have decreased cytotoxic effects but increased ability to produce a 
large number of cytokines, chemokines and angiogenic growth factors [81, 82]. Gene ablation 
studies in mice lacking uNK cells have emphasised how important these cells are in leading to 
sufficient angiogenesis and blood vessel structural integrity [83]. The latter study also 
underscored the importance of uNKs in the modification of spiral arteries to allow sufficient 
blood flow during placental formation and indeed lack of these modifications as well as impaired 
angiogenesis is known to lead to conditions such as preeclampsia and fetal growth restriction 
[84]. 
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Other immunomodulatory mechanisms include the high expression of galectin-1 by decidualised 
cells, which is a glycan-binding lectin known to be implicated in many biological processes, 
including autoimmune disease and tumour progression [85, 86]. It is known to prevent T cell 
proliferation and inhibits T cell expression of proinflammatory cytokines. In galectin-1 deficient 
mice, which have high rates of fetal loss, treatment with recombinant galectin-1 re-established 
fetal tolerance [87].  
1.6.4 Oxidative stress responses 
During early pregnancy, there is significant vascular remodelling and as a consequence oxygen 
concentrations fluctuate profoundly at the feto-maternal interface [88, 89]. Due to these intense 
changes as well as inflammatory responses, reactive oxygen species (ROS) including superoxide 
anion, hydroxyl radical, and hydrogen peroxide are produced. ROS, when not quenched by 
antioxidative defences, can damage nucleic acids, proteins and lipids and cause cell death [90]. 
Decidualised cells acquire the ability to resist oxidative cell death by producing ROS scavengers 
including thioredoxin, peroxiredoxin, and most prominently superoxidase dismutase (SOD2), 
which is upregulated by the forkhead transcription factor FOXO1 [91]. In contrast, 
undifferentiated cells exposed to ROS upregulate FOXO3a and cannot survive under oxidative 
stress but, if this transcription factor is silenced, this prevents apoptosis [92]. Therefore, 
undifferentiated cells only adopt pro-survival behaviour upon decidualisation and otherwise will 
self-destruct following exposure to oxidative stress.  
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 Human Chorionic Gonadotrophin 1.7
The decrease of progesterone from the decidualised endometrium signifies the beginning of 
menstruation. During pregnancy however, the invading embryo synthesises and secretes human 
chorionic gonadotrophin (hCG) and prevents menstruation by rescuing the corpus luteum which 
will then continue to produce progesterone [93]. hCG is one of the first factors that is produced 
by the embryo and it is secreted no later than day 7 in the blastocyst stage [94]. hCG reaches its 
peak at 10 weeks of gestation and is continued to be produced throughout pregnancy, but its role 
in progesterone production only spans the first 3-4 weeks following implantation [95]. This 
suggests that progesterone production is not the only role of hCG and indeed it is now well-
known that the role of hCG goes beyond corpus luteum rescue and has many roles in relation to 
extra-gonadal cell type function.  
1.7.1 Structure of hCG 
hCG is a heterodimeric glycoprotein hormone and along with its closely related sister hormone, 
the luteinising hormone (LH), they are both known to act via their cognate receptor the 
luteinising hormone/chorionic gonadotrophin receptor (LH/CGR). hCG and LH are structurally 
similar, both belonging to the cysteine knot family of growth factors and comprised of common α 
subunit and varying β subunit [96]. Due to structural differences, particularly in the β subunit, and 
post-translational modifications, hCG is more stable than LH and has a considerably longer half-
life (several hours for hCG compared to 60-120 minutes for LH) and is therefore considered the 
‘super-agonist’ of the two [97]. Their structural and stability differences have recently been 
shown to be reflected in their downstream signalling potencies in a study that compared 
recombinant hCG and LH actions in granulosa cells [98]. hCG is unique in that it has five 
variants, hCG, sulphated hCG, hyperglycosylated hCG, the free hCG β subunit and a 
hyperglycosylated free hCG β fragment. These have been shown to have diverse functions [95].  
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1.7.2 Expression of the LH/CGR in the endometrium  
As described above, the principle function of hCG was thought to be in communicating with the 
corpus luteum in order to maintain levels of progesterone. However, it is now clear that hCG has 
a more direct, paracrine role at the feto-maternal interface during implantation. Many studies 
have investigated its effects in endometrial epithelial and endometrial stromal cell populations 
using primate and mouse models as well as primary human endometrial cell cultures. The 
presence of the LH/CGR receptor in the endometrium has been confirmed using a variety of 
different methods in many species including in the baboon [99], mouse [100-102] and human 
tissues [103-107]. However, LH/CGR regulation and expression in the endometrium still appear 
to be undetermined. In the baboon it has been shown that the receptor is absent in the 
proliferative phase of the cycle, but expression is evident during the secretory phase and 
additionally, decidualisation appears to decrease receptor protein levels [99]. It has also been 
shown in human endometrial biopsy samples that LH/CGR mRNA is present throughout both 
phases of the menstrual cycle and the full-length receptor appeared to be down-regulated during 
the late secretory phase. This study also showed that splice variants of the receptor may be 
present in human endometrium [108]. However, since RNA was extracted from whole-tissue 
samples, it is unclear whether this expression is from the epithelial or stromal compartments. It 
has also been shown that expression of the LH/CGR in decidualising HESCs is reliant on the 
presence of hCG [109]. 
1.7.3 Functions of hCG at the embryo-endometrial interface 
hCG has a wide spectrum of roles within the endometrium. An early study showed that hCG acts 
directly on the stromal cells causing morphological changes, as well as inducing the secretion of 
the decidual genes [20], but this was conflicted by a later study which did not observe any 
morphological changes in HESCs induced by hCG [109]. The study was also disputed by in vivo 
studies in humans using an intrauterine microdialysis technique that locally administered hCG 
showing that in fact it decreases rather than increases genes associated with decidualisation, in 
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particular IGFBP-1 and prolactin [110, 111]. These latter studies were further substantiated in 
vitro using HESCs where hCG reduced levels of IGFBP-1 and prolactin in a dose-dependent 
manner as well as levels of prokineticin 1 (PROK1), another classic decidualisation marker [112, 
113]. In Ishikawa cells, which are often used as a model of the endometrial epithelium, PROK1 is 
induced following treatment with hCG and followed by an increase in LIF [114]. It may be that 
hCG causes an initial but temporary increase in these factors to enhance embryo receptivity at the 
epithelium, but upon breaching it and contact with the stromal cells, receptivity begins to taper by 
the decrease in these factors.  
Although the above studies demonstrate that hCG has a negative effect on 
decidualisation, there is still further study needed to broaden our understanding of this and some 
studies are conflicting. The Notch1 signalling pathway is known to regulate the decidual process 
and induce IGFBP-1 expression [36, 115] and hCG has recently been shown to increase levels of 
Notch1 in human uterine fibroblasts (HuFs), an extensively used cell line to examine stromal cell 
function [116] suggesting that it could indirectly upregulate IGFBP-1. The free radical scavenger 
SOD2 has also been shown to be upregulated at the protein level by HESCs exposed to hCG 
[109]. These studies demonstrate that hCG may have divergent roles in decidualisation, on the 
one hand to enhance it and on the other to decrease it. It may well be that hCG acts on different 
subsets of genes to different degrees and it is the balance of this that aids in the spatiotemporal 
control of endometrial receptivity.  
In addition to the role of hCG decidualisation of HESCs, there are a number of other 
components which hCG modulates that can have an impact on embryo invasion and implantation. 
hCG has been purported to have influences on MMPs which are known to be important for 
trophoblast invasion. Tissue inhibitors of metalloproteases (TIMPs) inhibit the action of MMPs 
[117] and hCG has been shown to downregulate a subset of TIMPs in stromal cells [118, 119]. 
Since TIMPs are thought to represent a substantial obstacle during embryo invasion [120] this 
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decrease by hCG suggests that it negates this, thereby facilitating implantation. hCG has been 
shown to aid in implantation by enhancing the sensitivity of HESCs to other embryonic signals, 
namely interleukin-1 (IL-1) and this in turn upregulates monocyte chemotactic protein (MCP-1) 
[121]. MCP-1 is known to promote angiogenesis in various cell types [122] therefore the indirect 
induction of this suggests that hCG acts as a pro-angiogenic factor during implantation. It has 
also been shown to directly enhance angiogenic factors in the endometrium for example vascular 
endothelial growth factor (VEGF) [110, 123] and in LH/CGR-null mice, angiostimulation by 
hCG is abolished [123].  
hCG is known to act as a protective agent preventing the apoptosis of HESCs which are 
exposed to H2O2-dependent oxidative stress and this is reported to be due to a hCG-dependent 
induction of both Bcl2, an anti-apoptotic protein, and SOD2 [109]. This anti-apoptotic effect has 
also been seen in endometrial biopsies taken from women that had been injected with hCG during 
the luteal phase, where evidence of apoptosis was significantly reduced as were levels of Bax, a 
pro-apoptotic protein, compared to women that did not receive hCG [124]. This pro-survival 
characteristic of hCG has also been shown in other cell types including human endometrial 
stromal fibroblasts isolated from placental tissue [125] and primary granulosa cells [126]. This 
role of hCG in apoptosis in HESCs may need further investigation as it does not correspond with 
findings that hCG inhibits prolactin in decidualising HESCs since prolactin is known to promote 
survival and prevent apoptosis [127, 128]. Furthermore, hCG has been shown to up-regulate the 
Fas-Fas ligand (FasL) (a system involved in apoptosis) and increase morphological features of 
apoptosis in HESCs [129]. Since apoptosis is known to be a normal event during the initial stages 
of implantation [130] it could be that hCG first transiently aids in this process but then prevents 
extensive cell death in the stromal compartment to allow embryo-stromal cross-talk.  
hCG has also been assigned a role in immunomodulation and inflammation at the fetal-
maternal interface. As described previously (section 1.6.3), uNK cells are known to be important 
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in innate immune responses in the endometrium and comprise around 70% of the leukocyte 
population [131]. hCG has been shown to act directly on uNK cells and induce their proliferation 
[132]. T-regulatory cells are powerful mediators to supress auto-immune responses which 
prevents embryo rejection and studies have also shown that hCG can up-regulate some T-cell 
populations [133-135] and supress mitogen-induced response of T and B lymphocytes [136-138]. 
In HESCs, hCG causes the secretion of a number of cytokines that are involved in immune 
responses, including interleukin-25 (IL-25) which is known to act on a number of immune cells 
including T-cells and monocytes, as well as promoting angiogenesis [139, 140]. Implantation 
encompasses both anti- and pro-inflammatory effects. One mediator of the anti-inflammatory 
factors is apolipoprotein A-1 (Apo-A1) and in decidualised HESCs hCG has been shown to 
powerfully reduce it, suggesting it may promote inflammation [141]. On the other hand, hCG 
might mediate anti-inflammatory events and tolerance of implantation since it is known to 
upregulate the inflammatory interleukin IL-6 in endometrial epithelial cells [142].  
Overall, it is becoming increasingly clear that the role of hCG in the endometrium is 
multifaceted, with possible implications in decidualisation, inflammation, angiogenesis and 
oxidative stress responses. Figure 1.4 provides a schematic summarising some of these known 
functions.  
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Figure 1.4. Multifaceted roles of hCG in the endometrium. hCG is classically known to produce 
progesterone production from the corpus luteum, but it is now emerging that it plays multiple roles at 
the embryo-endometrium interface, having the ability to modulate a number of locally secreted factors 
as well as being involved in important processes such as angiogenesis and decidualisation. Refer to 
section 1.7.3 for descriptions of these.  
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 G-protein coupled receptors 1.8
The mechanism by which hCG exerts its action is through the luteinising hormone/chorionic 
gonadotrophin receptor (LH/CGR), a member of the G-protein coupled receptor (GPCR) 
superfamily, which share a common seven transmembrane (TM) topology. With >800 members 
in humans, GPCRs are the most dominant receptor family within cells [143, 144]. In addition to 
transducing signals from proteins such as hCG, they are known to transduce signals from a 
diverse array of other extracellular ligands, including neurotransmitters, odorants, photons, ions 
and small organic molecules [145]. Due to the sheer number of receptors and their ability to 
respond to an assortment of agonists, as well as their ubiquitous expression, GPCRs are involved 
in many physiological pathways and pathophysiological processes. The classic model depicting a 
GPCR exerting its action is by operating like an on-off button; existing normally in an inactive 
state and switched to an active state by the binding of its cognate agonist which then renders it 
capable of signalling. This model is now known to be far more complex and intricately designed 
so as to give appropriate responses to the diverse range of ligands in the external environment, 
and is refined and regulated by various processes such as docking of different adaptor proteins 
and GTPases, various modes of endocytic trafficking and interactions with other receptors, to 
name but a few [146]. The following section will review some of the basic concepts of GPCR 
biology as well as some newer and emerging mechanisms which regulate their function.  
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 GPCR structure 1.9
GPCRs are categorised into six separate sub-families based on their sequence and functional 
similarities. The majority of receptors are in Class A (rhodopsin-like) and the remainder are Class 
B (secretin-like), Class C (metabotropic-glutamate receptors), Class D (pheromone receptors), 
Class E (cAMP receptors) and Class F (frizzled and smoothened receptors) [147]. Although they 
are separated into these sub-categories, the entire superfamily shares many architectural features 
and applied to all is the heptahelical hydrophobic TM spanning domains, an extracellular N-
terminus and an intracellular C-terminus, and three extracellular and intracellular loops. This 
receptor structure is not rigid and GPCRs can adopt multiple transitory conformations which are 
altered by factors such as agonist association, binding to other receptors, proteins involved in 
signalling and post-translational modifications [148]. In addition, even though receptors share the 
similar overall structure, they possess only a small amount of sequence identity and each region 
of the receptor can vary hugely depending on the receptor group and sub-type. The C-terminus, 
the intracellular loops at TM5 and TM6 and the N-terminus is where the most variable structures 
in GPCRs can be found [149]. The N-terminus has the most diversity, and can vary in length for 
each receptor and can be responsible for ligand binding. Accordingly, for GPCRs with small 
ligands, for example peptides, the N-terminal sequence is reasonably short at 10-50 amino acids 
(for example, the protease activated receptors, PARs [150], for larger ligands, such as whole 
proteins, the sequence is considerably larger at between 350-600 amino acids (for example, the 
glycoprotein hormone receptors [151] and adhesion receptors have undoubtedly the largest N-
terminal domains, up to 1000 amino acids or more [152]. Noteworthy, size of the ligand is not 
necessarily a predictor of the size of the extracellular N-terminal domain, for example, for 
example, Ca2+ binds to its receptor which has a large N-terminus [153]. Ligands do not bind 
exclusively to the N-terminal region, but the entire extracellular region of the receptor including 
the extracellular loops (ECLs) can be involved as well as the TM helix bundle [148]. For many 
GPCRs, their ECLs contain disulphide bridges which contribute to the overall stability of the 
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receptor as well as helping to evade promiscuous GPCR signal transduction. Accordingly, 
cysteine mutants that disrupt disulphide bridges have altered receptor stability and signalling 
properties [154]. The mode of binding can vary for ligand and receptors, but in most cases, ligand 
binding causes the GPCR to undergo dynamic conformational changes in the TM and 
cytoplasmic domains [155]. These conformational changes include movement of TM3 and in the 
intracellular loops (ICLs). Mutations within these ICLs can cause aberrant G-protein binding and 
signalling, as seen in rhodopsin [156]. Crystallography of GPCRs has proven extremely 
challenging, but recent major advances in this area has enabled further insights of the structure of 
these receptors as well as how they undergo these conformational changes upon binding to 
agonists, antagonists and inverse agonists (reviewed in [157]).  
Simply put, the structure of a GPCR comprises three main regions which together make up 
a ‘doorway’ to receptor signalling; (1) the extracellular part, which can mediate agonist binding; 
(2) the TM regions, which make up the structural core, can also bind agonist and, via 
conformational changes, relay signals to the intracellular region and (3) the intracellular part, 
which provides the interface whereby the receptor interacts with cytosolic signalling proteins.  
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 G-protein dependent signalling 1.10
The primary mode of G-protein signalling is via heterotrimeric G-proteins, Gα, Gβ and Gγ. There 
are >30 different subunits of these G-proteins, and although this number is relatively minor 
compared to the number of GPCRs within cells, G-proteins play a major role in defining GPCR 
signalling specificity as well as the timing of signal transduction [158]. G-proteins are thought to 
be either pre-coupled to inactive GPCRs or laterally diffuse within the plasma membrane, binding 
with only active GPCRs [158]. Gα proteins are located in the plasma membrane via their N-
terminal domain, Gβ proteins do not link directly to the plasma membrane but bind strongly to 
Gγ via hydrophobic interactions and together all three form one tightly bound complex [159, 
160]. In order to allow dynamic coupling and uncoupling of the GPCR to its signalling effectors, 
cycling of this heterotrimeric G protein between inactive and active states is essential. In the 
inactive state, the Gα subunit, which is bound to GDP, remains bound to the Gβγ subunits. When 
the GPCR to which heterotrimeric G proteins are associated is activated it acts as a guanine 
nucleotide exchange factor (GEF) by causing the Gα-bound GDP to be exchanged for GTP. 
Consequently, the Gα monomer is dissociated from the Gβγ dimer which can each then go on to 
modulate the activity of various downstream effector molecules, for instance enzymes and ion 
channels (Fig. 1.5). Via the hydrolysis of GTP into GDP by Gα, the heterotrimeric complex is 
then restored.  
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Figure 1.5. GPCR signalling via heterotrimeric G-proteins. GPCRs cycle between active and 
inactive states by the dissociation and association of their cognate G-proteins. When bound to ligand, 
GPCRs undergo a conformational change and act as a guanine nucleotide exchange factors (GEF), 
causing the GDP-bound Gα to be GTP-bound. It therefore uncouples to Gβγ and each can go on to 
control downstream signalling pathways (see text for further details).  
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1.10.1 Gα effectors  
There are four main types of Gα family proteins, Gαs, Gαi/Gαo, Gαq/Gα11, and Gα12/Gα13, and 
each initiate a specific signalling cascade via their respective effectors (Fig. 1.5) [161]. Some of 
the Gα family are ubiquitously expressed, while others are cell type specific. The first effectors of 
the Gα family to be recognised were the adenylate cyclases [162], which are membrane bound 
enzymes involved in the modulation of cAMP levels. The Gαs and Gαi/Gαo play opposing roles to 
change intracellular cAMP levels via modulating adenylate cyclase activity, Gαs being 
stimulatory and thereby increasing cAMP and Gαi/Gαo being inhibitory thereby decreasing 
cAMP. The Gαq/Gα11 family is classically defined as the pathway which is activated by GPCR 
ligands which stimulate phospholipase C-β (PLCβ) (as well as other isoforms of this enzyme). 
The latter acts by hydrolysation of phosphatidylinositol 4,5-bisphosphate [PtdIns(4,5)P2], a 
plasma membrane bound lipid [163] and in doing so, generates inositol 1,4,5-trisphosphate 
[Ins(1,4,5)P3] and diacylglycerol (DAG) second messengers which then activates phosphokinase 
C (PKC) [164]. Many lines of evidence have also shown that Gαq also stimulates phospholipase 
D (PLD) [165]. When Ca2+ is released following activation of these effectors, in many cell types 
this then in turn opens Ca2+ channels on the plasma membrane allowing the influx of calcium 
[166]. Finally, the Gα12/Gα13 family mediates its effects through instigating Rho GEF activity, 
which in turn activate Rho proteins and effectors [167]. It has been known for some time that via 
this activation of the Rho family, the Gα12/Gα13 are responsible for a variety of effects including 
regulating the Na+-H+ exchanger and cytoskeletal rearrangements.  
1.10.2 Gβγ effectors 
The Gβγ dimer subunit was originally thought to be a negative regulator of Gα due to its guanine 
nucleotide dissociation inhibitor (GDI) activity but research over a number of years has shown 
that directly activates various effectors [168]. The first Gβγ effector to be identified was the 
cardiac muscarinic gated inwardly-rectifying K+ channels [169] and since then, Gβγ have also 
been found to modulate N- and P/Q-type Ca2+ channels (for example in sensory neurons, [170]. 
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Additionally, they are known to regulate MAPKs, such as p38 as well as small G proteins such as 
Ras and Rac [171, 172]. Other roles of Gβγ include direct regulation of phosphoinositide-3′ 
kinase-γ (PI3Kγ) [173], positive and negative regulation of adenylate cyclase isoforms [174] and 
regulation of PLC-β [175] and PLC-ɛ [176]. More recent research has shown that the scope of 
Gβγ effectors is wider than anticipated (recently reviewed in [177]). Some GPCRs are known to 
mediate chemotaxis through Gβγ modulating actin filaments and a new Gβγ effector, ElmoE, has 
recently been shown to be responsible for this [178]. Interestingly, Gβγ has been shown to 
mediate its signalling by interacting directly with components of organelles, including 
endosomes, the golgi apparatus and endoplasmic reticulum [177].  
 
 Regulation of GPCR signalling  1.11
GPCRs can activate several downstream signalling pathways through multiple mechanisms; a 
summary of some of these is shown in Figure 1.6. An important property of GPCRs is to be able 
to respond to extracellular stimuli in order to drive these signalling pathways in timely and 
appropriate manner. To aid this, receptors can be modulated at a various number of steps along 
their lifetime and with the involvement of a large plethora of adaptor proteins in order to dampen 
or amplify their signalling. There are two main ways by which receptors can dictate their own 
signalling; (1) by controlling the amount of receptors on the plasma membrane and (2) by 
controlling the degree of signalling efficiency of the receptors on the plasma membrane. 
Receptor-mediated internalisation is followed by endocytic sorting and subsequent recycling. 
This plays a dominant role in GPCR signalling and the subsequent paragraphs will describe the 
fundamental aspects of this trafficking and how this is important for adjusting GPCR activity.  
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Figure 1.6. GPCR activation triggers multiple signal transduction cascades. Through signalling 
via their cognate G-proteins, GPCRs can elicit a number of downstream signalling profiles which are 
able to regulate cellular responses through changes in gene expression. Prototypical pathways 
include the cAMP/PKA pathways, calcium signalling and ERK1/2 and p38 kinase cascades. Cross-
talk with growth factors can also indirectly induce these signalling pathways. Taken from [179], with 
small modifications. 
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 Desensitisation and Internalisation  1.12
Activation-dependent regulation of receptors, also known as desensitisation, is the classic 
mechanism by which GPCR responsiveness is controlled [180, 181]. There are two primary steps 
involved in this process, GPCR serine/threonine phosphorylation and binding of arrestins. 
Arrestins are a family of four soluble proteins; arrestins 1 and 4 are known as the visual arrestins 
and are expressed exclusively in the retina [182] and arrestins 2 and 3, the non-visual arrestins, 
which are ubiquitously expressed in most tissues [183]. Arrestins 2 and 3 are more commonly 
known as β-arrestin 1 and β-arrestin 2 and these are known to be master regulators of GPCR 
desensitisation. GPCR kinases (GRKs) specifically phosphorylate ligand bound GPCRs at their C 
terminus creating binding sites for β-arrestins (known as homologous desensitisation). Receptors 
can also be phosphorylated by second-messenger protein kinases, such as PKA or PKC 
(heterologous desensitisation) [184]. Receptor activation and phosphorylation results in β-arrestin 
recruitment and high-affinity binding to the GPCR. This interaction uncouples the GPCR from 
binding to its cognate G-proteins and thereby terminates any further G-protein activation. The 
GPCR-phosphorylation-β-arrestin mechanism is a prerequisite for clathrin-dependent 
internalisation for many but not all GPCRs [185]. Following desensitisation, β-arrestins work as 
adaptors to link the GPCR to components of the endocytic machinery. When they are bound to a 
GPCR, they undergo a conformational change, which exposes their C-terminal domain allowing 
them to bind to clathrin and the β2-adaptin subunit of adaptor protein 2 (AP2), both essential 
components of clathrin coated pits (CCPs) [186, 187]. Progressively, these pits start to bud 
inwards from the plasma membrane to the cytosol; a vesicle is then pinched off by the GTPase 
dynamin and is then ready to undergo its respective endocytic sorting. In addition to β-arrestins 
binding to GPCRs and assembling them at CCPs, they can also augment further signal 
termination by directly promoting the degradation of second messengers, for example by 
physically interacting with diacylglycerol kinases (DGKs) which promote degradation of 
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diacylglycerol (DAG) [188]. In sum, this receptor sequestration by β-arrestin renders the GPCR 
unable to respond to further stimulation thus signalling is downregulated.  
 
 GPCR endocytic sorting  1.13
GPCRs are under tight control by the endocytic pathway. Once internalised, they are driven into 
early endosomes and then will either be directed to degradative or recycling pathways. 
Degradation occurs by the sorting of receptors into the intraluminal vesicles of multivesicular 
bodies (MVBs) which leads to the GPCR being finally directed to lysosomes where it will be 
degraded leading to long-term signal quenching [189, 190]. Alternatively, GPCRs will be 
recycled back to the plasma membrane and this allows further signalling and is known as receptor 
resensitisation. Figure 1.7 gives a schematic of these sorting pathways as well as newer GPCR 
mechanisms which are described later in this section.  
1.13.1 Lysosomal sorting  
Lysosomal sorting involves a highly conserved array of proteins associating with endosomes 
which aid in handling the diverse sets of cargo that pass through the endosomal system. One 
established pathway involved in directing GPCRs and other receptor types to the lysosomal 
pathway is the ESCRT (endosomal-sorting complex required for transport) machinery, which 
involves a complex set of proteins that direct ubiquitinated cargo for degradation [189, 191]. 
There are also other ubiquitin-independent pathways involved in GPCR degradation, such as via 
the GPCR associated binding protein-1 (GASP1) and dysbindin, which direct receptors to the 
ESCRT machinery [192, 193]. 
1.13.2 GPCR recycling 
The canonical view of endosome-to-plasma membrane trafficking was once that this occurred by 
bulk recycling [194], as is known for receptors which constitutively recycle such as the 
transferrin receptor [195, 196]. However a considerable amount of research has now shown that 
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recycling of many GPCRs is a highly regulated process and necessitates specific C-terminal 
located sequences. Many of these recycling sequences correspond to PDZ (postsynaptic density 
95/disc large/zonula occludens-1) ligands and this is harboured by many GPCRs including 
adrenergic, glycoprotein hormone and glutamate receptors [197]. PDZ proteins are adaptor 
proteins found in the cytoplasm and have highly conserved modules which allow the assembly of 
multiprotein signalling complexes by binding to their respective PDZ ligand at the receptors C-
terminal tail. GPCRs that lack the ability to bind to their PDZ proteins, for instance by mutations 
or phosphorylation of their C-terminal tail, can dramatically perturb their recycling abilities [198, 
199]. Simple removal of the C-terminal tail of some receptors can cause them to undergo 
lysosomal degradation or, conversely, if the C-terminal tail of a receptor that cannot recycle is 
exchanged for a C-terminal tail of a receptor that is able to recycle, it can escape degradation 
[198]. Much study of the function of PDZ ligands and recycling has been carried out on the β2-
adrenergic receptor (β2AR), a prototypical GPCR and the first membrane protein for which the 
PDZ-recycling hypothesis was formed [200]. Recent elegant studies have shown that the β2AR, 
in addition to a PDZ sorting sequence, requires other recycling machinery such as sorting nexin 
27 (SNX27), which mediates recycling via the PDZ-directed pathway [201]. Additionally, 
SNX27 is known to link the β2AR to retromer, a key player of endocytic sorting, and thereby 
facilitating endosome-to-plasma membrane trafficking [202, 203]. Due to the high diversity in the 
C-terminal tail of GPCRs, they are each capable of binding to specific PDZ proteins and 
depending on the which PDZ protein they bind, this can have different influences not only on 
recycling but also on G-protein coupling and desensitisation [197].  
In addition to PDZ domain binding proteins, there are a range of other proteins involved 
in receptor recycling. The early endosomal adaptor protein Hrs has been implicated in the 
recycling of the β2AR, calcitonin-like-receptor receptor and the mu-opioid receptor [204, 205] 
and cellular ablation of Hrs results in the receptor being retained at the early endosome. Other 
endosomally located proteins that control receptor recycling include the Rab GTPases. These 
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small GTPases are known to be important for endosome budding, fission and motility by 
recruiting components such as motor proteins and kinases [206]. They can mediate GPCR 
recycling as well as degradation by interacting with the receptor C-terminal tail [207]. Rab4 is 
known to be important in rapid recycling and accordingly, overexpression of a constitutively 
active Rab4 mutant enhances the resensitisation of some GPCRs, for example the angiotensin 1 
receptor [208]. Other Rab proteins involved in receptor recycling include Rab11, which is 
responsible for the slower recycling of receptors back to the plasma membrane [209].  
Research in the last 10-15 years has not only focussed on how receptors are directed to be 
recycled but how they fuse with and become inserted into the plasma membrane and the factors 
which govern this. Technological advances have enabled the visualisation of individual insertion 
events into the plasma membrane via total internal reflection fluorescence microscopy (TIRF-M). 
This microscopy technique is coupled with the use of receptors which are tagged at the N-
terminal with a GFP variant, superecliptic pHluorin, which only fluoresces when at neutral pH 
but not in the acidic lumens of endosomes. The combination of these techniques has provided a 
way by which receptor insertion events can be directly visualised at the plasma membrane with a 
high signal-to-noise ratio [210-212]. These studies have revealed that GPCRs have diverse modes 
of recycling, some of which are signalling dependent. For example, recycling of the β2AR has 
been shown to have two modes of recycling in neuronal cultures, where insertion events emerge 
at the plasma membrane followed by rapid lateral diffusion (events last <1 second) or where they 
linger at the plasma membrane for longer (>10 seconds), named transient or persistent events 
[212] (Fig. 1.7). Further, these events are modulated by agonist and PKA, with transient events 
being negatively regulated by the presence of these, and persistent events being positively 
regulated [212]. It has also been shown that the sorting of receptors to the recycling pathway can 
be modulated by Src family kinases, which act via phosphorylation of cortactin which regulates 
endosomal actin microdomains which are known to facilitate β2AR receptor recycling [213, 214].  
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 Newer and evolving concepts in GPCR biology 1.14
The study of GPCRs over the last half century or more has elucidated many of the fundamental 
pathways involved in their action. Increasingly, with more investigation into these receptors, it is 
becoming clear that their mechanism of action is even more complex than previously anticipated. 
In the subsequent section, I will outline some of the newer and developing concepts that have 
arisen which contribute to dictating GPCR function.  
1.14.1 G-protein independent signalling  
It has become clear that GPCRs can produce signals that are independent of their intrinsic GEF 
activity through scaffolding to other, non-G-protein effectors. Of these, probably the best-
characterised is that of signalling through the β-arrestins which, as described previously, were 
first known to be involved in GPCR signal down-regulation or desensitisation. It is now apparent 
that β-arrestins can transduce signals at the surface and as well as at endosomal compartments by 
binding to proteins which have catalytic activity, for example, the Src family of tyrosine kinases 
[215], the ERK1/2 and c-Jun N-terminal kinase 3 (JNK3) mitogen-activated protein (MAP) 
kinase cascades [216] and cAMP phosphodiesterases (PDE) [217], to name only a few. Through 
these interactions, β-arrestins confer an extra layer of intricacy to GPCR signalling and allow 
another way in which signals may be fine-tuned. Since the β-arrestins uncouple the activated 
receptor from its respective G-protein during desensitisation, but also then transmit pathways of 
their own, this allows temporal separation of signalling and they should in theory be mutually 
exclusive. Moreover, β-arrestins can allow more sustained MAPK signalling than G-protein-
dependent pathways, which are far more rapid and transient in comparison [218].  
1.14.2 Convergence of trafficking and signalling  
It is now clear that receptor endocytic trafficking and signalling are not mutually exclusive 
mechanisms and that they work together in order to mediate correct spatial and temporal 
signalling outcomes (Fig. 1.7). As described previously, one dramatic example of this is the 
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removal of plasma membrane GPCRs from the cell surface via endocytosis which in turn 
attenuates signalling followed by receptor degradation or resensitisation of the GPCR once it is 
returned to the plasma membrane. This plasma membrane-exclusive mechanism of signalling, 
however, has now been challenged by data showing unequivocally that receptor signalling can 
also occur from endosomes [219]. Therefore, they not only act as sorting stations to direct 
receptors to their respective recycling or degradative fates, but they also act as signalling stations. 
They do this by both maintaining signals from receptors which originated at the plasma 
membrane as well as initiating new signals from endosomes [220]. This is known now to occur in 
a G-protein independent manner, for example through the scaffolding by β-arrestins on 
endosomally located GPCRs and, more recently, in a G-protein dependent manner. Examples of 
the latter include cAMP generation from studies on the Gαs coupled parathyroid hormone 
receptor type 1 (PTHR) and the thyroid stimulating hormone receptor (TSHR), which both 
showed via the use of cAMP biosensors that sustained cAMP signalling requires internalisation 
[221, 222]. A recent seminal study used a GFP-tagged nanobody as a biosensor which could 
specifically detect the active conformation of Gαs-coupled β2AR and this also revealed Gαs 
signalling occurs from endosomes [223]. Importantly, it has been shown for the β2AR that if 
cAMP signalling only occurs from the cell surface, it elicits different downstream transcriptional 
responses than when cAMP propagation occurs from endosomes, which further highlights the 
prominence of endosomal signalling [224]. In addition to this, endosomal Gαs subunits have also 
been implicated in directing early endosomal maturation as well as GPCR lysosomal degradation, 
implicating them as dual players in receptor signalling as well as controlling endocytic routes of 
GPCRs [225, 226].  
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Figure 1.7. GPCR endocytic trafficking and spatial control of signalling. When internalised, 
GPCRs classically undergo clathrin-mediated internalisation and desensitisation which is facilitated by 
arrestins. They then are routed to the early endosome (EE) where they are known to be able to 
undergo further rounds of signalling via arrestins or G-protein mediated pathways. Some GPCRs are 
sent to degradative pathways via multivesicular bodies (MVBs) to lysosomes. Other GPCRs will 
undergo bulk or sequence specific recycling (see text), which allows them to become resensitised at 
the plasma membrane and available for further activation by ligand. The Very Early Endosome (VEE) 
is a novel endocytic compartment also known to be important for GPCR signalling and recycling, and 
this is described in detail later in section 1.15.9. Schematic is adapted from [227].  
 
 
Chapter 1: Introduction 
 
61 
 
1.14.3 Receptor homo- and heterodimerisation 
The hypothesis that GPCRs do not only act in their monomeric state but can bind and dimerise 
with other GPCRs was once a highly controversial statement in the field. However, it has become 
accepted that many GPCRs can form homodimers, heterodimers and oligomers and, importantly, 
that these have functionally relevant cellular outcomes [228]. They can form dimers or oligomers 
during their biosynthesis and following internalisation after signalling [229]. Many studies using 
bioluminescence energy transfer (BRET) or fluorescence resonance energy transfer (FRET) have 
shown these interactions and that they also can depend on agonist activation or are profoundly 
modulated with agonist [230, 231] and additionally, for a number of Family C GPCRs, 
dimerization can occur in a constitutive manner [232]. Following dimerization, there can be 
significant changes in G-protein coupling and signalling, as well as receptor trafficking and 
regulation. For example, a recent study demonstrated that cellular depletion of the chemokine 
receptor CXCR4 could dramatically influence the function of the α1-adrenergic receptor in 
vascular smooth muscle cells and additionally treatment with the CXCR4 agonist could increase 
the potency of the α1-adrenergic receptor agonist [233]. Dimerization therefore allows another 
mechanism by which GPCRs can fine-tune their signalling and adapt to their physiological 
surroundings. Much of the research on dimers has been carried out in heterologous cell systems, 
but new and emerging technological tools are beginning to allow a more thorough understanding 
of dimerization in these platforms as well as to confirm receptor interactions in native tissues 
[234]. With a fuller understanding of their relevance in vivo, receptor dimers may become widely 
used targets for pharmacological intervention and indeed, one heterodimer, the mu-delta opioid 
receptor complex, has undergone late stage clinical trials [235]. 
 
Chapter 1: Introduction 
 
62 
 
 The LH/CGR 1.15
LH and hCG bind to the same GPCR, the luteinising hormone/chorionic gonadotrophin receptor 
(LH/CGR) which is a member of the Class A family of GPCRs, and of the sub-family of 
glycoprotein hormone receptors, along with the FSH receptor and thyroid stimulating hormone 
receptor (FSHR and TSHR) [236]. Like all GPCRs, it has a 7TM spanning domain, but it also has 
a large extracellular domain and this is characterised by leucine-rich repeats as well as numerous 
glycosylation sites [237]. In line with its function in reproduction, the LH/CGR is expressed in 
many cell types in the ovary, including granulosa, luteal and theca cells and it has also been 
reported to be expressed in non-gonadal tissues, including the uterus, myometrium, trophoblasts 
and tumour tissues [238].  
1.15.1 LH/CGR splice variants 
The LH/CGR is located on the short arm of chromosome 2 (2p21) [239]. Its gene is 
approximately 80 kb in size and consists of 10 introns and 11 exons [240] and splice variants of 
the receptor have been identified in the corpus luteum of many species including sheep [241], rats 
[242] and humans [243]. In the corpus luteum and ovary of humans, there are three alternative 
splice variants. LH/CGR-A encodes the full-length receptor, LH/CGR-B lacks exon 9, and 
LH/CGR-C and D miss the first 266 nucleotides of exon 11. LH/CGR-D is the most truncated 
form and lacks exon 9 in addition [244]. Exon 9 appears to be important for the binding of hCG, 
since LH/CGR-B has been reported to be unable to elicit signalling in COS-7 cells and in 
addition LH/CGR-B significantly reduces the surface expression of the full-length receptor [245, 
246]. In addition, LH/CGR-B has also been shown to negatively regulate the surface expression 
of the FSHR [247]. A study has documented that the LH/CGR-D can modulate full-length 
receptor signalling and has impacts on its expression during luteolysis [248]. This data is 
intriguing but the physiological consequence of LH/CGR splice variants requires further research.  
Chapter 1: Introduction 
 
63 
 
1.15.2 Function of the LH/CGR 
The LH/CGR is essential for reproduction (Fig. 1.8). In regard its function via LH in females, it is 
essential for the regulation of ovulation during normal menstrual cycles. In brief, during the 
course of the cycle, gonadotrophin releasing hormone (GnRH) acts on the cells of the anterior 
pituitary and causes the release of both FSH and LH which in turn are required for follicular 
growth and estrogen secretion in the ovary. As the levels of estrogen rise during the middle of the 
cycle, the LH surge occurs which terminates FSH-mediated steroidogenesis and follicular growth 
and simultaneously promotes somatic cell differentiation into luteal cells [9, 249]. The high level 
of LH also causes gene expression changes which then ultimately cause follicle rupture and 
ovulation [250]. Ovulation requires a step-by-step process of oocyte meiosis resumption, 
expansion of cumulus granulosa cells and lastly, follicular wall rupture, which allows the oocyte 
to be released.  
In males, the signalling of LH via the LH/CGR is required for androgen production in the 
Leydig cells of the testis. Chronic actions of LH are required to maintain normal Leydig cell 
morphology and promote the expression of steroidogenic enzymes which are required for the 
synthesis of testosterone from cholesterol [251-253]. Acutely, LH causes the transfer of 
cholesterol to the inner mitochondrial membranes of Leydig cells which is subsequently 
converted to pregnenolone by cytochrome P450 cholesterol side-chain cleavage enzyme 
(P450scc). Pregnenolone is then converted to testosterone in the endoplasmic reticulum by 
steroidogenic enzymes and this process is indispensable for spermatogenesis [252]. In LH/CGR 
knockout mouse models (LuRKO mice), Leydig cells are much smaller in size and fewer in 
number and testosterone production is 20-30 times lower than in wild-type mice [254, 255]. In 
addition, case reports in humans with Leydig cell hypoplasia have been shown to result from 
mutations in the LH/CGR gene [256].  
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In regard to hCG, released by the trophoblast, the classic role is to mediate progesterone 
production from corpus luteum during pregnancy [257]. Both LH and hCG act via signalling 
through the LH/CGR and multiple signalling cascades are known to be involved in mediating 
these functions.  
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Figure 1.8. Functions of the LH/CGR in human reproduction via LH and hCG. LH acts via the 
LH/CGR to produce testosterone in male and to trigger ovulation in females. hCG is essential during 
pregnancy to maintain progesterone production from the corpus luteum. See text for further details on 
these functions.  
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1.15.3 LH signalling and oocyte maturation  
The LH/CGR is classically known to be coupled to the G-protein Gαs in order to increase levels 
of intracellular cAMP, which is in general regarded to be the main mechanism by which the 
receptor exerts its function. An important function of this pathway is to activate the expression of 
EGF-like growth factors in granulosa cells, which then go on to transactivate the EGF receptor in 
mural and cumulus cells which surround the oocyte [250]. The ERK1/2 MAPK cascade is then 
activated causing the expression of several genes which aid in cumulus expansion [258, 259]. LH 
also aids in reinitiating meiosis in the oocyte by indirectly reducing intraoocyte cAMP levels. It 
does so by again working through the EGF network, causing a decrease in cGMP levels in mural 
and cumulus granulosa which leads to phosphodiesterase 3A (PDE3A) activity, thus reducing 
oocyte cAMP levels [250, 260, 261]. During rupture of the follicular wall, which is LH-
dependent, the expression of the progesterone receptor in mural granulosa cells is essential as this 
enhances expression of proteins, such as metalloproteases, required for this process [262]. Studies 
have shown that this may be dependent on not only Gαs activity but also on Gαq/11, but a 
prerequisite of coupling with this G-protein is a high number of LH/CGR as well as a high 
concentration of ligand [263]. Gαq/11 coupling was recently shown for the first time in vivo in a 
granulosa specific Gαq/11 knockout mouse model, where female mice had lack of follicular 
rupturing, reduced progesterone receptor expression and severe subfertility [264]. Overall, these 
signalling cascades including others [250] can act in parallel, or in a sequential manner, and 
ultimately converge together in order to propagate the signalling of LH from the outer cells of the 
follicle to the oocyte.  
1.15.4 LH signalling and steroidogenesis 
In regard to LH signalling in males, Gαs coupling is the prominent pathway and the induction of 
steroidogenesis relies primarily on the cAMP-PKA pathway which initiates the expression as 
well as regulation of Steroidogenic Acute Regulatory protein (StAR), steroidogenic cytochrome 
P450 (CYP) enzymes and contributes to intracellular increase of calcium [265, 266]. The latter 
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has also recently been shown to be partially dependent on activity of PKC [267]. Further, it is 
also known the PDEs can modulate the signalling of LH within Leydig cells in order to govern 
the duration, intensity and possibly desensitisation of the LH signal [268].  
1.15.5 hCG signalling in the ovary and establishment of pregnancy 
As mentioned previously, due to the structural and stability differences of LH and hCG, their 
signalling potencies are known to differ [98], however much of the signalling pathways they 
activate are the same. hCG is rapidly able to activate ERK1/2 and cAMP in porcine and human 
granulosa cells [269, 270]. Corpus luteal treatments with hCG in vivo have been shown to cause a 
decrease in basal levels of PKA, although this does not perturb cAMP-dependent PKA activation 
and progesterone is still produced [271]. VEGF-A, a crucial component of angiogenesis in the 
ovary, is also known to be upregulated by hCG and downregulation of the LH/CGR is 
concomitant with a decrease in VEGF-A expression [272]. The key role of hCG however is to 
maintain progesterone production during pregnancy.  
1.15.6 LH/CGR homo- and heterodimers 
As described in section 1.14.3, GPCRs have the ability to form complexes with identical GPCRs 
and often different subtypes and this di/oligomerisation is also known for the LH/CGR. Co-
immunoprecipitation experiments have shown the latter and that LH/CGR dimers increase and 
stabilise with agonist addition [273]. This was functionally demonstrated when a hormone 
binding-deficient LH/CGR mutant was co-expressed with a signalling-deficient LH/CGR mutant 
in HEK293 cells and cAMP signalling was able to be induced compared to single expression of 
these constructs where signalling could not occur [274]. This has also been shown in vivo using 
transgenic mice co-expressing the signalling and binding-deficient LH/CGR mutants where 
normal functions of LH were restored [275]. An elegant study has recently demonstrated via 
super-resolution microscopy that these mutants preferentially form oligomers rather than dimers 
and also showed that these associations can occur at multiple receptor interfaces thus is 
Chapter 1: Introduction 
 
68 
 
potentially a way for the LH/CGR to finely modulate signalling [263]. The LH/CGR can also 
form heterodimers, an example being with the FSHR and by doing so, signalling via cAMP for 
both receptors is attenuated [276]. 
1.15.7 Internalisation of the LH/CGR 
As described in section 1.14.2, GPCR signalling, including that of the LH/CGR, is critically 
determined by their intracellular trafficking modes. The initial step in this process is the 
internalisation and desensitisation of activated receptors from the plasma membrane, mediated by 
various recruited adaptor proteins. The classic desensitisation adaptor proteins are the β-arrestins 
and these are indeed known to be involved in the first steps of LH/CGR internalisation. This was 
first shown in a physiological setting in porcine ovarian follicular membranes where use of 
neutralising arrestin antibodies blocked receptor desensitisation which was then rescued with a 
synthetic peptide corresponding to the antibody-binding epitope on β-arrestin-1 [277]. Later, a 
direct interaction was shown between β-arrestin-1 and the LH/CGR, which interestingly did not 
depend on receptor phosphorylation but was dependent on interactions with the third intracellular 
loop, rather than at the C-terminal tail which is common for most GPCRs [278, 279]. The same 
was then also shown for β-arrestin-2 where receptor activation, not phosphorylation, was the 
primary determinant for recruitment and subsequent receptor internalisation [280]. Functionally, 
β-arrestin-2 has shown to be an intermediary in activation of the Src kinase family member Fyn 
in response to hCG in MA-10 Leydig cells [281]. 
For the LH/CGR, as well as some other GPCRs, it is now recognised that another player 
in this process of internalisation is the ADP-ribosylation factor (ARF) GTPase, ARF6 [282, 283]. 
Located at the cell periphery and by cycling between active GTP- and inactive GDP-bound states, 
ARF6 mediates receptor internalisation and actin cytoskeletal rearrangements beneath the plasma 
membrane [284]. Use of inhibitory peptides of ARF6 or knockdown by siRNA has shown that 
this severely impairs agonist induced LH/CGR internalisation and desensitisation and increases 
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levels of intracellular cAMP due to receptor surface restriction in HEK293 cells [285]. ARF6 
activation is also thought to mediate the release of plasma membrane-bound β-arrestin required 
for LH/CGR desensitisation [286]. Additionally, ARF6 is implicated in both clathrin-independent 
and clathrin-dependent endocytosis of GPCRs, so it may mediate the mechanism of endocytosis 
of the LH/CGR as it is known to undergo clathrin-dependent endocytosis [287, 288].  
1.15.8 Post-endocytic trafficking of the LH/CGR 
Knowledge of how the LH/CGR may be controlled on the level of endocytic sorting first came 
about through studies that have shown that only a small amount of human LH/CGR is directed to 
the lysosomal pathways following internalisation and the majority is recycled back to the cell 
surface. The first study that recognised this used receptor chimeras of the rat LH/CGR with the 
human LH/CGR. The rat variant is known to poorly recycle and be degraded following 
internalisation and therefore results in a net loss of cell surface receptor [289] but the human 
variant on the other hand is distinct from the rat LH/CGR in that it readily recycles upon agonist 
induced internalisation [290]. Chimeras of these two receptors allowed the identification of a 
GTALL amino acid sequence located on the C-terminal tail of the human receptor which, when 
grafted on to the rat LH/CGR, induced its recycling and prevented degradation [290]. It was then 
later found that two residues of the last 17 residues of the C-terminal tail, cysteine (amino acid 
699) and leucine (at amino acid 683), present in the LH/CGR were also responsible for recycling 
since simultaneous removal or mutations of these caused lysosomal re-routing of the receptor 
[291]. Further, merely grafting the last 17 residues of the human LH/CGR to the mouse δ-opioid 
receptor, which undergoes degradation rather than recycling, allows it to undergo recycling back 
to the cell surface [291].  
1.15.9 The Very Early Endosome 
In addition to the above, studies using yeast two-hybrid screens have shown that certain regions 
of the C-terminal tail are responsible for binding to the PDZ domain containing protein GIPC 
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(GAIP-interacting protein C terminus) and mutation of the last four residues of the human 
LH/CGR reduced this binding. Importantly, receptor recycling and maintenance of cell surface 
receptor levels were greatly reduced if the GIPC-LH/CGR binding was impaired by these C-
terminal mutations [292]. This data was consistent with data from other GPCRs, where the PDZ 
ligands located on the C-terminal tail of receptors prove critical for their trafficking and function. 
GIPC was originally identified as a protein which binds to the C-terminal of GAIP, which is a 
member of the RGS (regulators of G-protein signalling) family and known to directly interact 
with Gαi via its RGS domain [293]. The same laboratory had previously found that GAIP is 
membrane anchored and localises to the membranes of clathrin coated vesicles, highly relevant 
for GPCR related studies where many GPCRs undergo clathrin mediated endocytosis [294, 295]. 
GIPC has been implicated in a number of cellular processes including the sorting of proteins in 
the biosynthetic pathway, for example by modulating the cell surface expression of the TGFβ 
type III receptor [296], clustering receptors with signalling molecules, such as the tyrosine kinase 
receptor TrkA [297], in endocytic compartments with G-proteins [298] and recruitment of the 
motor protein myosin 6 during receptor internalisation [299, 300].  
Recently, data from our laboratory has confirmed the aforementioned study that GIPC 
directly interacts with the LH/CGR and has also shown that it is not only responsible for the 
recycling of this receptor, but re-directs it to a previously unidentified endosomal compartment 
upstream from the early endosome (EE), termed the very early endosome (VEE), and this 
compartment is also the site from where it undergoes recycling [301] (refer back to Fig. 1.7). This 
compartmentalisation was separate from the prototypical β2AR, which localises primarily to the 
EE and then rapidly recycles. The VEE is a distinct compartment from the EE and does not 
contain the known classical EE markers namely EE antigen 1 (EEA1) and phosphatidylinositol-3 
phosphate [302, 303] and was initially identified due to its considerably smaller size. It had been 
previously documented that there are subpopulations of EEs thought to be EE precursors and 
these bind to the effector protein of the GTPase Ras related protein Rab5 and APPL1 (Adaptor 
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protein containing PH domain, PTB domain and Leucine zipper motif) [304]. However, the 
LH/CGR located to endosomes positive for APPL1, but did not require Rab5 for activity, 
indicating that the receptor may localise to distinct pre-EE compartments. Additionally, routing to 
the VEE required GIPC since preventing the LH/CGR interaction with GIPC forced the receptor 
into an EE compartment, thus GIPC is required for the sorting as well as recycling of the 
receptor. This study also highlighted how sequence-directed sorting does not just occur from the 
EE but from other compartments and indeed it has been shown recently for the β1AR [305].  
Importantly, the VEE not only represented a sorting station but provided a way in which 
LH/CGR signalling could be spatially regulated. When the LH/CGR was prevented from entering 
the VEE, either by GIPC ablation or truncations in the C-terminal tail of the receptor, the ERK1/2 
signalling profile became significantly different, from being sustained to transitory. Therefore, 
this signifies how compartmental bias can occur across distinct endosomal populations. In other 
systems, APPL endosomes have been shown to be signalling hubs for other receptors including 
the epidermal growth factor receptor (EGFR), tropomyosin receptor kinase A and the adiponectin 
receptor, and in some instances may be essential for cell survival [306-309]. The downstream 
cellular outcomes resulting from the LH/CGR signalling via the VEE is not yet known, but the 
LH/CGR does signal in a sustained manner in other cellular platforms, such as in granulosa cells. 
The latter attenuates aromatase expression and it may be that this is due to the sustained ERK1/2 
signalling originating from the VEE [98]. In sum, the VEE represents a novel way in which 
hormone signalling can be governed and it is possible that re-routing the receptor away from the 
VEE, or retention in the VEE, could underlie the pathology of some diseases, for example, 
polycystic ovarian syndrome (PCOS), where theca cells exhibit higher sensitivity to LH [310].  
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 Clinical perspective  1.16
Worldwide many couples are not able to conceive naturally due to infertility or miscarriage, 
which can cause psychological and physical trauma, and has both social and economic 
implications [311]. Assisted reproductive techniques, including in vitro fertilisation (IVF) and 
embryo transfer techniques are widely used and although their success rates are improving, 
implantation remains the limiting step in their success [312, 313]. Successful implantation 
requires both a viable embryo and a receptive endometrium. In addition to this, there must be a 
reciprocal dialogue at the feto-maternal interface. Therefore, to improve pregnancy success rates 
and prevent miscarriage, research efforts have been aimed at gaining a clearer understanding 
about the mechanisms involved during the dynamic process of implantation via the use of in vivo 
animal models and in vitro cell culture models. Despite the vast amount of research, our 
knowledge of the implantation process has not yet been translated into useful clinical applications 
in order to identify biomarkers of pre-receptive or receptive endometrium, thus more study is 
needed in this area [8]. 
1.16.1 Fertility and Infertility 
Fertility can be measured by time-to-pregnancy (TTP), which is expressed in the monthly 
fecundity rate (MFR), and is only approximately 20% in humans [311]. On the basis of the MFR, 
fertile couples will have a 74% success rate of conceiving after 6 months and 100% success rate 
of conceiving after 24 months [2]. Subfertility and infertility represents ~18% of couples. MFR 
rates for subfertile couples can range between 5 to 1% in severe cases. In addition to this, ~3% of 
the population is classed as superfertile and this is characterised as having an MFR of 60% or 
above [2, 311]. Infertility is defined as the inability to fall pregnant within a year without using 
contraceptives and in couples of fertile age, this affects 10% of the population [314]. 
Approximately over a third of infertility cases are caused by male factors, over a third by female 
factors and approximately a fifth of cases are idiopathic [315]. Male factor infertility can be 
caused by sperm and genetic defects or are unexplained [316]. Female factor infertility can be 
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due to a number of reasons such as neuroendocrine, immune and reproductive tract disorders 
[311]. Polycystic ovarian syndrome (PCOS) is a major cause of infertility and over 90% of 
anovulatory women presenting in infertility clinics have PCOS [317]. Other major factors include 
endometriosis, which affects 6-10% of women with reproductive age [318] and tubal factor 
infertility, but in some cases the causes are unknown [319].  
1.16.2 Recurrent Miscarriage 
Besides subfertility and infertility, humans have an extraordinarily high rate of embryo wastage 
and pregnancy loss, estimated to be 30% prior to implantation (termed pre-implantation loss), an 
additional 30% before 6 weeks gestation (termed early pregnancy loss) and 10% of clinical 
pregnancies, normally before 12 weeks gestation [2, 315]. Furthermore, some women will suffer 
from recurrent miscarriages (RM) and this affects 1-2% of the population and is defined as three 
or more consecutive miscarriages in Europe [320]. In general, miscarriage is attributed to uterine 
factors or either chromosomal or developmental embryonic abnormalities. Currently there are no 
prevailing or specific identifiers for women with RM, although there are a number of endocrine, 
immune, genetic and anatomical disorders that have been implicated as causes [320]. The general 
concept of poor embryo quality control is thought to be the main causal factor [321]. It has been 
reported that women who have RM, in particular those who have reported a high number of 
pregnancy losses, can experience remarkably high conception rates. Therefore, a significantly 
high number (40%) of RM patients are deemed to be superfertile [113].  
Research into RM has focussed on oocyte quality, sperm defects, embryonic factors, 
systemic factors and endometrial defects. It is thought that some patients with RM may suffer 
from premature ovarian aging, which ultimately results in a reduction in both oocyte number and 
quality [322]. The role of sperm in RM is not yet defined and it is controversial as to whether 
sperm defects are a factor although recently it has been reported that sperm DNA fragmentation 
may correlate with increased miscarriage [323]. Pre-implantation screening to detect embryo 
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aneuploidy is thought to improve rates of pregnancy and reduce miscarriage rates but use of this 
is under debate due to lack of evidence of efficiency in RM patients [324]. In addition, even in 
young fertile women, embryo chromosomal abnormalities are exceptionally high (90%) 
suggesting that this is likely not to be the cause of RM and supports the concept instead of 
abnormal embryo quality control [325]. Systemic factors have been linked to thyroid 
abnormalities, PCOS and insulin resistance to RM, although treatments for these to reduce 
miscarriage rates still remain controversial [320]. 
Besides the above, a large proportion of research has investigated endometrial defects as 
well as the interactions that occur at the embryo-endometrial interface and how these may be 
perturbed in women with recurrent miscarriage. In order to sense and reject or accommodate an 
implanting blastocyst, the decidualising cells must enlarge their endoplasmic reticulum and 
acquire a secretory phenotype [79]. An important study found that HESCs from RM patients 
mount an abnormal decidual response, which is associated with not a weak response to 
decidualising cues but a prolonged, disordered and highly pro-inflammatory response [326]. This 
study demonstrated that there was disordered secretion of the interleukin IL-33 and unlike control 
patient HESCs, RM HESCs were not able to transit between a pro-inflammatory and anti-
inflammatory decidual response. More recently, it has been shown that a deficiency of stem cells 
and enhanced cellular senescence can obstruct the decidualisation capacity of the endometrium 
and this may contribute to subsequent pregnancy loss [327]. Additionally, in assays which have 
analysed cell migration, HESCs from RM patients are not able to distinguish between high and 
low-quality embryos [72]. This data indicates that aberrant decidualisation may drive the inability 
to respond appropriately to implanting embryos. Indeed, RM patients have been reported to 
respond abnormally to embryonic hCG. As described previously (section 1.7.3), decidualising 
HESCs from control patient samples respond to hCG to reduce levels of decidual mRNA markers 
PRL and PROK1. In contrast, hCG induces an increase in PRL and PROK1 levels in HESCs 
from RM patients [113]. There is a remarkable lack of understanding as to how RM patients 
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respond to hCG and what remains to be identified are the reasons behind this reversed response 
and in addition if it relates to abnormal LH/CGR activity in RM patients. 
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 Hypothesis and Aims 1.17
As described in this chapter, pregnancy requires highly specialised decidualised HESCs that can 
respond to embryonic cues in a timely and appropriate manner and have the ability to 
discriminate between chromosomally or developmentally compromised embryos, thereby co-
ordinating successful implantation or rejection of an invading blastocyst. The embryo-secreted 
hormone hCG is known to be involved in maintaining progesterone production from the corpus 
luteum, but has also been purported to be involved in the embryo-endometrial dialogue, 
triggering processes which may facilitate appropriate implantation, such as the attenuation of 
decidual gene expression. Importantly, it has recently been documented that HESCs from patients 
with RM have perturbed responses to hCG and, paradoxically, increase rather than decrease 
levels of decidual markers in response to hCG.  
The cognate receptor of hCG, the LH/CGR, is expressed in HESCs but there is a 
significant gap in our knowledge of its mode of function and how it mediates the biological 
functions of hCG in the endometrium. In other cell systems, its signalling and trafficking 
mechanisms are relatively well characterised. Recent reports have shown that it internalises to a 
novel endocytic compartment the VEE, which is critical for spatiotemporal control of signalling.  
Therefore, my overall objective is to identify the hCG-induced upstream signalling pathways and 
mechanism of regulation in HESCs and if perturbations in these pathways evoke the abnormal 
downstream effects observed in RM patients.  
My specific aims are to: 
1) Characterise the fundamental hCG-induced signalling pathways in control patients. 
2) Establish the modes of endocytic trafficking of the LH/CGR in control patients and if this 
governs hCG signalling. 
3) Examine if the above pathways of hCG signalling and LH/CGR action are perturbed in 
RM.  
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 Materials 2.1
2.1.1  Primary Antibodies 
 
2.1.2 Secondary Antibodies 
   
Dilution 
 
Supplier Catalogue 
number 
WB IF 
Alexa-fluor 488 goat anti-mouse IgG Invitrogen A-11001 N/A 1:1000 
Alexa-fluor 488 goat anti-rabbit IgG Invitrogen A-11008 N/A 1:1000 
Alexa-fluor 555 goat anti-mouse IgG Invitrogen A-21422 N/A 1:1000 
Alexa-fluor 555 goat anti-rabbit IgG Invitrogen A-21428 N/A 1:1000 
Alexa-fluor 647 goat anti-mouse IgG Invitrogen A-21235 N/A 1:1000 
Alexa-fluor 647 goat anti-rabbit IgG Invitrogen A-21245 N/A 1:1000 
Horseradish Peroxidase (HRP)-
conjugated goat anti-mouse IgG 
Dako P0260 1:1000 N/A 
Horseradish Peroxidase (HRP)-
conjugated goat anti-rabbit IgG 
Dako P0448 1:1000 N/A 
    
Dilution 
Antibody Species Supplier 
Catalogue 
number 
WB IF 
APPL1 rabbit Cell Signalling 3858 1:500 1:500 
Flag rabbit Sigma F7425 N/A 1:500 
Flag M1 mouse Sigma F3040 N/A 1:500 
GAPDH mouse Millipore AB2302 N/A 1:10,000 
GIPC rabbit Santa Cruz sc-25556 1:250 N/A 
HA.11 mouse Covance MMS-101P N/A 1:500 
Phospho-
ERK1/2 (Thr202/Tyr204) rabbit Cell Signalling 9101 1:1000 N/A 
Phospho-JNK (Thr183/Tyr185) rabbit Cell Signalling 9251 1:500 N/A 
Phospho-p38 (Thr180/Tyr182) rabbit Cell Signalling 9211 1:300 N/A 
Total-ERK rabbit Cell Signalling 9102 1:1000 N/A 
Total-p38 rabbit Cell Signalling 9212 1:1000 N/A 
βArrestin 1/2 rabbit Cell Signalling 4674 1:1000 N/A 
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2.1.3 Plasmids 
Plasmid Source Source 
APPL1-GFP Pietro De Camilli  Yale University  
Flag-LH/CGR Ilpo Huhtaniemi Imperial College London 
Flag-LH/CGR-644T 
Generated in 
Hanyaloglu lab 
Imperial College London 
Flag-LH/CGR-683T This work  Imperial College London 
Flag-β2AR 
Generated in 
Hanyaloglu lab 
Imperial College London 
GIPC-GFP Marilyn Farquhar University of California, San Diego 
HA-LH/CGR-B This work  Imperial College London  
β-Arrestin1-YFP Jeffrey Benovic Thomas Jefferson University 
 
2.1.4 Kits 
Kit Supplier 
Catalogue 
number 
Direct cAMP ELISA kit Enzo Life sciences ADI-900-066 
HiSpeed Plasmid Maxi kit Qiagen 12663 
Human Phospho-MAPK Array RnD Systems ARY002B 
QIAprep Mini prep kit Qiagen 27104 
QIAquick PCR Purification kit Qiagen 28104 
Quick Ligation kit New England Biolabs M2200S 
Site-directed mutagenesis kit  Agilent Technologies 200521 
 
2.1.5 siRNA 
 
 
 
 
Target Supplier 
Catalogue 
number 
GIPC Invitrogen  HSS145785 
Non-targeting Invitrogen 12935112 
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2.1.6 Enzymes 
Enzyme Supplier 
Catalogue 
number 
RNase Out Invitrogen 10777-019 
Superscript II Reverse Transcriptase Invitrogen 18064014 
DNase I Sigma AMPD1 
SYBR Green Taq JumpStart Polymerase Sigma S4438 
ApaI restriction endonuclease New England Biolabs R0114S 
AfeI restriction endonuclease New England Biolabs R0652S 
 
2.1.7 Inhibitors 
Pathway inhibitors 
 
Supplier 
Catalogue 
number 
Working 
concentration 
Target 
Dyngo-4a Abcam ABI20689 30µM Dynamin 
SR141716A  Tocris 0923 100nM CB1 
 
 
Protease inhibitors 
   
 
 
Supplier 
Catalogue 
number 
Working 
concentration 
 
Protease inhibitor 
tablets  
Roche 4693159001 1 in 10ml 
 
Phenylmethylsulfonyl 
fluoride (0.1M) 
Sigma P7626 1:1000 
 
 
 
Phosphatase 
inhibitors 
 
 
 
 
 
 
  
 
 
Supplier 
Catalogue 
number 
Working 
concentration 
 
Sodium Fluoride 
New 
England 
Biolabs 
P0759S 5mM 
 
Sodium Vanadate Sigma S6508 2mM 
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2.1.8 Reagents 
Absolute Ethanol VWR 
30% Acrylamide/Bis solution (37.5:1) Bio-Rad 
Ampicillin Fisher Scientific 
8-Bromoadenosine-3,5'-cyclic monophosphate 
sodium salt (8-Bromo-cAMP) 
Sigma 
Agarose powder Appleton Woods 
Ammonium Persulphate Sigma 
Bovine Serum Albumin Sigma 
Bromophenol Blue Sigma 
Chloroform Sigma 
Deoxynucleotide Triphosphate (dNTPs) Life Technologies 
DEPC-treated water Sigma 
Dimethyl Sulphoxyde (DMSO) Sigma 
Dithiothreitol (DTT) Sigma 
Estradiol  Sigma 
Ethylene Diamine Tetraacetic Acid (EDTA) Sigma 
Glucose  Sigma 
Glycerol Sigma 
Hydrochloric Acid Sigma 
Insulin Sigma 
Isopropanol Sigma 
Lysogeny Broth MP Biomedicals 
Magnesium Chloride Sigma 
Magnesium Sulphate Sigma 
Medroxyprogesterone Acetate (MPA) Sigma 
Methanol VWR 
Paraformaldehyde Sigma 
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Phosphate Buffered Saline (PBS) with Ca2+ Sigma 
SDS (10% w/v) solution  BD Healthcare 
Sodium Azide Sigma 
Sodium Chloride  Sigma 
Sodium dodecyl sulphate (SDS) BD Healthcare 
Tris Base Sigma 
Tris HCl Sigma 
Triton X-100  Sigma 
Tween 20 BD Healthcare 
β-mercaptoethanol Sigma 
 
2.1.9 Cell Culture Materials 
Antibiotic/antimycotic (x100) Invitrogen  
Collagenase Type IA Sigma 
Deoxyribonuclease I (DNase I) Roche 
Dextran-coated charcoal Sigma 
Dulbecco’s modified eagles medium (DMEM) Sigma 
Dulbeccos modified eagles medium (DMEM)/F-
12 (1:1) 1 x Nutrient mixture, with L-Glutamine, 
15mM HEPES ± phenol red 
Invitrogen  
Fetal Bovine Serum Sigma 
Heat-inactivated Fetal Bovine Serum  Invitrogen  
L-Glutamine, 200mM (x100) Invitrogen  
Opti-MEM I Reduced serum media Invitrogen  
Penicillin/streptomycin Invitrogen  
Tissue Culture plasticwear Corning 
Trypsin-EDTA solution  Invitrogen  
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2.1.10 Miscellaneous 
0.22 µM syringe filters Millipore  
3-Isobutyl-1-methylxanthine (IBMX) Sigma 
96 well plates for RTQ-PCR Applied Biosciences 
Coverslips  Menzel-Glazer 
DNA stain  Invitrogen 
ECL Hyperfilm GE Healthcare 
Hybond Blotting Paper  GE Healthcare 
Hyperladder DNA markers Bioline 
Lipofectamine 2000  Invitrogen 
Lipofectamine RNAi MAX Invitrogen 
Luminata Classico HRP substrate Millipore 
Luminata Forte HRP substrate Millipore 
Nitrocellulose Blotting membranes GE Healthcare 
PageRuler Plus Prestained Protein Ladder Fermentas 
Primers  Invitrogen 
RnaseZap Ambion 
Skimmed Milk Powder Sigma  
SYBR Green PCR Mastermix  Applied Biosciences 
Trizol Reagent  Invitrogen 
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2.1.11 Buffers and solutions 
Solutions were stored at room temperature, unless otherwise stated. All buffers were made with 
deionised or distilled water.  
Phosphate Buffered Saline (PBS) 
140 mM NaCl  
2.5 mM KCl 
1.5 mM KH2PO4 
10 mM Na2HPO4 
 
Tris Buffered Saline (TBS) 
130 mM NaCl  
20 mM Tris, pH 7.6 
 
TBS-Tween 20 (TBS-T) 
0.1% Tween 20 in TBS 
 
Basic Cell Lysis Buffer 
10 mM Tris-HCl, pH 7.5 
5 mM EDTA 
150 mM NaCl 
1% (v/v) Triton X-100 
 
Protein Loading Buffer (Laemmli Buffer) (X2) 
4% (v/v) SDS 
20% (v/v) Glycerol  
Tris HCl, pH 6.8 
10% (v/v) β-mercaptoethanol  
0.002% (w/v) Bromophenol Blue 
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4 % PFA 
4% (w/v) PFA in PBS, pH 7.4 
 
Flow Cytometry Buffer 
2% (v/v) FBS in PBS 
 
Western SDS Running Buffer (X10) 
250 mM Tris Base 
1.9 M Glycine 
1% (w/v) SDS  
 
Western Transfer Buffer  
25 mM Tris Base  
192 mM Glycine, pH 8.3 
20% (v/v) methanol 
 
Western Blocking Buffer and Primary Antibody Incubation Solution  
5% (w/v) skimmed-milk in TBS-T or 5% (w/v) bovine serum albumin (BSA) in TBS-T 
 
Western Stripping Buffer 
100 mM β-mercaptoethanol 
2% (v/v) SDS 
62.5 mM Tris HCl, pH 6.8 
 
Immunofluorescence blocking solution 
2% (v/v) FBS in PBS with Ca2+ 
 
Immunofluorescence Primary Mouse Anti-Flag Antibody stripping solution 
2% (v/v) FBS in PBS  
0.04 M EDTA 
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Immunofluorescence Permeabilisation Solution 
2% (v/v) FBS in PBS with Ca2+ 
0.2% (v/v) Triton X-100 
 
Immunofluorescence Primary and Secondary antibody dilution solution  
2% (v/v) FBS in PBS with Ca2+ 
 
2.1.12 SDS Polyacrylamide Gels 
Resolving Gels 
380 mM Tris HCl, pH 8.8 
0.1% (v/v) SDS 
12% (v/v) Acrylamide Bis Solution (37.5:1) 
0.03% (w/v) APS 
TEMED added at 1:1500 
 
Stacking Gels 
130 mM Tris HCl, pH 6.8  
0.1% (v/v) SDS 
5% (v/v) Acrylamide Bis Solution (37.5:1) 
0.06% (w/v) APS 
TEMED added at 1:1500 
 
pH adjustments 
pH is the logarithm of the hydrogen ion concentration of an aqueous solution. pH is a numerical 
scale which specifies the alkalinity (basicity) or acidity of a solution. Solutions with a pH of less 
than 7 are acidic and solutions with a pH more than 7 are alkaline. Where necessary, the pH of 
solutions and buffers was adjusted. 
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2.1.13 Bacterial Media and Strains 
L-agar 
1.0% (w/v) Bacto Tryptone 
0.5% (w/v) Yeast Extract 
0.05% (w/v) NaCl 
0.1% (w/v) Bactoagar 
 
L-Broth 
1.0% (w/v) Bacto Tryptone 
0.5% (w/v) Yeast Extract 
0.5% (w/v) NaCl 
0.1% (w/v) Glucose 
 
2.1.14 Cell Culture Media 
HESC Media 
Maintenance Media 
DMEM/F-12 (with phenol-red) with: 
10% (v/v) DCC-FBS 
2 mM L-Glutamine 
Antibiotic-Antimycotic:  
  100U/ml penicillin 
  100µg/ml streptomycin 
  0.25µg/ml Fungizone Antimycotic 
2µg/ml Insulin 
1 x 10-6 M Estradiol  
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2% Media (Undifferentiated HESCs) 
DMEM/F-12 (without phenol-red) with: 
2% (v/v) DCC-FBS 
2 mM L-Glutamine 
Antibiotic-Antimycotic:  
  100U/ml penicillin 
  100µg/ml streptomycin 
  0.25µg/ml Fungizone Antimycotic 
 
2% Media (Decidualising HESCs) 
DMEM/F-12 (without phenol-red) with: 
2% (v/v) DCC-FBS 
2 mM L-Glutamine 
Antibiotic-Antimycotic:  
  100U/ml penicillin 
  100µg/ml streptomycin 
  0.25µg/ml Fungizone Antimycotic 
 0.5 mM 8-Bromo-cAMP 
 1µM MPA 
 
Transfection media  
DMEM/F-12 (without phenol-red) with: 
5% (v/v) DCC-FBS 
2 mM L-Glutamine 
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HEK293 Cells 
Maintenance Media 
DMEM (with phenol red) with:  
10% FBS 
100 U/ml penicillin/streptomycin 
Transfection Media 
DMEM (with phenol red) with:  
10% FBS 
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 Methods 2.2
2.2.1 Endometrial Samples 
2.2.1.1 Ethical Approval and Patient Recruitment 
This study was permitted by Hammersmith and Queen Charlotte’s & Chelsea Research Ethics 
Committee (Ref: 1997/5065). All participants in this study read the patient information form and 
written informed consent was obtained from all patients prior to endometrial sampling.  
2.2.1.2 Patient details 
Patients were recruited from women undergoing treatments for infertility, of which the primary 
causes were male factor infertility, tubal or filling defects or unexplained infertility. Patients were 
also recruited that did not have a history of fertility problems or had proven fertility (2 or more 
unproblematic pregnancies). The latter subsets were referred to as control patients here, since 
hCG responses have been shown to be equivalent in fertile and infertile patients [113]. Women 
who had a history of PCO, PCOS or endometriosis were excluded from the study. Recurrent 
miscarriage (RM) samples were provided by Prof. Jan Brosens (University of Warwick). These 
patients were defined as having RM if they had 3 or more consecutive miscarriages within the 
first trimester of pregnancy. Details of all patients used in this study can be found in Appendix 
III.  
2.2.1.3 Endometrial tissue samples for primary cell culture 
Endometrial biopsies were obtained by pipelle or curettage from women aged 18-42 years at the 
time of diagnostic hysteroscopy or hysterectomy. Biopsies were collected in PBS or DMEM/F-12 
with 10% (v/v) DCC-FBS and 1% (v/v) antibiotic/antimycotic.  
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2.2.2 Cell Culture 
2.2.2.1 Preparation of Dextran coated charcoal stripped fetal bovine 
serum (DCC-FBS) 
FBS contains endogenous steroid hormones that mask the effect of some exogenous ligands and 
therefore FBS used for HESC culture was stripped of small molecules by DCC treatment. 500 ml 
of FBS had 1.375g of DCC added and was heated in a water bath to 56°C for 2h, with regular 
mixing. The solution was then centrifuged at 3000 x g for 30 min and the supernatant was then 
filter-sterilised using a 0.2µm filter system into a sterile bottle before aliquoting and stored at -
20°C until use. DMEM/F12 was supplemented with 10, 5 or 2% v/v DCC-FBS for cell culture.  
2.2.2.2 Isolation of endometrial stromal cells from tissue samples 
Endometrial stromal cells were isolated using a standard protocol, the purity of which has been 
well-established. Endometrial biopsies were placed in a Petri dish and finely minced using sterile 
scalpels. The tissue was then suspended into 10 ml of digest media and added into a T-25 cm² 
flask. The digest media consisted of phenol-red free DMEM/F12 supplemented with 
antibiotic/antimycotic, 0.5 mg/ml collagenase type IA (Sigma) broke up the extracellular matrix 
and 0.1 mg/ml of DNAse I (Roche) which removed the viscous DNA released during the 
digestion when cell apoptosis takes place. The endometrial digest mix was left to digest at 37°C 
with vigorous shaking every 10-20 min. After 1 hour (or 1.5 hours for larger samples), the 
digested sample was centrifuged at 1000 rpm for 5 min and the supernatant was discarded. The 
pellet, containing stromal, epithelial, glands and blood cells, was then resuspended in 20ml of 
10% DCC-DMEM/F12 and, depending on biopsy size, the suspension was transferred into a T-25 
cm² flask or a T-75 cm² flask and placed for 1 hour in a 37°C incubator. The media was then 
removed and fresh 10% DCC-DMEM/F12 was added. This allowed for the separation of 
epithelial and stromal cells and was necessary as stromal cells adhere more rapidly than epithelial 
cells.  
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2.2.2.3 General maintenance of HESC cell cultures 
Proliferating stromal monolayers were maintained in 10% DCC-DMEM/F12 in a cell culture 
incubator which had a humid atmosphere of 5% v/v CO2 and was at 37°C. When confluent, 
stromal cells were passaged by removing media and adding 5 ml 0.05% trypsin/EDTA in PBS (at 
37°C) to wash and remove excess media. A further 5 ml 0.05% trypsin/EDTA was added to the 
flask and the cells were placed at 37°C for 5 min and gently tapped to ensure all cells were lifted 
from the surface of the flask. Trypsin activity was quenched by adding 15 ml of 10% DCC-
DMEM/F12, and the suspension was centrifuged at 1000 rpm for 5 min. Cells were then 
resuspended and reseeded out into flasks or plates at a suitable dilution. Experiments were 
performed in 6-, 12- or 24-well plates. Experiments on cells did not exceed passage 3 and were 
performed when cells reached 80% + confluency.  
2.2.2.4 Decidualisation of HESCs 
When cultures were decidualised, this was carried out in 2% DCC-DMEM/F12 media (phenol-
red free). Cells were grown to confluency, and either left untreated in 2% DCC-DMEM/F12 
alone, or were cultured in 2% DCC-DMEM/F12 media containing 0.5 mM 8-Br-cAMP and 1µm 
medroxyprogesterone acetate (MPA).  
2.2.2.5 Maintenance of HEK293 cell stocks 
HEK293 cells (human embryonic kidney cells) were grown in a monolayer in a T-75 cm² flask at 
a humid atmosphere of 5% v/v CO2 at 37°C. Cells were maintained in DMEM supplemented 
with 10% (v/v) FBS and 1% penicillin/streptomycin. Depending on growth, cell cultures were 
passaged 1-2 times per week. Briefly, the medium was removed, cells were washed with 5ml 
PBS and then 2ml 0.05% trypsin/EDTA in PBS (at 37°C) was added. The cells were incubated 
for 5 min at 37°C and the flask was tapped to ensure full removal of cells from the surface. 
Trypsin activity was stopped with the addition of 8ml of 10 % DMEM and cells were diluted and 
seeded out as appropriate. Experiments were normally carried out in 6-, 12- or 24 well plates.  
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2.2.3 Bacterial Propagation of Plasmids 
2.2.3.1 Preparation of chemically competent bacteria for transformations 
Propagation of all plasmids in this work was carried out using the Escherichia coli (E.coli) DH5α 
strain. Bacteria were thawed on ice, plated onto L-agar plates and incubated at 37°C overnight. A 
single colony was then picked and grown in 5 ml L-broth. This colony was grown at 37°C 
overnight on a rocking platform shaker. The following day, 200µl of the bacterial culture was 
added to 200 ml of L-broth and placed on a rocking platform shaker. Aliquots were taken at 
regular intervals and the OD was measured. When the OD600 reached 0.2-0.4 the culture was 
chilled on ice for 10 min before centrifugation at 1000rpm for 10 min at 4°C. The supernatant 
was removed and the pellet was resuspended in 30ml of ice-cold solution containing 100 mM 
CaCl2 and 10% glycerol. The cells were then aliquoted and snap-frozen with dry ice. This 
procedure was carried out near a flame to ensure sterility.  
2.2.3.2 Heat shock transformation of bacteria and DNA amplification 
DH5α cells (usually 50 or 100µl aliquots) were thawed on ice and 2-5µl of plasmid DNA to be 
amplified was added and gently mixed. The cells were incubated on ice for 30 min and then heat-
shocked on a 42°C heat block for 45 sec before being placed on ice for a further 2 min. 800 µl of 
L-broth was then added and the mix was placed on a rocking platform shaker for 45 min at 37°C. 
Subsequently, 200 µl of the cells were spread on appropriate antibiotic-containing (100µg/ml of 
ampicillin or 30 µg) L-agar plates and placed in a 37°C incubator overnight. The following day, a 
single colony was picked and inoculated in 200 ml of L-broth containing 100 µg/ml of ampicillin 
or 30 µg/ml of kanamycin, as appropriate, and grown at 37°C on a rocking platform overnight. 
Cells were then centrifuged at 3000 rpm at 4°C and the supernatant was removed. Amplified 
DNA was purified from this pellet using the High Speed Maxi Plasmid kit and instructions were 
followed as per the kit manual. All DNA was eluted in DEPC-treated water, purity and 
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concentration was determined using the ND-2000 spectrophotometer (NanoDrop) at A260/A280 
and A260 respectively. The ideal A260/A280 ratio is ≥ 1.8, which indicates pure DNA.  
 
2.2.4 Cloning 
2.2.4.1 HA-tagging LH/CGR-B  
The LH/CGR-B (LH/CGR with Exon 9 deleted) we obtained needed to be N-terminally HA-
tagged in order to carry out confocal imaging and Flow Cytometry experiments. To do this, I 
used a construct which had already been generated and had a HA-tag, the HA-FSHR. The full-
length LH/CGR-B was amplified from the plasmid using 5’-3’ primers containing restriction 
sequences recognised by the enzymes ApaI and AfeI (primer sequences in Appendix II), which 
were present in the appropriate regions of the HA-FSHR. This PCR reaction mix was produced as 
follows: 5 µl Q5 High GC Enhancer, 5 µl Q5 Reaction Buffer, 1 µl of each forward and reverse 
primers (at 100 µM), 1µl of Q5 High Fidelity DNA polymerase, 10 ng of LH/CGR-B template 
and made up to a total of 50µl with DEPC-treated water. The reaction mix was then subjected to 
the following cycling conditions: 95°C for 2 minutes (denaturation), 35 cycles of: 95°C for 20 
seconds (denaturation), 67°C for 30 seconds (annealing) and 70°C for 60 seconds (extension); 
followed by a final elongation step of 70°C for 10 minutes. 
The LH/CGR-B insert and the HA-FSHR plasmid were then both digested using the same 
restriction endonucleases, ApaI and AfeI. This was done by incubating 41 µl of amplified 
LH/CGR-B product with 5 µl of CutSmart Buffer and 2 µl of each of the ApaI and AfeI 
restriction endonucleases to make a final volume of 50 µl. For the HA-FSHR, the same mix was 
used with 1 µg of plasmid and made up to 50 µl with DEPC-treated water. The mixes were 
incubated for 2 hours at 37°C and the reaction was then stopped by heating to 65°C before being 
purified using the QIAquick PCR purification kit. Digested products were separated by being run 
using electrophoresis on a 1% (w/v) agarose gel containing SYBR Safe DNA Gel stain (1:10000). 
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The electrophoresis process was run for 1 hour at 100V. A molecular weight marker, 
HyperLadder, was loaded alongside the samples in order to determine size. The gel containing 
the separated digested products and the molecular weight marker was exposed to UV illumination 
and the insert (approximately 1.5kbp) and linearised plasmid lacking FSHR (approximately 
5.4kbp) were excised. The products were purified with QIAquick PCR Gel Extraction Kit and 
concentration was determined using a ND-2000 spectrophotometer (NanoDrop). 
Ligation was then carried out using the Quick Ligation Kit. 50-100 ng of linearised plasmid was 
used with a 3- or 4-fold excess of insert and the volume was then adjusted to 10 µl using DEPC-
treated water. 10µl of 2 X Quick Ligation Buffer was then added and mixed, followed by 1 µl of 
T4 DNA Ligase and further mixing. This reaction was incubated for 20 min at room temperature 
before bacterial transformation as described elsewhere. Colonies were picked and plasmid DNA 
was isolated using the QIAprep Spin Miniprep Kit. Sequencing was then carried out by Beckman 
Coulter Genomics to confirm if the cloning was successful.  
2.2.4.2 LH/CGR-644T mutant  
In order to generate the Flag-LH/CGR mutant with the large C-tail truncation, the LH/CGR-
644T, a stop-codon was introduced with site directed mutagenesis. Primers were designed so that 
this stop-codon would be introduced after the palmitoylated cysteines on the C-terminal tail 
(primer sequences in Appendix II). The design of the primers was guided by the specification 
given by the Site Directed Mutagenesis kit (Agilent Technologies) and the protocol provided in 
the kit was followed to carry out the mutagenesis. Briefly, a mix was made of the following: 5 µl 
of 10 X reaction buffer, 10 ng of Flag-LH/CGR plasmid (in pcDNA 3.1), 125 ng of LH/CGR-
644T primer 1, 125 ng LH/CGR-644T primer 2 and 1µl of dNTP. H2O was then added to a final 
volume of 50 µl. Finally, 1 µl of PfuUltra HF DNA polymerase (2.5 U/µl) was added and gently 
mixed. The following cycling conditions were then used for the reaction: 95°C for 2 minutes, 
followed by 18 cycles of: 95°C for 30 seconds, 55°C for 60 seconds, and finally 68°C for 7.5 min 
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(the latter time calculated according to plasmid size, 7.5kb). This reaction was then put on ice to 
cool it to 37°C. After the reaction was cooled, 1µl of the restriction enzyme Dpn (10 U/µl) was 
added and thoroughly mixed by gentle pipetting, this was then left at 37°C for 2 hours to digest 
the non-mutated DNA. Next, 50 µl of XL1-Blue supercompetent cells were thawed on ice and 5 
µl of the Dpn digest was added and gently mixed. Following this, the remainder of the protocol 
for transforming bacteria as described below was followed. Once bacteria were transformed, 
colonies were picked and plasmid DNA was isolated using QIAprep Spin Miniprep Kit. 
Sequencing was then carried out by Beckman Coulter Genomics (primers: universal T7 and SP6) 
to confirm that the mutation was successful.  
 
2.2.5 Transfections 
2.2.5.1 Transient transfection of plasmid DNA in HESCs  
HESCs were routinely transfected using Lipofectamine 2000. The following method describes 
transfection method for a 6-well plate but cells were also transfected in 12 and 24-well plates and 
amounts were adjusted according to surface area. Cell confluency was 85-95% for transfection. 
Prior to transfection, the media was changed to 2ml of DMEM/F12, only containing 5% DCC-
FBS, without antibiotics. For each well, a transfection mix was first made as follows: in a 1.5 ml 
eppendorf, 5 µl of Lipofectamine 2000 was added to 100 µl of Opti-MEM and in a separate 1.5 
ml eppendorf, the appropriate amount of plasmid DNA was added (typically 4 µg, see Materials) 
with 100 µl of Opti-MEM. These mixes were incubated for 5 min and then gently mixed together 
and incubated for a further 20 min at room temperature to allow the complexes to form. The 200 
µl mix was then added dropwise to the cells and incubated at 37°C with 5% CO2 for 6-8 hours. 
Depending on the experiment being carried out, the media was then changed back to general 
culture media or decidualisation media. Cells were not passaged following transfection due to 
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increased cell death. Transfections were generally carried out 48 hours prior to the experiment 
endpoint.  
2.2.5.2 Transient transfection of plasmid DNA in HEK293 cells using 
Lipofectamine 2000 
This method was the same as for HESCs (above), however the transfection media comprised of 
DMEM with 10% FBS without antibiotics and the transfections were carried out overnight, as 
opposed to 6-8 hours. Additionally, cells were transfected at 70-80% confluency and were split 
into experiment format (i.e., 6-, 12-, or 24-well plates) following transfection.  
2.2.5.3 Transfection of siRNA in HESCs  
Cells were seeded in 6-well plates or 24-well plates with coverslips, as above, and grown to 80-
90% confluency. To ensure sufficient levels of protein knockdown, cells were transfected twice 
with siRNA at 96 and 48 hours prior to experiment end-point. The method described is for a 6-
well plate, this was scaled down as appropriate for 24-well plates. As above, the media was 
changed to 2 ml of DMEM/F12, only containing 5% (v/v) DCC-FBS without antibiotics. In a 1.5 
ml eppendorf, 100 µl of Opti-MEM was mixed with 7.5 µl of Lipofectamine RNAiMAX and in a 
separate eppendorf, 100 µl of Opti-MEM was mixed with 20 µl of siRNA (at 20 µM stock). The 
two were incubated for 5 min and then mixed together and incubated for a further 20 min at room 
temperature. This mix was then added dropwise to each well and cells were incubated at 37°C 
with 5% CO2 for 6-8 hours. The media was then changed back to general culture or 
decidualisation media and cells were treated as indicated.  
 
Chapter 2: Materials and Methods  
 
98 
 
2.2.6 Protein analysis 
2.2.6.1 Protein extraction from cells for Western Blot analysis 
HESCs or HEK293 cells were grown in 6-well or 12-well plates and treated as appropriate 
(decidualised and/or transfected and/or hCG-stimulated). Cells were washed with ice-cold PBS 
and were lysed on ice by adding 50-100 μl of Basic Lysis buffer (see Materials, section 2.1.11) 
which contained protease inhibitors and, in some experiments, also contained phosphatase 
inhibitors (cell signalling assays). Cells were scraped to ensure maximum protein retrieval, 
transferred into a 1.5 ml Eppendorf tube and centrifuged at 4°C at 16,000 rpm for 10 min. The 
supernatants were transferred to new tubes on ice and either aliquoted and stored at -20°C or 
analysed for protein concentration, normalised and combined with Laemmli buffer, then heated to 
95°C for 5 min and loaded on SDS-polyacrylamide gels.  
2.2.6.2 Protein concentration determination 
In order to ensure the same amount of protein was loaded on the Western gel between samples, 
the concentration of each sample was determined using the Bradford assay reagent, which 
contains a commassie dye. When protein is added, the reagent binds to the arginine and 
hydrophobic amino acid residues of the protein, causing a colour change. The bound form of the 
dye turns blue and can be read using a spectrophotometer at 595 nm wavelength. An increased 
colour change corresponds to a more concentrated sample. To determine exact concentration, a 
set of standards were made using bovine serum albumin (BSA) provided with the kit.  
2.2.6.3 SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
Proteins were resolved on polyacrylamide gels using the Mini-PROTEAN Tetra Cell system from 
Bio-Rad. Gels were prepared using the Bio-Rad glass casting modules to form the stacking and 
resolving parts of the gel. The resolving gels were normally 12% acrylamide, 1% SDS, 375 mM 
Tris-HCl pH 8.8. The stacking gel was 5% acrylamide, 1% SDS, 125 mM Tris-HCl pH 6.8. 
These mixes were polymerised using both TEMED and ammonium persulphate (APS). Once the 
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gel had fully set, an equal amount of each sample was loaded. Pre-stained molecular weight 
markers were loaded alongside samples. Gels were run with SDS running buffer at 100 V for 20 
min. This was to ensure that all samples aligned together before entering the separating gel. The 
gel was subsequently run at 140 V for 1-2 hours, depending on the size of the protein of interest 
and the degree of separation required. Lastly, the gels were removed from the glass modules, 
ready for transfer. 
2.2.6.4 Protein transfer to nitrocellulose membranes 
Gels were transferred onto nitrocellulose blotting membranes using a wet transfer system. All 
parts of the transfer were pre-wetted with transfer buffer (TB). A ‘sandwich’ was created – 
sponge, filter paper, nitrocellulose membrane, the gel, filter paper and sponge and tightly sealed. 
This was then placed perpendicular to a voltage gradient of 100 V at 4°C for 1 hour. The 
negatively charged proteins on the gel then migrated towards the anode and were deposited on the 
nitrocellulose membrane.  
Following transfer, the membranes were removed and briefly washed with Tris-Buffered saline 
with 0.5% Tween20 (TBS-T). The membrane was then blocked in either 5% skimmed milk (from 
powder) in TBS-T or 5% BSA in TBS-T for 30 min at room temperature. The membrane was 
then washed briefly with TBS-T, placed in the primary antibody at appropriate dilution (see 
Materials) and incubated overnight on a roller at 4°C. The following day, the membrane was 
washed (3 X 15 min washes) in TBS-T, and the appropriate HRP-conjugated secondary (diluted 
in TBS-T or blocking buffer) was added for 30 min at room temperature. A further 3 X 15 min 
washes in TBS-T were carried out, and proteins were seen using Luminata Forte or Classico 
Western HRP substrate from Millipore. The membrane was subsequently exposed to 
autoradiography films or was imaged using the ImageQuant Las 4000 chemiimager (GE 
Healthcare).  
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2.2.6.5 Stripping membranes for Western Blotting  
When two proteins of the same or similar molecular weights needed to be visualised on the same 
membrane, primary and secondary antibodies were stripped off the membrane using Western 
Stripping buffer (see Materials). The buffer was first heated to 60°C, fresh β-mercaptoethanol 
was added, and membranes were incubated with this mix for 20 min on a roller at room 
temperature. The membrane was washed extensively with TBS-T (typically 6-10 washes) to 
remove any remaining stripping buffer and was re-blocked with the appropriate blocking buffer, 
primary antibody was then added as above.  
 
2.2.7 Real-Time Quantitative PCR (RTQ-PCR) 
2.2.7.1 RNA isolation and extraction  
In order to isolate RNA from HESCs, TRIzol® Reagent from Invitrogen was used. When 
handling during RNA extraction, all surfaces were decontaminated using RNAseZap. Cells that 
had been grown in a 6-well plate were treated as appropriate, washed with PBS and then 1ml of 
TRIzol at room temperature per well was added to fully homogenise the sample. The sample was 
then transferred to an RNase free 1.5 ml eppendorf tube. The protocol from Invitrogen was then 
followed to isolate RNA. Briefly, TRIzol homogenised samples were incubated at room 
temperature for 10 min, 200 µl of chloroform was then added and the tube shaken vigorously for 
15 sec before a brief 3 min incubation. The sample was then centrifuged at 12000 xg for 20 min 
at 4°C, separating the solution into three phases: a lower red, phenol-chloroform phase, an 
interphase, and a colourless aqueous phase. The upper aqueous phase contained RNA and so was 
removed and placed in a clean eppendorf and 500 µl of isopropanol was added. This mix was 
then incubated for 10 min at room temperature before centrifugation at 12000 xg for 20 min at 
4°C. Following this, the supernatant was discarded the white RNA pellet left behind was 
resuspended in 75% v/v ethanol and centrifuged again at 7500 xg for 10 min at 4°C. This 
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washing step was repeated twice more. The pellet was then air-dried to ensure the removal of any 
residual ethanol before dissolving in 17 µl of DEPC-treated water. To remove any DNA 
contaminants the RNA was DNase treated by adding 2 µl of DNase I Reaction Buffer (Sigma) 
and 1 µl of DNase I (Sigma), the tube was gently flicked and left at room temperature for 15 min. 
Stop solution (Sigma) was then added and the sample was vortexed before being heated to 65°C 
to ensure quenching of enzyme activity. RNA concentration was then determined at A260 using a 
ND-2000 spectrophotometer (NanoDrop).  
2.2.7.2 cDNA synthesis 
Typically, between 1–2µg of isolated RNA was used for reverse transcription by Superscript 
First-Strand synthesis kit. The following method was used for the reverse transcription of all 
RNA. RNA was mixed with 1 µl of dNTP mix and 1 µl of oligo (dT) 12‐18 (0.5µg/µl) and 
diluted in DEPC-treated water to a final volume of 13 µl. This was then heated using a thermal 
cycler and kept at 65°C for 5 min before the tubes were placed on ice. Following this, 2 µl of 0.1 
M DTT, 4µl of 5 X First Strand buffer, 1 µl of RnaseOUT and 1 µl of 200U/µl Superscript II 
were added and the mixture was heated to 42°C for 60 min. The reactions were stopped by 
incubation at 70°C for 15 min. cDNA was then stored at -20°C until required.  
2.2.7.3 RTQ-PCR analysis 
Gene expression was quantitated by measuring mRNA levels. This was carried out with the 
cDNA generated as described above and then relative quantitation of the target template by RTQ-
PCR using forward and reverse primers designed specifically for the gene of interest. In contrast 
to conventional PCR methods, RTQ-PCR is highly sensitive and precise and allows 
quantification of the amount of fluorescence produced at each cycle of the PCR reaction, as 
opposed to only an end-point read out.  
RTQ-PCR was carried out in 96-well plates using a total volume of 20 µl per reaction, of which 
10µl was Jumpstart SYBR‐Green PCR Mastermix and 1% ROX. To each reaction, 300 nM of 
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forward and reverse primers were added and 5µl of appropriately diluted cDNA. The volume was 
made up to 20 µl by addition of DEPC-treated water. Each reaction was carried out in triplicate in 
the same plate. To ensure there was no non-specific interaction of primers, 5 µl of DEPC-water 
was added in place of cDNA for a set of control wells for each primer set and this was done 
routinely in each experiment. For the reaction, the ABI StepONE sequence detection system was 
used with the following cycling conditions: 95°C for 15 min (denaturation), 40 cycles of 94°C for 
15 sec (denaturation) and 60°C for 30 sec (annealing), and finally 72°C for 30 sec (extension). 
The annealing temperature was changed according to the primers being used. Details of primer 
sequences are detailed in Appendix II.  
To analyse the results, the ΔCT and ΔΔCT method was used. The CT is the threshold cycle and 
decreases linearly with increasing amount of PCR target. It represents the number of cycles 
necessary in the reaction to achieve a designated level of fluorescence during the exponential 
phase of the target amplification. The CT values obtained from the gene of interest were 
normalised to CT values from two housekeeping genes, L19 and GAPDH and a control sample 
(for example, undifferentiated) and represented as fold-change over control.  
2.2.7.4 RTQ-PCR Primer Design and Optimisation 
The Prolactin (PRL), superoxidase dismutase 2 (SOD2) and prokineticin 1 (PROK1) primers 
used for RTQ-PCR in this work had previously been designed by Madhuri Salker (Imperial 
College London) and optimal conditions for these primers using the above method had already 
been established. Details of these are in Appendix II.  
The primer sequences used for the identification of the four splice variants of the LH/CGR had 
previously been generated by Dickinson, R.E., et al. [248]. Prior to use of these in all samples, the 
concentrations to be used were optimised by using concentrations between 100 nM to 600 nM 
and also using different amounts of diluted cDNA – 1:5, 1:10, 1:15 and 1:20. The best primer 
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concentration and cDNA amount was picked according to the one that gave the lowest Ct value 
and highest fluorescent values.  
 
2.2.8 Human Phospho-MAPK array  
Two patient samples were analysed using this array – a fertile patient and a recurrent miscarriage 
patient. HESCs from these samples were seeded into 6-well plates to allow for 0, 5 and 30 min 
hCG stimulation times (2 wells per condition). Cells were grown to confluency in general 
maintenance media and then decidualised for 72 hours or left undifferentiated as described 
previously. At 72 hours, media was then changed to DMEM/F12 media with 2% (v/v) FBS with 
antibiotics only and no cAMP or MPA for 6 hours in order to ensure the effects of hCG were not 
masked and to bring down any basal phosphorylation by these two components. Cells were then 
treated with 10nM hCG at the appropriate time-points and washed twice with ice-cold PBS on 
ice. Lysis Buffer 6 (provided with the array kit) was added (100µl/well) and cells were then left 
on a rocking platform shaker on ice for 20 min before being scraped and the lysates being 
transferred to pre-chilled 1.5ml eppendorf tubes (the lysates were pooled from duplicate wells for 
each time point). The lysates were then centrifuged at 14000 rpm at 4°C for 10 min and the 
supernatant was transferred to a new tube and the remaining pellet discarded. Total protein was 
then quantified as described previously and a total of 150µg of lysate was diluted in a total of 
400µl of Lysis Buffer 6 and incubated with the Phospho-MAPK array kit. The remainder of the 
procedure was carried out according to the manufacturer’s protocol. Membranes were then 
scanned and densitometry of spots was carried out using the ImageJ software. Normalisation was 
made to the reference spots as recommended by the kit.  
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2.2.9 Intracellular cAMP accumulation assays 
For cAMP assays, HESCs were grown in 6- or 12-well plates to confluency and decidualised for 
72 hours or left undifferentiated, as described previously. Prior to the experiment, IBMX (a 
specific inhibitor of cAMP phosphodiesterases) was added to DMEM/F12 with 2% (v/v) DCC-
FBS and antibiotics to make a final concentration of 0.5mM. This was then incubated in a water 
bath at 37°C to ensure full solubilisation of the IBMX powder. The cells were pre-treated for 5 
min with this media before being treated with hCG (10 nM), Forskolin (3 µM) or a combination 
of both for 30 min. The latter components were made up in the IBMX-containing media. After 30 
min, cells were quickly washed with ice-cold PBS and then lysed in 0.1 M HCl with 0.2% 
TritonX-100 (100µl/well) before being incubated at room temperature for 20 min. Plates were 
then scraped and lysates transferred to 1.5ml eppendorf tubes and centrifuged at 14000 rpm for 
10 min. The supernatant was transferred into a fresh eppendorf and the pellet discarded. The 
lysates were diluted as appropriate (generally 1:3) in 0.1M HCl with 0.2% TritonX-100 and were 
then analysed following the protocol provided by the kit in the non-acetylated format. The results 
were normalised to protein concentration which was determined as described previously. In some 
instances, inhibitors were used in the experiment and in each case these were added prior to 
IBMX-media pre-treatment and remained in the media during hCG and Forskolin exposures. For 
the CB1 antagonist, SR141516A, cells were treated for 3 hours prior to stimulations and for 
Dyngo-4a this was 15 min prior to stimulation.  
 
2.2.10 Flow Cytometry 
HEK293 cells were grown in 6-well plates to ~70% confluency and transfected for the Flag-
LH/CGR or HA-LH/CGR-B or both before being subject to analysis by flow cytometry to assess 
receptor surface expression. In order to do this, cells were pre-treated with rabbit anti-Flag 
(1:500) and/or mouse anti-HA (1:500) antibodies diluted in DMEM supplemented with 10% (v/v) 
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FBS at 37°C for 15 min. Cells were then washed 3 times with ice-cold PBS and harvested in 
500µl of FACS buffer which consisted of ice-cold PBS with 2% (v/v) FBS. Cells were 
transferred to round bottomed polypropylene FACS tubes, centrifuged at 1000rpm at 4°C and the 
supernatant was then removed and resuspended in FACS buffer containing the appropriate 
fluorescently conjugated secondary antibodies (either 488 or 647 fluorophores). The cells were 
then incubated for 1 hour on ice and kept in the dark during this period. Subsequently, the cells 
were centrifuged again as before and then resuspended in 1ml of FACS buffer. The latter washing 
step was carried out 3 times in total and the cells were then resuspended in a final volume of 
300µl. These cells were analysed on a FACS Calibur Flow Cytometer. Cells that had not been 
exposed to any antibodies or only secondary antibodies alone were used for controls, the latter 
allowing normalisation to basal cell fluorescence intensity.  
 
2.2.11 Microscopy 
2.2.11.1  Confocal immunofluorescent microscopy 
Cells were cultured in 12-well or 24-well plates with glass coverslips in DMEM-F12 with 10% 
(v/v) DCC-FBS, 1% (v/v) antibiotic/antimycotic, 1% (v/v) L-glutamine, 1 nM estradiol, 2 mg/ml 
insulin. At confluency, cells were changed to 2% (v/v) DCC-FBS, 1% (v/v) 
antibiotic/antimycotic and 1% (v/v) L-glutamine and remained undifferentiated or were 
decidualised with the addition of cAMP and MPA. For HEK293 cells, media was DMEM with 
10% (v/v) FBS and 1% (v/v) penicillin/streptomycin. Cells were transfected with the appropriate 
plasmid DNA / siRNA using the Lipofectamine 2000/ RNAi Max protocol, as described 
previously. In some conditions, cells were treated with ligand (hCG/isoproterenol) for various 
time-points as indicated. When staining for exogenous Flag-tagged receptors, an anti-Flag M1 
(Sigma) or anti-HA antibodies were added to the cells 15 min prior to agonist addition in order to 
label the cell-surface receptor. Following agonist treatment, cells were washed with ice-cold PBS. 
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For experiments where the anti-Flag M1 antibody was used, the PBS contained Ca2+, as binding 
of this antibody is Ca2+-dependent. In some circumstances, cell surface anti-Flag antibody was 
stripped by quickly washing the cells 5 times with PBS containing 0.05M EDTA (a Ca2+ 
chelator). Cells were then fixed with 4% PFA for 20 min at room temperature, followed by 
incubation with a blocking buffer consisting of PBS (-/+Ca2+) with 2% FBS. In order to allow 
binding of secondary antibody to intracellular primary antibodies, cells were permeabilised with 
PBS (-/+Ca2+) supplemented with 2% FBS and 0.2% TritonX-100 for 15 min at room 
temperature. Cells were then washed 3-4 times to remove residual permeabilisation buffer and, if 
required, were incubated with primary antibody diluted in blocking buffer for 1 hour at room 
temperature or overnight at 4°C. Cells were then washed 4 times with PBS (-/+Ca2+) before 
adding immunofluorescent secondary antibodies at room temperature for 30 min. The secondary 
antibodies were Alexa Fluor 488, 555 or 694 goat-anti rabbit or goat-anti mouse. Following 4 
further washes with PBS (-/+Ca2+) cells were mounted onto glass slides using Fluoromount 
reagent before being imaged with the Leica SP5 confocal microscope using a 60 X oil objective. 
2.2.11.2  Live-cell Total Internal Reflection Fluorescence (TIRF) microscopy 
For live-cell TIRF experiments, HESCs were cultured in 35mm glass bottom imaging dishes 
(MatTek) in DMEM-F12 with 10% (v/v) DCC-FBS, 1% (v/v) antibiotic/antimycotic, 1% (v/v) L-
glutamine, 1nM estradiol, 2mg/ml insulin. At confluency, cells were changed to 2% (v/v) DCC-
FBS, 1% (v/v) antibiotic/antimycotic and 1% (v/v) L-glutamine and remained undifferentiated or 
were decidualised with the addition of cAMP and MPA. They were cultured in this media for 72 
hours prior to imaging. 48 hours prior to imaging, HESCs were transfected with 4µg of SEP-
LH/CGR construct using the Lipofectamine 2000 protocol, as described previously. 
Approximately 15 min prior to imaging, culture media was replaced with Opti-MEM Reduced 
serum media which was optimal for visualisation of fluorescence. Imaging was then performed 
using a Zeiss Elyra PS.1 microscope controlled at 37°C with 5% CO2. SEP-LH/CGR-expressing 
cells were first identified under wide-field fluorescence and brought into focus using a TIRF oil 
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immersion objective. Illumination was then switched to TIRF. The TIRF angle was then changed 
as appropriate so that recycling events could be seen. Movies of whole cells were taken for 60 
sec, at 10 frames per second (fps).  
2.2.11.3  Quantitation of exocytic events from TIRF movies 
Exocytic events were identified and counted on a whole cell basis, for the entire 60 sec movie. In 
order to do this analysis, czi images were exported and viewed on the ImageJ/FIJI software (NIH 
program). Events were defined as a transient increase in fluorescence at the cell surface, which 
then diffused. Total number of events per cell was then calculated, and this was normalised to cell 
surface area. 
2.2.12 Statisical Analysis 
All data was analysed using the statistical program Graphpad Prism (Graphpad Software Inc, CA, 
USA). The paired Students t-test was used for all analyses.  
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 Introduction 3.1
In the human endometrium, one of the most remarkable features is the acquisition of a receptive 
phenotype which, irrespective of pregnancy, occurs in the mid-secretory phase of the cycle and 
coincides with transformation of the stromal compartment into highly specialised decidual cells. 
This decidual process is indispensable for pregnancy and involves intense tissue remodelling and 
vast reprogramming of the stromal cell transcriptome and proteome [8]. Decidual cells act as an 
interface to the invading blastocyst by their unique ability to respond to embryo-derived signals 
and facilitate implantation [10].  
As detailed in Chapter 1, one of the earliest embryonic signals is hCG, which is known to 
rescue progesterone production by the corpus luteum. However, evidence also suggests that hCG 
can directly signal to the endometrial stromal cells and modulate the uterine environment in 
preparation for implantation by, for example, protecting the decidua against oxidative stress, 
promoting angiogenesis and limiting cell death responses [328]. Its cognate receptor, the 
LH/CGR, is a key Gαs-coupled GPCR known to be indispensable for maturation and function of 
the ovary and testis [237]. Members of the GPCR superfamily have a multitude of functions in 
vivo and, mirroring this, are known to demonstrate complex and diverse signalling pathways. 
GPCRs can activate both G-protein and non-G-protein coupled signalling pathways, form homo- 
and heterodimers and an individual GPCR may elicit ligand-specific and tissue-specific signalling 
profiles [329]. It is also well established that signalling by some GPCRs can be modulated via 
endocytosis – a simple example being that of signal attenuation following the removal of a GPCR 
from the plasma membrane [189]. It has recently become clear that endocytosis plays a much 
broader role in the organisation of receptor signalling circuits which control GPCR signalling 
both spatially and temporally and therefore signalling and endocytosis is now viewed as a single 
network [330]. One route which follows receptor endocytosis is receptor exocytosis (also known 
as receptor recycling or resensitisation) which can be under control by specific receptor sequence 
motifs and specific adaptor protein interactions. Receptor recycling, as well as sorting, can be a 
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fast and continuous process and minor changes in their rates can cause significant changes in 
plasma membrane localisation of signalling receptors, the end result being dramatic changes to 
cellular sensitivity. Previous studies have aimed to elucidate in detail the mechanisms involved in 
this process and how physiological stimuli might regulate these mechanisms [220]. Furthermore, 
subversion of membrane trafficking, and therefore signalling pathways, and the sorting of cargo 
has been implicated in a number of clinical conditions.  
Evidence has shown that hCG plays a paracrine role at the embryo-endometrium interface 
but surprisingly little is known about the signalling pathways it activates in HESCs or the 
trafficking mechanisms of the LH/CGR through which it mediates its effects. Accordingly, in this 
chapter, I elucidate some of the endogenous signalling pathways hCG exerts on HESCs as well as 
the trafficking and recycling profiles of the LH/CGR. I will also investigate whether LH/CGR 
activity is altered by stromal cell decidualisation. 
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 Results 3.2
3.2.1 Treatment of HESCs with cAMP and MPA induces expression of decidual 
gene markers 
A large part of this project is to unravel the mechanisms by which hCG might mediate its 
function during implantation via signalling to decidual stromal cells. Decidualisation in vivo is 
known to be able to be recapitulated in vitro by the addition of a combination of exogenous cues 
such as progesterone, estradiol and relaxin to isolated HESCs over time courses lasting between 
3-20 days [8]. Most common is the simultaneous use of analogues of cAMP and progesterone, 8-
Bromo-cAMP and medroxyprogesterone acetate (MPA) which are known to induce the 
expression of decidual mRNA as early as 1-3 days after addition [42, 58]. In order to confirm that 
decidual markers are induced in HESCs in my experiments, isolated HESCs were treated for 72 
hours with 8-Bromo-cAMP (0.5mM) and MPA (1µM) or left untreated. The time point of 72 
hours was chosen because, in addition to the previously reported robust induction of decidual 
markers, this time point is sufficient to observe attenuation of decidual mRNA when co-treated 
with hCG [113]. Expression of decidual markers prolactin (PRL), prokineticin 1 (PROK1) and 
superoxidase dismutase (SOD2) was analysed via RTQ-PCR. IGFBP1 was not measured here as, 
although this is a classic decidual marker, PRL, PROK1 and SOD2 are also well-established 
markers of decidualisation therefore sufficed here to confirm HESCs had undergone 
decidualisation. In HESCs treated with 8-Bromo-cAMP and MPA, I observed an increase in 
mRNA in all three markers (Fig. 3.1). PRL transcript levels appeared to be the highest when 
compared to untreated cells (Fig. 3.1A) and a significant increase was also observed for PROK1 
and SOD2 transcript levels (Fig. 3.1B&C, respectively). These results confirm that treating 
HESCs with these cAMP and progesterone analogues for 72 hours is sufficient for 
decidualisation. Consequently, results shown in this chapter and in future chapters use this 3 day 
protocol with cAMP and MPA in order to decidualise cells and compare with undifferentiated 
(untreated) HESCs.  
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Figure 3.1. Decidual gene markers are expressed following 72 hours of cAMP and 
progesterone. HESCs were grown to confluency and treated with 8-Bromo-cAMP (0.5mM) and MPA 
(1µM) for 72 hours or left untreated. Cells were then harvested and RTQ-PCR was carried out to 
assess the mRNA levels of prolactin (PRL) (A), prokineticin 1 (PROK1) (B) and superoxidase 
dismutase 2 (SOD2) (C) which were then normalised to the levels of a housekeeping gene L19 and 
expressed in arbitrary units (A.U.). n=3-6 infertile (control) patients. Horizontal bars indicate the mean 
expression for each group. Students t-test, *= P <0.05 and **= P <0.01. 
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3.2.2 hCG does not activate Gαs signalling 
The classic G-protein coupling of the LH/CGR is to Gαs which, when active, results in an 
increase in the levels of intracellular cAMP. hCG-mediated activation of the LH/CGR has been 
shown in multiple cellular systems to couple to Gαs, acting via the cAMP/PKA pathway [98, 331, 
332] but it has also been reported to act in a cAMP/PKA-independent manner in endometrial 
epithelial cells [333, 334]. The cAMP signalling mechanisms in HESCs remain as yet unexplored 
and therefore I asked if hCG would induce LH/CGR coupling to Gαs in HESCs. To this end, 
undifferentiated and decidualised HESCs from 3 control patient cultures were treated with hCG 
for a period of 30 minutes and then assessed for levels of intracellular cAMP accumulation using 
an ELISA-based cAMP assay. A 30 minute stimulation time period was chosen as this gave 
sufficient time for any cAMP accumulation to be observed. I compared cAMP levels to levels in 
untreated cells. In both undifferentiated and decidualised cells, there was no accumulation of 
cAMP levels above that of untreated cells (Fig. 3.2A), suggesting that hCG does not couple to 
Gαs in HESCs.  
 
3.2.3 hCG activates the MAPK signalling pathway 
The previous result showed hCG does not activate the second messenger cAMP. However, GPCR 
ligands including hCG are known to act via many other second messengers and downstream 
pathways. Signalling via MAPKs are common downstream pathways activated by many GPCRs 
[335]. Therefore, to ascertain if hCG has the ability to activate MAPK signalling, undifferentiated 
or decidualised HESCs were stimulated for 0 – 45 minutes with hCG and ERK1/2 
phosphorylation was assessed by Western blotting (Fig 3.2B). In both undifferentiated and 
decidualised HESCs, hCG induced a rapid activation within 5 minutes and this activation 
continued to increase and was sustained during the 45 minutes of hCG treatment, with a peak at 
about 15 minutes. This activation by hCG has been consistently observed across patients and the 
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pooled data of 5 patients is shown (Fig 3.2B). Therefore, although hCG does not appear to 
activate cAMP, HESCs do have the ability to respond to hCG by activating the MAPK signalling 
cascade and that this pathway is not altered by decidualisation.  
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Figure 3.2. hCG-induced signalling profiles in HESCs. (A) HESCs were grown to confluency and 
remained undifferentiated or were decidualised for 72 hours with 8-Bromo-cAMP and MPA. Cells 
were then stimulated for 30 minutes with hCG (10nM) or left unstimulated and intracellular cAMP 
accumulation was analysed using an ELISA-based cAMP assay (Enzo Life Sciences). cAMP levels 
shown are normalised to levels of protein. n=4 infertile (control) patients. (B) Undifferentiated or 
decidualised HESCs were treated with hCG (10nM) for the indicated times and phosphorylation of 
ERK1/2 was determined by Western blotting. Total ERK was used as a loading control. (C) 
Densitometric analysis of p-ERK1/2 was normalised to 0 min stimulation and is shown in the bar 
graph. Data represents mean ± SEM, n=5 infertile (control) patients.  
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3.2.4 hCG may activate a Gαi signalling pathway in HESCs to reduce cAMP 
production  
The above data indicates that HESCs are hCG-responsive, but hCG does not activate Gαs 
signalling, I speculated that there may be another G-protein mediated signalling pathway in these 
cells. A likely candidate was Gαi/o, which acts in the opposite manner to Gαs to decrease 
intracellular levels of cAMP. In order to explore this, I treated undifferentiated or decidualised 
cells as described above with hCG for 30 minutes and measured cAMP accumulation. To assess 
if hCG could reduce levels of cAMP and if this was Gαi/o mediated, cells were treated with hCG 
and Forskolin (Fsk), an artificial elevator of cAMP by the activation of adenylate cyclase [336]. 
To confirm dependence on this G protein for signalling, pertussis toxin (Ptx), an inhibitor of the 
Gαi subunit via its ADP-ribosylating activity [337] was also used. Levels of cAMP for each 
condition were then calculated and normalised to levels of Fsk alone (Fig. 3.3A&B, dotted line). 
For one subset of patients (Fig. 3.3A), and as seen before, cAMP accumulation was absent in 
cells treated with hCG alone. However in cells treated with hCG and Fsk, there was a decrease in 
levels of cAMP compared to that of Fsk alone. This was observed in both undifferentiated and 
decidualised cells, where the levels were reduced by 29.8 ± 5.0% and 18.6 ± 7.0% respectively. 
Strikingly, in cells which had been treated with hCG and Fsk in combination with Ptx, the hCG-
dependent inhibition of Fsk described was reversed and levels of cAMP increased above levels of 
Fsk and Ptx alone by 47.0 ± 30.6% for undifferentiated cells and 48.2 ± 8.5% for decidualised 
cells. This was an hCG-induced effect as cAMP levels in cells treated with only Fsk and Ptx 
without hCG did not change. However, in a second subset of patients, this effect was not 
observed and hCG was not able to decrease levels of cAMP induced by Fsk alone. Additionally, 
no change in cAMP levels was observed in treatments combined with Ptx (Fig. 3.3B). This data 
shows that hCG has the ability to decrease levels of cAMP in HESCs and that it does this by 
acting via Gαi. However, this effect may not be consistent among patient samples.   
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Figure 3.3. Effects of hCG on levels intracellular cAMP in the presence of a Gαi inhibitor. (A & 
B) HESCs were decidualised with cAMP and MPA for 72 hours or remained undifferentiated. Cells 
were treated with or without pertussis toxin (200 ng/ml, 18 hours) and subsequently stimulated with 
hCG (10nM) or forskolin (Fsk) (3 µM) for 30 minutes as indicated. Intracellular levels of cAMP were 
then measured using an ELISA-based assay (Enzo Life Sciences). The percentage change was 
calculated and is relative to the cAMP levels induced by Fsk alone (dotted lines). Data represent two 
separate patient pairs (A) and (B). n=2 infertile (control) patients per patient group.  
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3.2.5 Gαi-mediated effects of hCG on decidual gene expression 
In view of the finding that hCG may mediate its action via Gαi, I asked what the downstream 
consequences of this were. Since hCG has been shown to inhibit the expression of decidual gene 
markers such as PRL [112, 113], a cAMP-responsive gene [338], I speculated that the inhibition 
of its expression by hCG could be due to hCG activating Gαi in these patients. In order to test 
this, HESCs were decidualised using cAMP and MPA, with or without hCG. To assess the Gαi-
dependence, treatments were combined with Ptx for the full decidual time-course. Levels of PRL 
transcripts in each condition were then measured using RTQ-PCR and normalised to PRL levels 
in decidualised cells without hCG or Ptx (Fig. 3.4). This experiment was carried out in 6 patients 
in total and there appeared to be distinct groups of responses across patients. For patients A, B, C 
and D (pairs 1 & 2), levels of PRL transcripts were distinctly reduced in cells decidualised with 
hCG by between 20-90%. For pair 1, this effect was reversed in cells treated with hCG and Ptx, 
most strikingly for patient B where the level of PRL increased by 215 ± 37.8% above cells 
decidualised with Ptx alone. For pair 2, this reversal was not evident and levels of PRL remained 
the same in the presence of Ptx. For pair 3, there was no inhibition of PRL levels with hCG 
treatment yet hCG appeared to act by inducing levels of PRL above that of cells treated with only 
cAMP and MPA, by 30.2 ± 2.5% for patient E and 105.0 ± 32.7% for patient F. Additionally, in 
these patients the combined treatments with hCG and Ptx appeared to inhibit this induction of 
PRL compared to hCG alone by 40.5 ± 4.5% for patient E and 85.0 ± 3.1% for patient F. Overall, 
in the majority of patient samples (pairs 1 & 2) there is an hCG-dependent inhibition of PRL and 
in some cases this is Ptx sensitive (pair 1). However, some patients (pair 3) cause an hCG-
dependent induction of PRL which also appears to be Ptx sensitive.  
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Figure 3.4. Effects of hCG on decidual prolactin levels in the presence of a Gαi inhibitor. 
HESCs were decidualised with cAMP and MPA for 72 hours. As indicated, some cultures were 
decidualised in the presence of hCG (10nM), pertussis toxin (Ptx) (200ng/ml) or both. PRL transcript 
levels were determined using RTQ-PCR and the percentage change relative to expression levels in 
cultures treated with vehicle (dotted lines) is shown. n= 6 control patients.  
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3.2.6 HESCs display changes in receptor trafficking following decidualisation 
that is receptor specific to the LH/CGR  
Since receptor trafficking plays an important role receptor signalling, I asked what the trafficking 
profile/fate of the LH/CGR is in HESCs. To assess this, HESCs were either undifferentiated or 
decidualised and subsequently transfected with Flag-tagged LH/CGR and immunofluorescently 
labelled in live cells to assess receptor localisation before and after treatment with hCG (see 
Methods). In undifferentiated HESCs, before agonist treatment internalisation of the receptor was 
evident (Fig. 3.5A, left panels) showing that this receptor displays constitutive internalisation 
with no apparent further internalisation observed following hCG treatment. In contrast, a large 
proportion of decidualised HESCs across patients exhibited a marked reduction in this 
constitutive internalisation and the receptor was predominantly distributed diffusely on the cell 
surface (Fig.3.5A, decidualised (i)). In a smaller proportion of decidualised HESCs, constitutive 
internalisation of the receptor was evident (Fig. 3.5A, decidualised (ii)). Following hCG 
treatment, the majority of cells had predominantly plasma membrane receptor distribution 
(decidualised (i)). But again in a smaller proportion of cells internalisation could be seen 
(decidualised (ii)). I then asked if the constitutive activity displayed is specific to this cell type or 
to the receptor. HESCs were transiently transfected with the prototypical GPCR, the β2-
adrenergic receptor (β2AR), for which the endocytic trafficking is well characterised [339, 340]. 
Interestingly, in undifferentiated cells constitutive trafficking of β2AR was not evident and the 
receptor was clearly distributed primarily on the cell surface (Fig. 3.5A, right panels). 
Furthermore, the receptor exhibited robust ligand-induced internalisation in both undifferentiated 
and decidualised cells. Thus, the trafficking phenotype of the LH/CGR observed in HESCs and 
the change following decidualisation is perhaps due to receptor-specific alterations, rather than 
differences in core machinery used by many receptors within these cells. Furthermore, the 
constitutive internalisation was unique to the LH/CGR in HESCs; in HEK293 cells expressing 
the LH/CGR the receptor is known to be principally on the plasma membrane and only 
Chapter 3: Results I 
 
121 
 
internalises following addition of hCG [301], I confirmed this here in HEK293 cells transiently 
expressing the LH/CGR (Fig. 3.5B).  
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Figure 3.5. Trafficking of the LH/CGR alters between undifferentiated and decidualised HESCs 
and this is receptor specific. (A) HESCs were seeded into 35 mm imaging dishes and subsequently 
remained undifferentiated or were decidualised for 72 hrs with cAMP/MPA. Cells were then 
transfected 48 hrs prior to imaging with Flag-LH/CGR or Flag-β2 adrenergic (β2AR) receptor 
constructs. Surface receptors were labelled with fluorescently conjugated anti-Flag antibodies. 10 nM 
hCG and 10 µM isoproterenol (20 min) were used to activate each receptor respectively. 
Representative confocal microscopy images from fixed cells are shown from n=3. (20 cells analysed 
per condition). (B) Representative images of HEK293 cells transiently transfected with the LH/CGR 
and treated with or without hCG. Scale bars: 10µm. n= 3 infertile (control) patients.  
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3.2.7 Single-event recycling of the LH/CGR can be observed in HESCs and is 
modulated by the presence of hCG 
Human LH/CGR is known to be sorted to the recycling pathway following ligand-induced 
internalization [341]. I have shown that the LH/CGR in HESCs exhibits constitutive 
internalisation in undifferentiated cells and this appears to be reduced upon decidualisation, 
where internalisation is only observed in a subset of cells following treatment with hCG. I asked 
whether the constitutive internalisation resulted in constitutive recycling of the receptor and 
whether the alteration in trafficking during decidualisation would either be due to: (1) a 
mechanism preventing the internalisation of the LH/CGR or (2) that internalisation does occur 
but the recycling mechanism is so rapid in decidual cells that it is not readily observed using 
confocal microscopy. To address these questions, I investigated the recycling of the LH/CGR in 
undifferentiated versus decidualised cells utilising live-cell total internal reflection fluorescence 
microscopy (TIRF-M) which permits detection of cellular events occurring at the plasma 
membrane, such as receptor recycling. This is possible as TIRF-M uses light reflected at a 
refractive interface that creates an evanescent wave which diminishes exponentially with distance 
from the interface. A shallow field of illumination (~100nm) is therefore generated by this 
evanescent field, so only fluorescent molecules located at or close to the plasma are illuminated, 
making it an ideal technique to observe receptor recycling [342]. This approach was combined 
with the expression of LH/CGR N-terminally tagged with a pH sensitive GFP variant, 
superecliptic pHluorin (SEP). SEP-LH/CGR fluoresces at the neutral pH of the cell culture 
media, but when in the acidic lumen of endosomes (pH 6.0), this fluorescence is rapidly 
quenched (Fig 3.6A) [211, 343]. Thus, the use of this construct further enhances the high signal-
to-background ratio that is achieved with TIRF-M, enabling visualization of individual receptor 
recycling/insertion events.  
To investigate the recycling of the LH/CGR, HESCs isolated from 4 patients were first 
grown to confluency and subsequently remained undifferentiated or decidualised for 72 hours 
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prior to imaging. The SEP-LH/CGR was transiently transfected 48 hours prior to imaging. 
Transfected HESCs were selected using widefield epifluorescent microscopy and then imaged 
with TIRF-M before and following addition of hCG, 10-15 cells were imaged at regular intervals 
over a time period of 50 minutes. Since individual recycling events are known to happen with fast 
kinetics, images were acquired at 10 frames per second (fps) and movies were taken for a total 
duration of 60 seconds. In both undifferentiated and decidualised cells, I observed rapid and 
transient bursts of increased SEP-LH/CGR fluorescence at the plasma membrane, indicative of 
recycling events. These events appeared as bright spots in maximum intensity images generated 
from a 60 second movie (see representative images from each condition, Fig. 3.6B). The lateral 
spread of SEP-LH/CGR fluorescence which followed the insertion events can be seen more 
clearly in the sequential time series panel (Fig. 3.6C) where a bright spot suddenly appears and 
then disperses across the plasma membrane within seconds. These events could be seen both in 
unstimulated cells and also following the addition of hCG (10nM). The number of events differed 
between patient samples so each has been represented in a single bar graph and the values are the 
average number of recycling events across cells imaged per condition and normalised to cell 
surface area (Fig. 3.6D). Pooled data for all 4 patients is represented as a dot plot (Fig. 3.6E). For 
all patient samples, I observed constitutive recycling events in undifferentiated cells, with an 
average of 17.8 ± 2.5 events/min/cell. This increased upon hCG stimulation to 39.9 ± 14.6 
events/min/cell, although in particular patients, such as patient 1, average event number reached 
as high as 62.2 ± 17.5 events/min/cell. Decidual cells also displayed constitutive recycling but 
this was significantly lower than in undifferentiated cells, with on average 7.0 ± 0.7 
events/min/cell. hCG addition resulted in a significant increase above this basal recycling to 20.4 
± 2.7 events/min/cell. In general, the hCG-induced increase in recycling event number was lower 
than that in undifferentiated cells; particularly in patient 4 where undifferentiated cells had 47.3 ± 
9.3 events/min/cell whereas decidualised cells had less than half of that at 18.4 ± 3.7 
events/min/cell. Overall this data indicates that the constitutive internalisation seen previously 
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(section 3.2.6) results in constitutive recycling in undifferentiated cells and that in decidualised 
cells this constitutive recycling is inhibited, thus underscoring the switch in trafficking 
mechanisms I observed previously.  
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Figure 3.6. Visualisation of SEP-LH/CGR recycling events in HESC cultures. (A) Schematic 
illustrating how recycled SEP-LH/CGR is detected using TIRF-M in a pH-dependent manner. (B) 
Representative maximum intensity projection images of undifferentiated and decidualised HESCs 
from 60s movies without and with exposure to hCG. Maximal intensity refers to the maximal pixel 
density for each pixel across the 60s movie. Red arrows indicate recycling events. (C) Example of an 
individual SEP-LH/CGR insertion event: sequential 500 ms frames are shown, time stamp is in the 
lower right hand corner. (D) Recycling events per minute movie across 4 separate infertile/fertile 
patients in cells that were undifferentiated or decidualised with cAMP/MPA for 72 hours, without and 
with hCG exposure. 4-14 cells were analysed per condition and events normalised to cell surface 
area. (E) Pooled average recycling event number from patients shown in (D). Paired Students t-test, 
*= P <0.05 and **= P <0.01.  
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3.2.8 Distinct modes of SEP-LH/CGR recycling are observed in HESCs 
For other GPCRs it has previously been observed that there are distinct modes of recycling events 
as measured by TIRF-M – some can be on the plasma membrane for a very short time (transient 
events), while others can linger for longer before their lateral diffusion (persistent events) [210, 
212, 344]. I also observed distinct modes of insertion for SEP-LH/CGR in HESCs (Fig. 3.7). A 
large proportion (70.1 ± 6.5%) of SEP-LH/CGR fluorescent puffs appeared abruptly at the 
plasma membrane before their rapid diffusion to the level of surrounding fluorescence intensity. 
These were defined as ‘transient’ events where the spots remained visible for <2 seconds. A 
smaller proportion (19.6 ± 4.7%) of events persisted on the plasma membrane for a prolonged 
time before either their sudden or gradual diffusion. These were defined as ‘sustained’ events and 
remained as visible spots for >2 seconds, although in some cases they could remain on the plasma 
membrane for more than 10 seconds. A third group of events were termed as ‘pretail’ events; 
these events were defined as such as they had a small but significant increase in fluorescence 
lasting between 2-15 seconds that preceded a transient burst of fluorescence. These types of 
events represented 10.3 ± 5.8% of total events. When plotted on kymographs and intensity plots 
over time, the differences in these events are easily visible (Fig. 3.7). This is consistent with data 
from others that GPCR recycling can occur via different modes, although the reasons for and 
implications of this divergence are as yet unknown.  
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Figure 3.7. Characterisation of SEP-LH/CGR recycling modes in HESCs. Representative 
kymographs which demonstrate three distinct kinetic properties SEP-LH/CGR recycling: transient, 
sustained and pre-tail events (top) and corresponding fluorescent intensity plots (bottom). n= 4 
infertile (control) patient samples.  
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 Discussion 3.3
Decidualisation of HESCs differentiates the cells into a secretory and epithelioid-like phenotype, 
altering expression of a variety of genes which ultimately prepares the endometrium for 
pregnancy [8]. These cells exist to develop a highly-specialised uterine microenvironment 
beneficial at the time of implantation and this is a tightly controlled process, disorders of which 
can lead to pregnancy complications [345]. This study aimed to investigate the activity of the 
LH/CGR in endometrial stromal cells and if it changes its activity during decidualisation, 
indicating that it may be another key factor in preparing the endometrium for an implanting 
embryo.  
As described in Chapter 1, signalling and trafficking of GPCRs are known to be 
intrinsically linked where each has dramatic implications on the other [227, 330]. However, since 
the endogenous pathways of hCG function in HESCs has been relatively understudied, the 
mechanisms of its proposed in vivo and in vitro actions shown in the literature remain ambiguous. 
Therefore, it was necessary to first elucidate the hCG signalling profiles in HESCs. GPCRs are 
known to signal via multiple G-proteins and effector molecules and via these are able to activate 
downstream MAPK signalling cascades. Gαs signalling is widely viewed as the classical mode of 
hCG-induced LH/CGR signalling in the majority of cell systems [237] however, the data I have 
shown demonstrates that hCG does not increase levels of cAMP in undifferentiated and 
decidualised HESCs and indicates that hCG does not couple to Gαs in these cells. Indeed, cAMP-
independent signalling of hCG has been shown in other studies in human endometrial epithelial 
cells [333, 334]. Many previous reports have shown that hCG can activate MAPK signalling 
responses in a variety of cell types including granulosa and endometrial epithelial cells [269, 
333]. In HESCs, I observed a robust and sustained induction of the ERK1/2 signalling cascade in 
both undifferentiated and decidualised cells. MAPK signalling is involved in a number of cellular 
processes and since hCG has been implicated in a variety of processes, including inflammation 
and decidualisation in HESCs, it may mediate some of these functions through the ERK1/2 
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pathway as well as via other MAPKs. I have not yet elucidated that mechanism by which this 
pathway is activated in these cells. GPCRs are known to activate MAPKs via G-proteins and in a 
G-protein-independent manner, for example through β-arrestins [346] and further study could 
examine these pathways in HESCs.  
Another explanation for the lack of Gαs-coupling but signalling via MAPK could be that 
hCG is not acting via the LH/CGR and indeed it has been reported that hCG can mediate its 
action via other receptors. In a trophoblast cell line, hCG has been shown to cause cellular 
migration via the insulin-like growth factor-II/mannose-6-phosphate receptor (IGF-II/M6PR) 
[347], in JEG3 carcinoma cells it has been shown to modulate trophoblast invasion in the absence 
of LH/CGR [348] and, in an LH/CGR knock-out mouse model, hyperglycoslated hCG was 
shown to stimulate angiogenesis via the transforming growth factor receptor β receptor (TGFβR) 
[349]. Recently, the hCG used in these studies has been brought into question and it has been 
shown that highly purified hCG fails to mediate TGFβR signalling as previously shown. This was 
due to the finding that previous preparation methods contained epidermal growth factor (EGF) 
and TGFβ1 contaminants [350]. Unlike these studies, the recombinant hCG used in my 
experiments is likely to be purer than the hCG isolated using the latter method of affinity 
chromatography purification of conditioned media from human carcinoma JEG3 cells [350]. 
Additionally, in HEK293 cells not expressing LH/CGR, MAPK signalling is not activated by 
recombinant hCG (data not shown) even though they are known to express endogenous growth 
factor receptors [351-353].  
Instead of Gαs coupling, it seems that in a subset of patients, hCG was able to activate 
Gαi to reduce levels of cAMP. It is uncertain why in some patients this response was not 
detectable although this may be due to differences in receptor levels in detecting this upstream 
pathway, where downstream ERK activation may be evident. The hCG-induced activation of Gαi 
for a subset of patients motivated further study into the downstream consequences of this 
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pathway. As previous reports had found [112, 113], I observed hCG-dependent inhibition of the 
decidual gene marker PRL. Strikingly, in some patients, this was shown to be via a Gαi-
dependent mechanism and was reversed upon Ptx treatment. This corresponds to the previous 
findings as PRL is a cAMP-dependent gene, so an increase in levels of cAMP is likely to result in 
a concomitant increase in PRL. Interestingly, in some patients where hCG inhibited PRL 
transcript levels, this appeared to be a Gαi-independent mechanism. The predominant G protein 
pathway by which GPCRs inhibit cAMP is via Gαi/o and Ptx inhibits all known isoforms of this 
family of G proteins. Ptx insensitive inhibition of cAMP is extremely rare, although it has been 
reported for the human 5-hydroxytryptamine7 (h5-HT7) GPCR [354]. The less characterised G-
protein Gαz is the only inhibitory G-protein that is insensitive to Ptx [355] yet its expression is 
specific to a subset of tissues and is not reported in the human endometrium [356]. Notably, some 
patients did not exhibit hCG-dependent inhibition of PRL and PRL levels were increased. 
Unexpectedly, it was apparent that this increase was reversed by Ptx. Although Gαi-coupling 
typically attenuates cAMP accumulation, persistent activation of Gαi-coupled receptors is known 
to produce a paradoxical augmentation of levels of cAMP (an effect known as heterologous 
sensitisation or supersensitisation), and is thought to be a cellular compensatory mechanism 
following a chronic inhibitory stimulus [357, 358]. This could indeed be occurring in this patient 
subset, which would explain the opposing effects here. Overall, although the MAPK signalling 
was consistent, the cAMP and PRL data obtained here show different profiles across patients. 
Since this work is carried out on primary HESCs, results can be highly variable owing to the 
heterogeneous nature of patient specimens. There could be, for example, broad differences 
between the proteins expressed which may impact upon the signalling profiles. A larger 
population size will need to be examined in further work to ascertain what the overall G-protein 
signalling trend may be. 
Interestingly, I have shown that there is a change in both the internalisation and recycling 
of the LH/CGR between undifferentiated and decidualised HESCs. In undifferentiated cells I saw 
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constitutive endocytosis of cell surface LH/CGR, which was lost upon decidualisation, and was 
receptor-specific as constitutive internalisation of the β2AR was not observed. This is the first 
cell type for which constitutive trafficking of human LH/CGR has been reported and, to my 
knowledge, the first cellular system where trafficking could be reprogrammed by differentiation 
The physiological role for constitutive trafficking is unclear but some studies suggest that it may 
be important for appropriate receptor redistribution, such as for the cannabinoid receptor-subtype 
1 (CB1) where it is necessary for targeting the receptor to axonal membranes [359]. The 
underlying constitutive internalisation of the LH/CGR in HESCs may be connected to basal 
signalling although changes in basal ERK1/2 and cAMP levels were not observed. Potential 
modulators of constitutive internalisation in HESCs are further explored in Results Chapter 2.  
This ‘switch’ in receptor trafficking was also evident in TIRF-M experiments which 
enabled quantitative measurement of LH/CGR recycling. Using this method, the constitutive 
internalisation in the confocal imaging of the HESCs was corroborated where I observed 
constitutive recycling events in undifferentiated cells that were reduced in decidualised cells. The 
number of events increased following agonist exposure, indicating that hCG-induced 
internalisation occurs, which was not clearly evident via confocal imaging due to the high basal 
internalisation. However, it is also a possibility that some of the recycling events seen here could 
be originating from the biosynthetic pathway and in additional experiments with cycloheximide 
could be used in order to block protein synthesis to test this possibility. This has been carried out 
in HEK293 cells for the SEP-LH/CGR, without showing an effect on recycling event number 
(Hanyaloglu lab, unpublished data). Collectively, the data from the trafficking and recycling 
experiments highlights novel ‘reprogramming’ of LH/CGR in HESCs, where receptor 
internalisation and recycling in undifferentiated cells is decreased following decidualisation.  
Examining the profiles of individual recycling events gave further insight into the modes 
of recycling of LH/CGR in these cells. The primary mode of exocytosis was determined to be a 
Chapter 3: Results I 
 
133 
 
transient one, and this was true regardless of cell state and in unstimulated and non-stimulated 
conditions. The other mode of insertion was a sustained one, where events were characterised by 
long-lasting spots on the plasma membrane before gradual or abrupt diffusion, also termed a 
‘kiss-and-wait’ mode of membrane insertion [212]. These two distinct events have been observed 
before, for example for the β2AR and the GluR1-containing AMPA in primary neuronal cultures 
[212, 360], however the physiological role of the different recycling mechanisms has not yet been 
determined. The third event I observed was termed ‘pretail’ and to my knowledge such a 
recycling mode has not been observed before. As with the other distinct kinetic events, the 
physiological reason for these and indeed the proteins which may be modulating them are 
currently unknown – they could be mediated, for example, by distinct Rab or motor proteins as 
has been shown for the mu-opioid receptor (MOR) [361]. It is also possible that the modes of 
recycling represent the targeting of receptors to specialist microdomains at the plasma membrane 
required for signalling, such as to lipid rafts or A-kinase anchoring proteins (AKAPs) [227]. 
Interestingly, it has been shown by others that recycling can be acutely modulated by levels of 
cAMP, for example fast recycling of MOR is induced by forskolin [361]. Bulk and sequence-
dependent recycling of the β2AR has also been shown to be modulated by protein kinase A 
(PKA), the activity of which is dependent on levels of cAMP [362]. This effect would be 
interesting to investigate in HESCs with the recycling of the SEP-LH/CGR and especially 
pertinent since decidualisation is initiated by addition of cAMP and I have observed a difference 
in receptor trafficking in decidual cells. Further studies could also ascertain if the reduction in 
constitutive trafficking events seen in decidual cells is due to cAMP and/or MPA derived 
signalling.  
In summary, the data presented here provides novel insights into the nature of 
endogenous hCG signalling in HESCs in terms of Gαi coupling to reduce cAMP levels and 
decidual gene expression, and signalling via MAPK. This chapter also provides evidence of a 
unique trafficking mechanism of the LH/CGR in HESCs which is potentially ‘reprogrammed’ 
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upon decidualisation and could represent a mechanism that is essential during the time of embryo 
implantation.  
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 Introduction 4.1
In the previous results chapter, I have shown that the LH/CGR exhibits constitutive 
internalisation in undifferentiated HESCs and this is reduced in decidualised cells. Therefore, the 
potential underlying mechanisms involved in the constitutive internalisation were next addressed, 
with a view to identifying a factor which, when blocked or manipulated, could mimic the change 
in trafficking seen in decidual cells. Pinning down a mechanism which programs the ‘switch’ in 
the trafficking in decidual cells would give us further insight into why hCG mediates its function 
and how this activity may play a role during early pregnancy.  
Receptor internalisation, both constitutive and agonist induced, is a complex process and 
can involve many steps and a plethora of scaffold and adaptor proteins. Internalisation after 
agonist binding has been well-documented and is classically viewed as the mechanism by which 
a GPCR is desensitised from further ligand stimulation and thus signalling magnitude and 
duration is controlled [184]. The canonical mode of GPCR internalisation is as follows: when 
bound to agonist, the GPCR undergoes a conformational change which allows activation of its 
cognate G-proteins and receptor phosphorylation then occurs by G-protein coupled receptor 
kinases (GRKs) which initiates the binding of β-arrestins, triggering the uncoupling of the 
receptor from the G-protein [363, 364]. Receptors then internalise by two main routes: clathrin-
independent endocytosis (CIE) or clathrin-dependent endocytosis (CDE). Often, the latter is 
mediated by β-arrestins via their ability to directly interact with both the endocytic adaptor 
protein AP2, involved in CDE, as well as the clathrin component of clathrin-coated pits (CCPs) 
[365]. Following formation of the endocytic bud, the GTPase dynamin facilitates fission to allow 
the formation of an endosome, which is then subject to sorting in the endocytic matrix [366]. CIE 
in general uses alternative mechanisms but is known to utilise some components of CDE such as 
dynamin [367].  
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GPCR internalisation was considered an agonist-driven phenomenon, but it is now apparent that 
it can occur in the absence of agonist i.e. constitutive internalisation. Constitutive internalisation 
can utilise the same mechanisms as agonist-dependent internalisation, for example, engaging β-
arrestins and undergoing clathrin-mediated endocytosis. The mechanisms and adaptor proteins 
involved for both constitutive and agonist-driven internalisation are largely GPCR and cell-type 
dependent. One process that regulates internalisation is receptor phosphorylation, which can 
occur at the C-terminal tail and second and third intracellular loops of the receptor. GPCRs can 
undergo site specific phosphorylation and this is known to dictate their interaction with β-
arrestins and thus mediates receptor internalisation and activity [368]. Another mechanism 
dictating internalisation and widely implicated for many GPCRs are proteins which interact with 
the C-terminal tail of the receptor such as the PDZ domain containing family of proteins (detailed 
in Chapter 1). These can regulate the endocytic sorting of the receptors as well as promote 
internalisation. As an example, the PDZ domain protein MAGI-2, when overexpressed, will 
enhance the internalisation of the β1-adrenergic receptor but another PDZ protein, PSD-95, 
significantly inhibits internalisation [369]. Thus specific protein motifs on receptors modulate 
their internalisation. It could be hypothesised then that the constitutive internalisation of the 
LH/CGR seen in undifferentiated HESCs is governed by phosphorylation or C-tail interactions 
that may not be utilised in decidualised cells.  
Another mode by which internalisation may be modulated is by the interaction with other 
GPCRs. The accepted view once was that GPCRs act as single subunits, or monomers, but 
substantial evidence over the last two decades has shown that routinely GPCRs can form homo- 
or heterodimers and/or higher order oligomers and formations of these can be dynamically 
regulated (reviewed in [370-373]). Both signalling and trafficking can be modulated by GPCR 
dimerisation (described in Chapter 1) including constitutive internalisation [374]. Therefore, I 
speculated that the atypical constitutive internalisation observed for the LH/CGR may be 
modulated by interaction with another constitutively internalising GPCR. Additionally, given the 
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Gαi coupling of hCG, heterodimerisation of the LH/CGR with an LH/CGR splice variant or 
another Gαi-coupled receptor could account for this signalling behaviour. In addition to splice 
variants, one candidate was the cannabinoid receptor 1 (CB1), a class A GPCR which is 
abundantly expressed throughout the central nervous system (CNS) where it is an important 
modulator of synaptic function [375]. I justified choosing the CB1R as a potential interactor of 
the LH/CGR for the following reasons: (1) CB1R constitutively internalises in its native state and 
this has been shown in cell cultures and neurons by immunocytochemical staining [376, 377], (2) 
it is known to couple to Gαi in most cells and tissues to inhibit adenylate cyclase [378], (3) in 
addition to the CNS, it is highly expressed in reproductive tissues including the testis, placenta, 
myometrium as well as in the stromal cells of the endometrium [379-382], (4) the 
endocannabinoid system is known to be important during early stages of embryo implantation 
and (5) the CB1R can heterodimerise with many other GPCRs including dopamine D2 receptors 
[383], orexin-1 receptors [384], adenosine A2A receptors [385] and the lysophosphatidylinositol 
receptor GPR55 [386] and by doing so, the signalling and trafficking properties of some of these 
receptors can be modulated.  
This chapter aims to investigate the mechanisms underlying constitutive internalisation in 
HESCs and its alteration during decidualisation. With the above mechanisms in mind, I will 
consider the following: 1) proteins known to be involved in CDE/CIE; 2) the requirement of the 
intracellular C-terminal tail of the LH/CGR; 3) influences of Gαi signalling on endocytosis; and 
4) heterodimerisation of the LH/CGR and its impact on internalisation. Investigating these key 
components will elucidate some of the possible underlying constitutive internalisation 
mechanisms of the LH/CGR in HESCs and indicate routes by which hCG signalling may be 
controlled.  
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 Results 4.2
4.2.1 Constitutive and agonist-induced internalisation of the LH/CGR is dynamin-
dependent 
The canonical internalisation of GPCRs is via CME and involves the pinching of budding 
vesicles from the plasma membrane into the cytosol by the GTPase dynamin. Thus, I asked if the 
LH/CGR utilises this mechanism in HESCs in both a constitutive and agonist induced manner. 
To investigate this, I took a pharmacological approach using a chemical inhibitor, Dyngo-4a, a 
known potent and specific inhibitor of dynamin GTPase activity [387] which has been shown to 
acutely block agonist induced LH/CGR internalisation and MAPK signalling in HEK293 cells 
[301]. To test if Dyngo-4a could inhibit internalisation of the LH/CGR in HESCs, cells were left 
undifferentiated or decidualised for 3 days and transfected with the LH/CGR. Cells were then 
pre-treated with vehicle (DMSO) or Dyngo-4a (30µm) for 15 minutes prior to receptor surface 
labelling and hCG stimulation. I observed a strong inhibition of both constitutive and agonist-
induced LH/CGR internalisation in undifferentiated cells (Fig. 4.1, upper panels respectively) and 
this inhibition was also observed for decidualised cells. Receptor localisation in Dyngo-4a-treated 
cells can be seen almost entirely on the surface in all conditions, whereas in vehicle treated cells 
LH/CGR containing endosomes are easily visible.  
Given this strong inhibition of exogenously expressed LH/CGR internalisation, I next 
examined the possibility that endogenous hCG signalling responses would also be modulated if 
endogenous LH/CGR internalisation can be blocked using Dyngo-4a. Undifferentiated and 
decidualised cells were pre-treated with DMSO or Dyngo-4a for 15 minutes and then stimulated 
at different time points (0-45 minutes) with hCG (10nM). Phosphorylation of ERK1/2 was then 
assessed via Western blotting. In both undifferentiated and decidualised cells treated with vehicle, 
I observed robust ERK1/2 activation across all time points, as previously seen (Chapter 3). In 
cells which had been treated with Dyngo-4a, the basal level of ERK1/2 signalling was slightly 
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increased, as we have previously observed in other cell types [301]. However there was a strong 
reduction in hCG-mediated responses in both undifferentiated and decidual cells at all time points 
(Fig. 4.2, A & B). Together, this data strongly suggests that constitutive and agonist induced 
endocytosis of the LH/CGR is dynamin-dependent and that blocking internalisation inhibits 
endogenous hCG-induced signalling in both undifferentiated and decidualised HESCs. It also 
indicates that constitutive endocytosis of the LH/CGR employs the same mechanism as agonist-
induced endocytosis.  
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Figure 4.1. Dynamin inhibition blocks constitutive and agonist induced internalisation of the 
LH/CGR. HESCs were undifferentiated or decidualised and Flag-tagged LH/CGR was transfected in 
24 hours after the start of decidualisation. Cells were then pre-treated with DMSO (vehicle) or Dyngo-
4a (30µM), a dynamin inhibitor, for 15 minutes prior to cell surface receptor labelling using anti-Flag 
antibodies. Cells were then either left unstimulated or stimulated with hCG (10nM) for 20 minutes. 
Cells were washed and fixed prior to permeabilisation and labelling with immunofluorescent 
antibodies. Representative confocal images are shown. Scale bars: 10 µm (large image), 5 µm 
(insets). n=3 control patient samples. 
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Figure 4.2. Dynamin inhibition blocks hCG-induced ERK1/2 signalling. HESCs were 
undifferentiated or decidualised before pre-treatment with DMSO (vehicle) or Dyngo-4a (30µM), a 
dynamin inhibitor, for 15 minutes prior to addition of hCG (10 nM) at the indicated time points. Cells 
were then collected for Western blot analysis and probed for p-ERK1/2 and t-ERK1/2 which was used 
as a loading control (A and B, undifferentiated and decidualised HESCs respectively). Densitometry 
analysis of p-ERK levels was normalised to the 5 minute stimulation point (A and B, lower panels). 
n=1 control patient sample.  
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4.2.2 LH/CGR constitutive internalisation is independent of its C-terminal tail 
The C-terminal tail of GPCRs, including the LH/CGR, can be a binding site of many GPCR 
adaptor proteins and these can regulate the signalling of receptors as well as their internalisation. 
In view of this, I aimed to investigate if any C-terminal tail interactions modulate the constitutive 
internalisation of the LH/CGR in HESCs. To this end, I initially compared both the full-length 
LH/CGR and a truncated form of the LH/CGR that lacks the last 17 residues of the C-terminal 
tail (termed LH/CGR-683T). The LH/CGR-683T was used since the last 17 residues of the 
LH/CGR contain amino acid sequences known to be important for the post-endocytic sorting of 
LH/CGR as well binding of PDZ domain proteins such as GIPC [290, 292, 341] (schematic 
shown in Fig. 4.3A). Undifferentiated HESCs were transfected with these constructs, 
immunofluorescently labelled and trafficking of the receptor was examined in fixed cells via 
confocal microscopy. As previously seen, undifferentiated cells exhibited strong constitutive 
internalisation in cells expressing full-length LH/CGR (Fig 4.3B). Cells expressing LH/CGR-
683T also exhibited agonist-independent endocytosis. Thus, it is likely that the last 17 residues of 
the C-terminal tail are not required for constitutive internalisation of the LH/CGR. I then 
questioned if upstream regions of the C-tail could be involved in internalisation by truncating a 
larger region of the C-tail, termed LH/CGR-644T (schematic shown in Fig. 4.3A). Residues 643 
and 644 are cysteines and are subject to palmitoylation, which is known to be important for 
GPCR stability, thus these residues remained to ensure receptor expression was not perturbed 
[388]. This truncated receptor was then transfected in HESCs and compared with the full-length 
receptor, however, constitutive internalisation was still evident (Fig. 4.3B). This indicates that the 
C-tail is not required in LH/CGR constitutive internalisation.  
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LH/CGR LH/CGR-683T LH/CGR-644T 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3. Constitutive LH/CGR internalisation is independent of associations with its C-
terminal tail. (A) A schematic of the LH/CGR C-terminal tail sequence. Red lines indicate the 
residues mutated to stop-codons to generate the truncated receptors LH/CGR-683T and LH/CGR-
644T. (B) Representative confocal images of HESCs transfected with different forms of the LH/CGR. 
Undifferentiated HESCs were transfected with either full length LH/CGR or the two truncated forms as 
indicated (all N-terminally Flag-tagged). Surface receptor was then labelled with an anti-Flag antibody, 
and cells were then fixed and permeabilised before labelling with immunofluorescent antibodies and 
imaged using confocal microscopy. n=2 infertile (control) patients.  
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4.2.3 LH/CGR recruits β-arrestin1 in a constitutive and agonist-dependent 
manner 
β-arrestins (β-ARR) are central to the internalisation of many GPCRs. My previous data showed 
that the C-terminal tail does not dictate constitutive internalisation of the LH/CGR but since β-
ARR has been shown to interact with the LH/CGR at intracellular loops of the receptor [279, 
389] I speculated that β-ARR was utilised in the context of LH/CGR constitutive internalisation 
in HESCs and/or the reduction in constitutive trafficking following decidualisation. Subtype 
specific β-ARR interaction is known to occur, therefore I first examined which subtypes, β-ARR1 
or β-ARR2, are expressed in HESCs and whether reduced constitutive internalisation of the 
LH/CGR was due to a change in the levels of one or both β-ARR subtypes following 
decidualisation. Protein levels of β-ARRs were assessed in undifferentiated and decidualised 
HESCs. HESCs were decidualised or undifferentiated, lysed and levels of β-ARR1 and β-ARR2 
were assessed by Western blotting using an antibody that recognises both subtypes. β-ARR1 and 
β-ARR2 have similar molecular weights, 48kDa and 46kD respectively, so in order to identify 
these, protein lysates from HEK293 cells, which are known to express both subtypes, were 
analysed in parallel and the blots are shown in Figure 4.4. I observed that HESCs only expressed 
the β-ARR1 subtype as a protein band detected at the appropriate molecular weight of β-ARR2 
was only detected in the HEK293 sample, known to express both proteins. β-ARR1 appeared to 
be abundantly expressed in both undifferentiated and decidualised cells, and the levels did not 
change significantly between the two cell states (Fig. 4.4). Therefore, the reduced constitutive 
internalisation in decidualised HESCs cannot be attributed to change in the total levels of β-
ARRs. However, I asked if β-ARR1 may still be recruited to activated (constitutive and ligand-
induced) LH/CGR in HESCs. In order to assess this question, I utilised a YFP-tagged β-ARR1 
construct co-expressed with the Flag-LH/CGR and sought to determine if they co-localised in 
undifferentiated and decidualised HESCs. Following transfection, cells were labelled for 
LH/CGR and remained unstimulated or were stimulated with hCG. Co-localisation was then 
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assessed in fixed cells. In undifferentiated cells I observed partial LH/CGR-β-ARR1 
colocalisation in unstimulated and stimulated cells (Fig. 4.5A). Co-localisation could be seen for 
the most part in endosomal structures, but also occasionally in punctate structures nearer to the 
cell periphery. When quantified, on average 35.3 ± 3.3% and 44.3 ± 2.9% of receptor endosomes 
were positive for β-ARR1 for unstimulated and stimulated cells respectively (Fig. 4.5D). I also 
examined the smaller proportion of decidualised cells that exhibited constitutive and agonist-
induced internalisation and LH/CGR-β-ARR1 colocalisation was observed, at the level of 37.1 ± 
2.6% and 45.6 ± 2.3% respectively (Fig 4.5B&D). I also noted that in decidualised cells where 
surface expression was predominant in many cells, there was no β-ARR1-YFP recruitment, 
suggesting that overexpression of this construct does not artificially induce the LH/CGR to recruit 
β-ARR1 and promote internalisation (Fig. 4.5C). Overall, these results suggest that the LH/CGR 
recruits and engages with β-ARR1 both constitutively and following hCG addition. Additionally, 
the amount of β-ARR1 colocalisation increased following agonist addition, which may suggest 
that recruitment is enhanced by the ligand-bound receptor. These results also indicate that this 
potential LH/CGR-β-ARR1 interaction is not unique to undifferentiated cells, as I saw co-
localisation regardless of cell state. However, since fewer decidualised cells exhibit constitutive 
internalisation, this does not rule out the possibility that there is a mechanism in undifferentiated 
cells which enhances the engagement of the LH/CGR with β-ARR1. 
 
  
Chapter 4: Results II  
 
147 
 
 
 
 
 
 
 
Figure 4.4. β-arrestin1 but not β-arrestin2, is expressed in HESCs. HESCs were undifferentiated 
or decidualised and protein lysates were then subject to Western blotting using an antibody 
recognising both β-arrestin 1 and 2 (βARR1, βARR2) subtypes. GAPDH was used as a loading 
control. Protein from HEK293 cells was also analysed in parallel to identify the subtype expressed. 
Densitometry was then carried out on levels of β-ARR1 in decidualised cells and was normalised to 
level (%) of undifferentiated cells. n=3 infertile (control) patient samples. Error bars: ± SEM.  
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Figure 4.5. LH/CGR recruits βARR1-YFP in a constitutive and agonist-dependent manner. 
HESCs were transfected for βARR1-YFP and undifferentiated or decidualised for 72 hours. The 
LH/CGR was transfected 24 hours following the start of decidualisation. Cells were then labelled for 
the LH/CGR using anti-Flag antibodies and stimulated with hCG (10nM) or left unstimulated. Cells 
were then fixed and imaged using a confocal microscope. Representative images are shown in (A) 
and (B) for undifferentiated and decidualised cells exhibiting internalisation respectively. Images for 
decidualised cells where the receptor was primarily on the surface are shown in (C). Scale bars: 
10µm and 5µm (zoom). The percentage of LH/CGR endosomes positive for β-ARR1 (in A&B) was 
then quantified (D). n=2 infertile (control) patient samples. Error bars: ± SEM.  
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4.2.4 Inhibition of Gαi does not block LH/CGR constitutive or agonist-induced 
internalisation in HESCs 
Signalling can drive receptor trafficking, thus it is another component which could be regulating 
LH/CGR constitutive internalisation. In Chapter 2, I observed that a subset of patients may 
respond to hCG via Gαi activation, suggesting that the LH/CGR may be Gαi-coupled in HESCs. 
In order to test the hypothesis that Gαi coupling could be mediating LH/CGR trafficking and 
constitutive internalisation, I examined the trafficking of the LH/CGR in undifferentiated cells 
treated with or without the Gαi inhibitor pertussis toxin (Ptx). Cells were transfected with 
LH/CGR and either unstimulated or treated with hCG. Localisation of the LH/CGR in cells 
treated with Ptx and control cells was then compared. Images showed that both constitutive and 
agonist induced internalisation of the receptor was present in both the control condition and in 
cells treated with Ptx (Fig. 4.6). This data indicates that although the LH/CGR may be coupled to 
Gαi, it does not regulate its internalisation. 
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Figure 4.6. Gαi inhibition does not prevent constitutive or agonist-induced internalisation of 
the LH/CGR. Undifferentiated HESCs were transfected with LH/CGR and were treated overnight with 
Ptx (200ng/ml) or left untreated. Receptor was then labelled with an anti-Flag antibody and cells were 
stimulated with hCG (10nM) or left unstimulated. Surface receptor was stripped using EDTA prior to 
fixation and cells were imaged using confocal microscopy. n=3 infertile (control) patients. 
Representative images from 1 patient sample is shown.  
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4.2.5 LH/CGR splice variants are expressed in HESCs 
As described, another possibility for the constitutive LH/CGR internalisation, as well as Gαi 
coupling in HESCs, is dimerisation with another GPCR. I speculated that interaction of the 
LH/CGR, known to require di/oligomerization for its function [275], with its own splice variants 
could be mediating these actions of the receptor in HESCs. It is well established that the LH/CGR 
is expressed in the endometrium and decidua [102, 107, 108], but it is not known which splice 
variants of the receptor are expressed. Therefore, the mRNA levels of the full length LH/CGR 
and its splice variants were first assessed both before and following decidualisation. I used 
primers designed against the LH/CGR-A, LH/CGR-B, LH/CGR-C and LH/CGR-D variants of 
the receptor, which have been reported to be present in other tissues [248]. LH/CGR-A encodes 
the full-length receptor, LH/CGR-B lacks exon 9 while LH/CGR-C and LH/CGR-D lack the first 
266 nucleotides of exon 11. LH/CGR-D also has exon 9 removed. A schematic of the splice 
variants are depicted in Figure 4.7A. In undifferentiated and decidualised cells all variants of the 
receptor were expressed (Fig. 4.7B), though there was no significant change in the mRNA levels 
for LH/CGR-A, LH/CGR-B and LH/CGR-C and LH/CGR-D following decidualisation. This 
highlights that the full-length LH/CGR is not the only variant expressed in these cells and 
therefore it could be interacting with one of its splice variants. In addition, it raises the possibility 
that hCG signalling may be mediated by a splice variant of the receptor.  
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Figure 4.7. LH/CGR splice variants are expressed in HESCs. (A) Schematic of LH/CGR isoform 
structure (taken from [248]). LH/CGR-A transcript variant encodes the full-length receptor and 
contains all 11 exons. The LH/CGR-B transcript encodes a protein lacking part of the LRR and H 
regions as it lacks exon 9. The LH/CGR-C and LH/CGR-D variants do not contain the first 266 
nucleotides of exon 11, which results in a frame shift and early stop codon. The LH/CGR-C and 
LH/CGR-D variants therefore are deficient of the rest of exon 11, which encodes the T and C regions. 
The LH/CGR-D variant also misses exon 9. S, Signal peptide; N, N-terminal cysteine-rich region; 
LRR, leucine-rich motif region; H, hinge region; T and C, transmembrane and C-terminal tail; U, 
unique C-terminal tail. (B) Expression of LH/CGR splice variants in primary undifferentiated and 
decidualised HESCs. RNA extracted from cultured HESCs at early passages from 5 patients was 
used as a template for RTQ-PCR using primers specific for each splice variant LH/CGR-A, LH/CGR-
B, LH/CGR-C and LH/CGR-D. n=3 infertile (control) patients. 
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4.2.6 Co-expression of LH/CGR-A with splice variant LH/CGR-B does not 
modulate receptor cell surface expression 
Given the expression of LH/CGR splice variants in HESCs, I aimed to establish if these may 
modulate full-length LH/CGR activity by focusing first on LH/CGR-B variant. LH/CGR-B was 
chosen as it is known to directly interact with LH/CGR-A, modulate its levels of expression at the 
cell surface and change its signalling profile [246]. Furthermore, it has its TM/intracellular region 
intact, unlike LH/CGR-C and D variant that if expressed at a protein level are likely to be soluble. 
Before assessing the role of LH/CGR-B variant in HESCs, HEK293 cells were first used as a 
model. These cells have a high-rate of transfection and are abundantly available, thus can be used 
in techniques such as flow cytometry and importantly, endogenously express neither receptor. 
The ability of LH/CGR-B expression to effect the internalisation of LH/CGR-A was first assessed 
by expressing either the full-length Flag-tagged LH/CGR-A with or without an HA-tagged 
LH/CGR-B. Surface receptor was then labelled live with either Flag and/or HA antibodies and 
cells were treated with or without hCG. In cells expressing the LH/CGR-A, the receptor was seen 
at the plasma membrane before cell stimulation and following stimulation, it was partially located 
to endosomes (Fig. 4.8A). In cells transfected with the LH/CGR-B alone, the receptor was not 
detected (data not shown). However, in co-expressing cells, I could observe expression of both 
receptors, co-localised at the surface prior to hCG and following agonist they were partially co-
localised in endosomes (Fig. 4.8B). This may suggest that the LH/CGR-B requires interaction 
with the LH/CGR-A in order to be processed and trafficked to the plasma membrane and 
importantly, that the LH/CGR-A may localise to the same compartment following agonist-
induced internalisation. However, LH-CGR-B did not induce constitutive internalisation of the 
LH/CGR-A in HEK293 cells, suggesting that this may not be the mechanism utilised by the 
constitutively internalising LH/CGR-A in HESCs. To determine if LH/CGR-B variant impacts 
the surface levels of the full length receptor LH/CGR-A surface expression was quantitated by 
flow cytometry, which allows sensitive quantitation of cell surface protein levels on a larger cell 
Chapter 4: Results II  
 
157 
 
population and therefore can detect small changes of receptor surface levels which may not be 
evident via confocal microscopy. Cells expressing LH/CGR-A with or without LH/CGR-B were 
labelled live with Flag antibodies and subsequently labelled using immunofluorescent secondary 
antibodies (see Methods) for flow cytometric analysis. Due to the varying levels of transient 
expression across experiments, surface levels of LH/CGR-A in the presence of LHCGR-B were 
normalized to levels of LH/CGR-B alone, where there was a 24.9 ± 6.6% decrease in the 
expression of LH/CGR-A.  
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Figure 4.8. Full-length LH/CGR-A colocalises with splice variant LH/CGR-B. HEK293 cells were 
transfected with LH/CGR-A, LH/CGR-B or both variants. Cells were then labelled with anti-Flag and/or 
anti-HA antibodies, and stimulated with hCG for 20 minutes or left unstimulated. Cells were then fixed 
and permeabilised using fluorescent secondary antibodies. LH/CGR-A singly expressing cells are 
shown in (A), LH/CGR-A and LH/CGR-B co-expressing cells are shown in (B). LH/CGR-B singly 
transfected cells were not detected (data not shown). Scale bars: 10µm and 5µm (zoom). White 
arrows indicate areas of co-localisation.  
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4.2.7 Consequences of hCG-induced signalling in cells co-expressing LH/CGR-A 
and LH/CGR-B  
As LH/CGR-A may co-traffic with the LH/CGR-B, I examined the functional impact of this on 
hCG-induced MAPK signalling. HEK293 cells expressing either or both receptors were treated at 
different time points with hCG (0-45 minutes) and ERK1/2 phosphorylation was assessed via 
Western blotting (Fig. 4.9A). In LH/CGR-A only cells, there was sustained ERK1/2 
phosphorylation which peaked at 5 minutes following hCG treatment, by 4.5-fold above basal 
(Fig. 4.9B). In cells expressing LH/CGR-B only, there was no activation of ERK1/2 at any time 
point (Fig. 4.9B), consistent with the lack of detectable receptor at the cell surface. In LH/CGR-A 
and LH/CGR-B co-expressing cells, the profile was comparable to LH/CGR-A only cells,. This 
suggests that although LH/CGR-B localises to LH/CGR-A, it does not change its signalling 
profile in terms of ERK1/2 activation.  
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Figure 4.9. Impact of LH/CGR-B expression on LH/CGR-A signalling. (A) HEK293 cells were 
transfected with LH/CGR-A, LH/CGR-B or both variants. Cells were then stimulated with hCG at 
different time points (0 – 45 minutes) as indicated. Levels of p-ERK1/2 were assessed by Western 
blotting and t-ERK was used as a loading control. Densitometry of p-ERK1/2 and t-ERK1/2 was 
carried out and levels of p-ERK1/2 were normalised to t-ERK1/2 (B). Error bars: ± SEM. n=3.  
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4.2.8 The CB1R and LH/CGR signalling 
As described in the introduction of this chapter, the CB1R is known to associate with a number of 
other GPCRs and this interaction can modulate their signalling outcomes. In order to investigate 
if the CB1R may be involved in the signalling of LH/CGR in HESCs, I used the CB1R specific 
inverse-agonist, SR141716A (SR1) (also termed rimonabant). Inverse agonists/antagonists of the 
CB1R have previously been shown to prevent its constitutive and agonist-induced internalisation 
[390, 391] and modulate its signalling profile. I hypothesised that if the endogenous LH/CGR and 
CB1R exhibit receptor crosstalk and the constitutive internalisation and/or the signalling activity 
of the CB1R is blocked, the cAMP or MAPK (ERK1/2) signalling profile of the LH/CGR may be 
altered in HESCs. To measure the effect of the CB1R inverse agonist on hCG-mediated cAMP 
signalling, undifferentiated HESCs were grown to confluency and pre-treated for 3 hours with 
100nM of SR1 or DMSO (vehicle). Cells were then treated with hCG, Fsk (the adenylate cyclase 
activator) or a combination of both and cAMP accumulation was then measured, levels of which 
are shown in Figure 4.10A. Consistent with previous results, hCG alone did not induce cAMP 
accumulation yet inhibited Fsk-induced cAMP levels from 374.3 ± 2.8 pmol/mg to 168.1 ± 4.2 
pmol/mg. However, following pre-treatment with SR1 hCG was able to induce an increase in 
cAMP levels, from 29.8 ± 2.8 pmol/mg to 56.8 ± 19 pmol/mg. Strikingly, this cAMP increase 
was amplified when hCG, SR1 and Fsk were applied, from 168.1 ± 4.2 pmol/mg in Fsk and hCG 
treated cells to 565.8 to 17.6 pmol/mg when combined with SR1. Notably, in cells treated with 
Fsk and SR1 alone, cAMP levels decreased from that of Fsk alone, to 153.0 ± 3.9 pmol/mg. This 
is somewhat confounding since SR1 inhibits the Gαi-coupled CB1R. Collectively, this data may 
suggest that CB1 inhibition via SR1 has a reversal effect on hCG cAMP signalling, allowing it to 
instead increase levels of cAMP. 
Whether CB1R could also be involved in hCG-induced MAPK signalling was also 
determined. HESCs were pre-treated with SR1 or DMSO as above and cells were then challenged 
at different time points with hCG. ERK1/2 activation was then determined via Western blotting 
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(Fig. 4.10B). In cells without SR1, a transient signalling profile was seen, with a peak 
phosphorylation at 5-10 minutes of hCG stimulation. In SR1 treated samples, the phosphorylation 
profile was more sustained, with phospho-ERK being present until the later time point of 45 
minutes. This preliminary data suggests that CB1R may regulate hCG-induced signalling in 
HESCs.  
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Figure 4.10. The CB1 inverse agonist SR1 may alter endogenous signalling in HESCs in 
response to hCG. (A) cAMP signalling profiles in HESCs treated with SR1. Undifferentiated HESCs 
were grown to confluency and treated with hCG or Forskolin (Fsk) or a combination of them both for 
30 minutes. Cells were treated with the CB1 inverse-agonist SR141716A (SR1) (100nM) or DMSO 
(vehicle) for 3 hours prior to hCG and Fsk treatments. Cells were then lysed and intracellular cAMP 
accumulation (pmol/mg) was analysed using an ELISA-based assay. Levels were then normalised to 
levels of protein. (B) ERK1/2 profiles of HESCs treated with hCG without or with SR1. Confluent 
undifferentiated HESCs were treated with either SR1 (100nM) or DMSO for 3 hours prior to 
treatments with hCG for 0 – 45 minutes. Cells were then lysed and phospho-ERK1/2 levels was 
analysed via Western blotting. Total-ERK1/2 was used as a loading control. Densitometry analysis of 
p-ERK1/2 activation normalised to t-ERK is shown in the bar graph (C). n=1 patient sample.  
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4.2.9 SR1 treatment may alter LH/CGR endosomal compartmentalisation 
Given CB1R is a known constitutively internalised receptor and that inhibition of CB1 activity 
with SR1 may modulate hCG-induced signalling, I speculated that blockade of CB1R activity 
(and internalisation) could also block LH/CGR internalisation. To test this notion, 
undifferentiated HESCs were transfected with LH/CGR and after 48 hours cells were exposed to 
SR1 or DMSO for 3 hours and receptor cell-surface labelling was carried out before exposure to 
hCG. In DMSO treated cells, internalisation of the LH/CGR was observed both in unstimulated 
and stimulated conditions. In cells treated with SR1, no difference was seen in the localisation of 
the LH/CGR compared to the control condition and therefore it did not appear that this inverse 
agonist could prevent LH/CGR constitutive or agonist-induced internalisation (Fig. 4.11A). 
However, it was noted that there was a change in endosome size in cells that had been exposed to 
SR1, in both unstimulated and hCG-stimulated conditions. Endosome size changes indicate 
alterations in the type of endosome compartment (described in Chapter 1) [301]. Quantitation of 
endosome diameter indicated that mean endosome size was 423.5nm ± 7.2nm in DMSO treated 
cells whereas in SR1 treated cells endosome size was on average larger at 525.7nm ± 34.8nm. 
The same was evident in hCG-stimulated cells, where endosome size was 414.9nm ± 6.5nm in 
control vs 543.1nm ± 27.1nm in SR1 treated cells (Fig. 4.11B). Strikingly, in some SR1 treated 
cells, the endosomes were of a size that the interior lumen could be seen (Fig. 4.11A, insets). 
Though this data does not indicate that the constitutive internalisation can be blocked by 
inhibiting the CB1 with SR1, it suggests that the constitutive and agonist-induced endocytic 
compartmentalisation and possibly endocytic fate of the receptor may be modulated by CB1R. 
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Figure 4.11. The CB1 inverse agonist SR1 modulates the trafficking of undifferentiated HESCs. 
(A) Representative confocal images of HESCs treated with or without SR1. Undifferentiated cells 
were transfected with LH/CGR and subsequently were exposed to DMSO or SR1 (100 nM) for 3 hrs 
prior to receptor anti-Flag antibody labelling and stimulation with hCG (10 nM) for 20 minutes. Surface 
receptor was stripped using EDTA prior to fixation. (B) Endosome size was measured and plotted (8-
10 cells/condition, 40 endosomes/cell measured). Scale bars: 10 μm (top panels), 5 μm (lower 
panels). n=1 infertile (control) patient sample. 
Unstimulated + hCG Unstimulated + hCG 
+ DMSO  + SR1 
A 
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 Discussion 4.3
My findings in Chapter 3 reported an atypical constitutive internalisation and recycling of the 
LH/CGR in HESCs and, importantly, a potential ‘reprogramming’ ability of its activity upon 
decidualisation. In this current chapter, I have explored potential mechanisms underlying this 
LH/CGR constitutive internalisation and, additionally, how some of these might play a role in 
receptor signalling.  
A prototypical protein player in GPCR internalisation is the GTPase dynamin and here I 
have shown that this is essential for LH/CGR internalisation in HESCs. Inhibition of dynamin 
markedly impaired constitutive and agonist induced internalisation of the receptor as well as 
MAPK activation. This confirms previous work that LH/CGR agonist-induced internalisation and 
signalling is dynamin-dependent [301]. It also highlights that the unliganded receptor may utilise 
the same internalisation machinery as the liganded receptor. Currently, it can only be assumed 
that this internalisation is via CDE because this is known to involve dynamin and because of 
previous knowledge that LH/CGR utilises this mechanism in other cell systems [285]. However, 
other pathways of endocytosis cannot be dismissed since dynamin is not exclusively involved in 
CDE [392]. These pathways include clathrin-independent pathways such as caveolae-mediated 
endocytosis, known to be involved in GPCR endocytosis [393], and the newly described fast 
endophilin-mediated endocytosis (FEME) [394]. Switching between CIE and CDE depending on 
constitutive or agonist driven internalisation is known for some GPCRs, for example, the β2AR 
and the M3 acetylcholine muscarinic receptor [395]. Thus it may be pertinent to investigate 
further the mechanism of internalisation of the LH/CGR and indeed if this switches following 
agonist exposure or between undifferentiated and decidualised cells. Blockade of receptor 
internalisation via inhibition of dynamin theoretically increases the availability of receptor to bind 
to ligand and prevents desensitisation, however it decreased the ability of the LH/CGR to signal 
meaning that internalisation is required for signalling, at least in terms of MAPK. Since cAMP 
signalling is known to occur from endosomes [223], it could be possible that dynamin inhibition 
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would also change the Gαi signalling profile or even cause coupling to Gαs. Although the 
integrated relationship between signalling and trafficking is well known, Gαi inhibition did not 
change the ability of LH/CGR to internalise. This may not be a component involved in the 
internalisation of the LH/CGR, but does not rule out the possibility that other signalling pathways 
may be involved in internalisation such as MAPK. Indeed MAPK activation has been shown to 
either inhibit or induce internalisation of other receptors [396, 397].  
I also report that the LH/CGR C-terminal tail is not required for its constitutive 
internalisation. This indicates that C-tail motifs, responsible for binding proteins such as PDZ 
domain containing proteins and a common site for receptor phosphorylation, are not required to 
interact with the receptor to facilitate its internalisation. However, this does not necessarily mean 
that these truncated receptors are functionally equivalent to the full-length LH/CGR, and indeed 
the last 17 residues of the receptor are known to be required for receptor recycling and MAPK 
signalling in HEK293 cells [301]. Thus phosphorylation of the intracellular loops of the receptor 
may be involved in its constitutive internalisation, especially the third intracellular loop given that 
I have also reported here that β-ARR1 co-localises with the LH/CGR, and this is known to be via 
this region [279].  
Interestingly, HESCs only express β-ARR1 and LH/CGR can recruit this protein in both a 
constitutive and agonist-induced manner. β-ARRs are not well-studied in HESCs and although 
there has previously been a report of β-ARR1 in these cells [398], to my knowledge this is the 
first time this has been compared with levels of β-ARR2 and thus the physiological significance 
for this preferential expression is unknown in these cells. As described, β-ARRs are prime 
candidates involved in GPCR internalisation so the co-localisation I observed is not necessarily 
unanticipated. However, what is intriguing is that the receptor can associate with β-ARR1 in its 
agonist-free state and, since β-ARRs canonically bind to agonist-activated, phosphorylated 
receptors, this is perhaps a less common occurrence [399, 400]. I did not investigate if co-
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localisation required basal or agonist-activated phosphorylation, however, phosphorylation-
dependent/independent, but β-ARR-dependent constitutive internalisation is known for other 
GPCRs such as the chemokine decoy receptor D6 and a mutant vasopressin receptor [401, 402], 
so the LH/CGR may not need to be phosphorylated to interact with β-ARR1 in these cells. 
Additionally, it is possible that if agonist-free LH/CGR and β-ARR1 do directly interact that this 
is not due to interactions with the C-tail, as previously reported [279]. Given the strong co-
localisation of the receptor with β-ARR1, this raises the question if β-ARR1 is another 
prerequisite for constitutive internalisation and signalling of LH/CGR, like dynamin. Attempts 
were made to deplete cellular β-ARR1 via RNA interference, however, due to the abundance of 
this protein in HESCs, knockdown levels were not efficient enough for subsequent trafficking or 
signalling experiments (data not shown). Any further experiments could use more recent genome 
editing methods to knockdown β-ARR1 in HESCs, for example via the Crispr/Cas9 system [403].  
I also investigated the hypothesis that this uncharacteristic LH/CGR constitutive 
internalisation and signalling profile is modulated by crosstalk with other GPCRs, such as its own 
splice variants and/or the constitutively active Gαi-coupled CB1R. I have shown here that all 
splice variants of the receptor are expressed in HESCs. In HEK293 cells, LH/CGR-B alone was 
not detectable at the cell surface, consistent with prior observations [246]. However, this 
expression was ‘rescued’ by the full length LH/CGR, although the expression of the full length 
receptor was negatively impacted. In cells that did co-express both receptors the LH/CGR-B co-
trafficked with the full-length receptor in HEK293 cells in response to hCG, although it is 
unknown if only LH/CGR-A is activated and/or both receptors respond to ligand activation. 
However, co-expressing this variant did not modulate the signalling profile following hCG 
addition, although given the decrease in LH/CGR-A levels in the presence of LH/CGR-B, this 
could be interpreted as a potential increase in activity. Prior studies in HEK293 and COS-7 cells 
have indicated a dominant negative function of these variants on full length receptor, primarily 
due to a strong inhibition of full-length receptor surface expression and retention in the ER/Golgi 
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[246, 248, 404]. This study agrees in part with these prior findings and together may suggest that 
detection of upstream hCG/LH/CGR G-protein signalling in HESCs may vary (Chapter 3) due to 
differences in expression of these variants. 
Despite the known constitutive properties of the CB1R, this receptor does not seem to be 
involved in the constitutive internalisation of LH/CGR in HESCs yet preliminary data indicate it 
may regulate the type of endosomes LH/CGR traffics to, a property that in other cell types can 
regulate temporal kinetics of MAPK signalling [301]. Using endosomal markers such as early 
endosomal antigen 1 (EEA1) would identify if the endosomes are indeed representative of a 
separate compartment. Furthermore, crosstalk of CB1R with LH/CGR may underlie its ability to 
activate Gαi signalling instead of Gαs. CB1R-dependent signalling changes have been reported 
before with other GPCRs, for example, for dopamine D2 receptors, the expected Gαi response 
from this receptor is switched to Gαs when it is co-expressed with CB1R in HEK293 cells [383, 
405]. Interestingly, CB1R seems to have a dual ability to either enhance or dampen signalling 
responses depending on the receptor it interacts with. Co-expression of orexin-1 receptors with 
CB1R causes orexin-1 ‘hypersensitivity’ in CHO cells, increasing MAPK activation by 100-fold 
compared to cells expressing the orexin-1 receptor alone [406], whereas another study reported 
that CB1R blunted MAPK activation from the mu-opioid receptor [407]. Thus, changes in 
trafficking and signalling I see with the LH/CGR in the presence of a CB1R inverse agonist is 
plausible if the receptor is indeed interacting with CB1R. I did not investigate a direct interaction 
of these receptors here, but this could be carried out using methods such as bioluminescence 
resonance energy transfer (BRET) or proximity ligation assays (PLA) (recently reviewed in [408, 
409]), the latter of which has been shown to detect the heterodimerisation of CB1R with CB2R 
[410]. The data on CB1R is preliminary but opens up novel possibilities on how LH/CGR may be 
regulated in HESCs.  
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In this Chapter I have investigated potential mechanisms underlying LH/CGR constitutive and 
agonist induced internalisation. However, the potential physiological reasons behind the 
constitutive internalisation have not been elucidated. There are several reasons that have been 
proposed for the constitutive internalisation of other GPCRs. Constitutive internalisation can be 
essential for function, for example, in the case of the thrombin receptor a pool of intracellular 
receptors is required for responsiveness to thrombin [411] and the CB1R internalises at the 
somatodendritic membrane to enable it to be re-routed to the axonal membranes [359]. At this 
stage, I can only speculate the reasons for LH/CGR constitutive internalisation in HESCs, and 
why this is reduced upon decidualisation. It may be simply to regulate receptor cell surface 
expression and increases at decidualisation so that the stromal cells can respond robustly to hCG. 
Although, the signalling I have observed is not amplified in decidualised HESCs (Chapter 3). 
Alternatively, constitutive internalisation may confer basal activity and this may be required for 
expression of proteins or receptors in preparation for decidualisation and/or negative regulation of 
decidualisation. More provocatively, the constitutive internalisation of the receptor could 
represent the existence of endogenous LH or hCG production or a novel class of LH/CGR ligands 
produced by undifferentiated HESCs, although this has never been reported.  
Overall, this chapter has unveiled some of the mechanisms involved in constitutive and 
agonist-induced LH/CGR internalisation and shown that this requires dynamin and involves 
recruitment of βARR1. Additionally, it suggests that the receptor signalling profile in HESCs 
may involve crosstalk with distinct GPCRs. In conclusion, this data provides novel insights into 
the intricacies of LH/CGR trafficking in HESCs and additionally highlights candidates which 
may regulate how hCG exerts its function.  
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 Introduction 5.1
It is now known that membrane trafficking in the endocytic pathway is deeply integrated with 
both short-term and long-term GPCR-mediated signalling pathways [330]. Understanding how 
trafficking and signalling are integrated has proved to be important in enhancing our 
understanding of how these receptors might function in vivo. What has become clear is that 
location is a highly important factor in signal regulation and delineating the mechanisms by 
which receptors are directed to their correct signalling site is paramount in the field of GPCR 
biology. Chapter 3 elucidated some of the fundamental trafficking profiles of the LH/CGR in 
HESCs and this current results chapter will assess the localisation of the receptor following 
internalisation and how that may impact on signalling responses.  
GPCR signalling from endosomes can change or be amplified as they move through the 
endocytic pathway to their degradative or recycling endpoints [412] and precise elucidation of 
receptor signal transduction requires parallel understanding of their endocytic trafficking routes. 
More recently our group has shown that the LH/CGR in HEK293 cells localises to a novel 
endocytic compartment, the very early endosome (VEE) [301] (described in detail in the Chapter 
1). In brief, the VEE is a distinct compartment upstream from the classic early endosome (EE), 
which is the prototypical cargo sorting station. It is considerably smaller in diameter, positive for 
the adaptor protein APPL1 but negative for the EE marker early endosome antigen 1 (EEA1) and 
requires the internalised LH/CGR to interact with GIPC in order to localise to this compartment. 
Importantly, if the LH/CGR is prevented from localising to the VEE (for example, by cellular 
depletion of GIPC) this can have dramatic consequences, for example, receptor recycling to the 
plasma membrane is inhibited and the spatiotemporal regulation of MAPK signalling is 
dramatically disrupted, meaning that the VEE is essential for the functionality of this receptor.  
The data from this study made it highly pertinent to investigate if this novel compartment 
may also exist in a physiologically relevant system for this receptor such as HESCs and its 
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downstream function in the endometrium. In the present chapter, I seek to address two principal 
questions; (1) does the LH/CGR localise to a VEE compartment in HESCs?; (2) if so, does 
prevention of the receptor from entering the VEE change the signalling profile of the receptor 
and/or have any impacts on downstream hCG action? 
 
 
 Results 5.2
5.2.1 Components of the VEE pathway, GIPC and APPL1, are expressed in the 
endometrium 
Before analysing potential trafficking of the LH/CGR to the VEE pathway in HESCs, I first 
addressed if the two known components of this pathway, GIPC and APPL1, are expressed in the 
human endometrium. Transcript levels of GIPC and APPL1 were assessed from microarray data 
available from the GEO (ID24460199) where gene expression through the four main phases of 
the cycle, the proliferative, early-secretory, mid-secretory and late-secretory phases, were 
analysed from endometrial biopsies of 28 women with normal cycles [413]. GIPC levels in each 
cycle was acquired from in silico analysis of this data and compared across each phase of the 
cycle (provided by Jan Brosens). Levels of both GIPC and APPL1 appeared to peak at the mid-
secretory phase and then drop significantly at the late-secretory phase (Fig. 5.1A). This change 
was interesting since the mid-secretory phase, which spans days 20-23, coincides with the 
window of implantation and the start of decidualisation and suggests they may be playing a role 
during this time. Microarray data that had been obtained from isolated HESCs from control 
patients and were undifferentiated and decidualised were also analysed (provided by Jan Brosens) 
and showed a slight increase of GIPC levels in decidual cells but this change was not significant 
(Fig. 5.5B, left panel). APPL1 levels appeared to decline slightly in decidualised cells, but again 
this was not a significant change (Fig. 5.1B, right panel).  
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In addition to gene transcript data, APPL1 and GIPC protein levels were determined in cultured 
HESCs before and after decidualisation via Western blot using APPL1 and GIPC specific 
antibodies. It appeared that both were present at comparable levels in undifferentiated and 
decidualised cells (Fig. 5.1C). Although expression of these proteins did not imply that they are 
involved in LH/CGR action, it did confirm that the main known components of the VEE are 
present in HESCs thus warranting further study into this compartment in the context of LH/CGR 
trafficking. 
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Figure 5.1. GIPC1 and APPL1 expression in the endometrium. (A) Data was acquired from 
publicly available microarray data (GEO profiles; ID24460199) [413] and analysed to generate levels 
of GIPC1 (left) and APPL1 (right) transcripts, expressed in arbitrary units (A.U.), in proliferative phase 
(PP), early-secretory phase (eSP), midsecretory phase (mSP), and late-secretory phase (lSP) human 
endometrium. (B) GIPC1 (left) and APPL1 (right) transcript levels (A.U.) as determined by microarray 
in undifferentiated versus decidualised HESCs from control patents. Data analysed and provided by 
Jan Brosens and Ruban Durairaj. (C) HESCs were either undifferentiated or decidualised for 72 hours 
with 8-Bromo-cAMP and MPA (C+M) before lysing for Western blot analysis. Membranes were 
probed using GIPC (left) or APPL1 (right) and GAPDH antibodies. Levels were quantified using 
densitometry and were both then normalised to relative levels of GAPDH. Graphs show fold change 
(F.C) of undifferentiated cells, n=4 infertile (control) patients. *, p<0.05 using the Student’s t-test. 
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5.2.2 The LH/CGR traffics to endosomes positive for GFP-tagged GIPC and 
APPL1  
In order to ascertain if expressed GIPC and APPL1 proteins were relevant in the endosomal 
targeting of LH/CGR in HESCs, I sought first to investigate if they both engage with the receptor 
at the level of LH/CGR containing endosomes. HESCs were decidualised or left undifferentiated 
and were transfected with LH/CGR and either GFP-tagged GIPC or APPL1 constructs. Cells 
were then exposed to hCG for 20 minutes or left unstimulated. There was clear co-localisation of 
LH/CGR endosomes with both APPL-GFP and GIPC-GFP (Fig. 5.2A&B) and approximately 20-
30% of LH/CGR endosomes were positive for APPL1-GFP and 40-50% were positive for GIPC-
GFP (Fig. 5.2C). This did not change significantly across conditions or if the cells were 
decidualised or undifferentiated.  
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Figure 5.2B 
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Figure 5.2. LH/CGR colocalises with GFP-tagged GIPC and APPL1. HESCs were undifferentiated 
or decidualised for 72 hours. Flag-tagged LH/CGR and GIPC-GFP or APPL1-GFP constructs were 
transfected in 24 hours following the start of decidualisation. Cells surface receptor was labelled using 
anti-Flag antibodies and cells were either left unstimulated or stimulated with hCG (10nM) for 20 
minutes. Cells were then washed before fixation, permeabilisation and staining with 
immunofluorescent secondary antibodies for LH/CGR shown in red. GIPC-GFP and APPL1-GFP are 
green. Representative confocal images from undifferentiated cells and decidualised cells are shown. 
White arrows indicate example areas of co-localisation. Scale bars: 10µm and 5µm (insets). (C) Bar 
graph showing the number of LH/CGR endosomes positive for GIPC-GFP and APP1-GFP (%) which 
was quantified from images in each condition (40-60 endosomes/cell, 5 cells/condition). Data is 
presented as mean (± SEM). n=3 infertile (control) patients. 
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5.2.3 The LH/CGR co-localises with endosomes positive for endogenous APPL1 
To substantiate the data showing that the LH/CGR co-localises with exogenously expressed VEE 
components, I next sought to establish if the receptor also co-localised with endogenous APPL1. 
Endogenous GIPC co-localisation could unfortunately not be performed due to lack of 
availability of antibodies suitable for immunofluorescent microscopy. HESCs were 
undifferentiated or decidualised, transfected with LH/CGR and were either untreated or 
stimulated for 20 minutes with hCG. Cells were stained for endogenous APPL1 post-fixation. 
Images are shown in Figure 5.3A. In unstimulated cells, 25.2 ± 3.6% and 20.7 ± 1.0% of 
LH/CGR endosomes were positive for APPL1 in undifferentiated and decidualised cells 
respectively. In stimulated cells, levels of co-localisation were similar, with 19.9 ± 3.2% and 19.8 
± 2.5% if LH/CGR endosomes positive for endogenous APPL1 (bar graphs shown in Fig. 5.3B). 
Thus, a sub-population of LH/CGR endosomes route to APPL1-positive compartments. It also 
infers that overexpression of APPL1-GFP is not artificially forcing the LH/CGR into APPL1 
endosomes as it locates to a comparable number of endosomes as the endogenous APPL1. 
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Figure 5.3. LH/CGR co-localises with endogenous APPL1. (A) HESCs were undifferentiated or 
decidualised for 72 hours. Flag-tagged LH/CGR was transfected in 24 hours following the start of 
decidualisation. Cell surface receptor was labelled using anti-Flag antibodies for 15 min and cells 
were either left unstimulated or stimulated with hCG (10nM) for 20 minutes. Cells were then washed 
before fixation, permeabilisation and staining with antibodies to APPL1. Immunofluorescent 
secondary antibodies were then used to stain LH/CGR (red) and APPL1 (green). Representative 
confocal images from undifferentiated cells and decidualised cells (A) are shown. White arrows 
indicate example areas of co-localisation. Scale bars: 10µm (upper panels), 5µm (insets). (B) Bar 
graph showing number of LH/CGR endosomes co-localised to APPL1 (%) which was quantified from 
images in each condition (50-90 endosomes per cell, 5 cells quantified/condition). Data is presented 
as mean (± SEM). n=1 infertile (control) patient sample.  
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5.2.4 The LH/CGR internalises into small, VEE-like endosomes 
In live HEK293 cells, the LH/CGR is known to localise to endosomes which are 400-500nm in 
diameter in contrast to the prototypical β2AR which is enriched into larger endosomes of 1200-
1400nm and is known to classically compartmentalise in the EE, not the VEE. Therefore, simply 
physical endosome size could be a preliminary indicator of VEE localisation and I sought to 
determine the size of LH/CGR endosomes in HESCs and additionally, if the β2AR was found in 
larger endosomes. To test this, undifferentiated and decidualised cells were transfected with the 
Flag-tagged LH/CGR or β2AR and cell surface receptor was labelled prior to stimulation with 
hCG or isoproterenol (the β2AR agonist) for 20 minutes or left unstimulated. Anti-Flag antibody 
was stripped with EDTA to allow easy visualisation of endosomal structures. Representative 
images of fixed cells taken by confocal microscopy are shown in Figure 5.4A. Endosome size 
measurements in experiments revealed that the LH/CGR is localised to endosomes of between 
200-700 nm in diameter in fixed cells but the majority of these endosomes were on average 
between ~360-380 nm diameter across conditions in undifferentiated and decidualised cells 
(shown in the bar graph, Fig. 5.4B). Since the β2AR does not exhibit constitutive internalisation 
(Chapter 3), receptor could not be observed following cell surface antibody stripping and 
therefore only images from stimulated cells are shown (Fig. 5.4A, right panel). In contrast to the 
LH/CGR, the β2AR localised to endosomes that were larger in fixed cells, ~550 nm on average in 
both undifferentiated and decidualised cells and in some cases, endosomes were found in 
structures of up to 1400 nm in diameter. Although the average β2AR size is smaller in fixed cells 
than observed in live HEK293 cells, it was still significantly larger than the LH/CGR and 
suggests that these receptors may locate to distinct sub-compartments. The small size of LH/CGR 
endosomes also suggests that the receptor could localise to VEEs in HESCs. Furthermore, the 
small LH/CGR endosomes primarily were enriched near the cell periphery, whereas the β2AR 
endosomes were located more towards the cell centre (Fig. 5.4A). Since the VEE is known to be 
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upstream of the EE, and possibly the first sorting station after endosome budding from the plasma 
membrane, this is consistent with the closer proximity of pre-early endosomes to the cell surface.  
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Figure 5.4. LH/CGR versus β2AR endosome size in HESCs. (A) HESCs were undifferentiated or 
decidualised for 72 hours. Flag-tagged LH/CGR or β2AR were transfected in 24 hours following the 
start of decidualisation. Cell surface receptor was labelled using anti-Flag antibodies for 15 minutes 
and cells were either left unstimulated or stimulated with hCG (10nM) or isoproterenol (10µm) for 20 
minutes. Cells were then washed and cell surface receptor stripped using EDTA before fixation, 
permeabilisation and labelling with immunofluorescent antibodies. Cells were then imaged using a 
confocal microscope. Scale bars: 10µm (large image), 5µm (insets) (B) Bar graph showing endosome 
diameter which was quantified from images in each condition (20-30 endosomes per cell, 5 cells per 
condition). Data is presented as mean (± SEM). n=3 infertile (control) patient samples.  
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5.2.5 Endocytic sorting of the LH/CGR is sequence-dependent 
In HEK293 cells, GIPC is required to direct the LH/CGR to the VEE. Considering that LH/CGR 
enriches in small, VEE-like endosomes, I wanted to assess if blocking the ability of the receptor 
to bind GIPC would change receptor endosomal location. GIPC is known to interact with the 
LH/CGR via its PDZ domain binding motif [292] and the mutant LH/CGR, LH/CGR-683T, 
lacking the last 17 residues of the C-terminal tail of the LH/CGR, which contains its PDZ ligand, 
causes the receptor to primarily locate to the EE and not the VEE in HEK293 cells [301]. Using 
the mutant LH/CGR-683T, I wanted to test if the latter was also true in HESCs. To address this 
question, I transfected undifferentiated or decidualised HESCs with full-length or truncated 
receptors and used confocal microscopy to visualise the co-localisation of these receptors with 
EEA1, an EE but not a VEE marker, with and without hCG stimulation (Fig. 5.5A&B). The cells 
were stripped of surface anti-Flag antibody to ensure only internalised receptor was visualised. 
The percentage of receptors positive for EEA1 was then quantified. In unstimulated 
undifferentiated HESCs, 44.3 ± 3.4% of LH/CGR endosomes co-localised to EEA1 in contrast to 
significantly more LH/CGR-683T endosomes that displayed 65.6 ± 3.3% co-localisation. 
Likewise, following stimulation co-localisation levels were 41.9 ± 3.5% for LH/CGR and 61.2 ± 
3.9% for LH/CGR-683T. This difference between the two receptors was also evident in 
decidualised cells which exhibited internalisation, with 44.7 ± 1.9% of LH/CGR and 66.5 ± 3.2% 
of LH/CGR-683T endosomes co-localising with EEA1 in unstimulated cells and 46.9 ± 3.5% of 
LH/CGR and 63.4 ± 3.2% of LH/CGR-683T positive for EEA1 in stimulated cells (Fig. 5.5C). 
This data demonstrates that the C-terminal tail is necessary for a proportion of LH/CGR to be 
targeted to EEA1-negative endosomes, and potentially could require the interaction of GIPC.  
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Figure 5.5. Truncation of the LH/CGR causes it to locate to a higher proportion of EEA1-
postive endosomes. HESCs were undifferentiated or decidualised for 72 hours. Flag-tagged 
LH/CGR or LH/CGR-863T was transfected in 24 hours following the start of decidualisation. Cells 
surface receptor was labelled using anti-Flag antibodies for 15 minutes and cells were either left 
unstimulated or stimulated with hCG (10nM) for 20 minutes. Cells were then washed before fixation, 
permeabilisation and staining with antibodies to EEA1. Immunofluorescent secondary antibodies were 
then used to stain LH/CGR and LH/CGR-683T (red) and EEA1 (green). Representative confocal 
images from undifferentiated cells (A) and decidualised cells (B) are shown. Scale bars: 10µm, 5µm 
(insets). (C) Bar graph showing the percentage of LH/CGR and LH/CGR-683T endosomes co-
localised to EEA1 (%) which was quantified from images in each condition (60-100 endosomes per 
cell, 5 cells quantified/condition). Data is presented as mean (± SEM). n=3 infertile (control) patient 
sample.  
 
 
 
 
C 
Chapter 5: Results III  
 
190 
 
5.2.6 GIPC knockdown may re-route more LH/CGR to the EE 
To directly address if GIPC is essential for endosomal targeting of LH/CGR in HESCs and the 
potential downstream role of this compartmentalisation in hCG function, cellular levels of GIPC 
were depleted in HESCs via siRNA. To this end, HESCs were grown to confluency and 
transfected with siRNA-GIPC or siRNA-NT (non-targeting siRNA) 24 hours prior to 
decidualisation. The LH/CGR was transfected along with re-transfection of siRNA oligos 24 
hours following the start of decidualisation. Cells were then stimulated with hCG after the full 3 
days of decidualisation and then assessed for levels of EEA1 co-localisation. Level of GIPC 
knockdown efficiency was assessed by Western blotting (Fig. 5.6B) and cells transfected for 
siRNA-GIPC were robustly depleted of GIPC compared to siRNA-NT transfected cells. 
Representative images of LH/CGR co-localisation with EEA1 in stimulated cells are shown in 
Figure 5.6A. In cells transfected with siRNA-NT, I observed 44 ± 5.2% of LH/CGR endosomes 
co-localising with EEA1, consistent with previous observations. In cells transfected with siRNA-
GIPC, this level of EEA1 co-localisation increased to 61.0 ± 4.7% (Fig. 5.6C). This appears to be 
consistent with the LH/CGR-683T data and suggests that GIPC may be mediating the endocytic 
sorting of the full-length receptor. However, this preliminary experiment has to this point only 
been carried out in 1 patient sample, thus needs to be repeated to ascertain if this is the case in a 
larger group of samples.  
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Figure 5.6. Effect of GIPC knockdown on LH/CGR compartmentalisation in decidualised 
HESCs. HESCs were transfected with either non-targeting (NT) or GIPC siRNA oligos for 72 hours. 
Cells were then decidualised with cAMP and MPA (C+M) and were re-transfected with siRNA oligos 
and Flag-tagged LH/CGR 24 hours after the start of decidualisation. After 72 hours of decidualisation, 
cell surface receptor was labelled with anti-Flag antibody and cells were stimulated with hCG for 20 
minutes. Cells were then fixed, permeabilised and subject to primary antibody staining for EEA1. Cells 
were then labelled with immunofluorescently tagged secondary antibodies for the receptor (red) and 
EEA1 (green). Representative images are shown (A). Efficiency of GIPC knockdown was assessed 
LH/CGR EEA1 Merge 
siRNA-NT 
siRNA-GIPC 
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Western Blot and is shown in (B). Confocal images were quantified to assess the % of LH/CGR 
endosomes positive for EEA1 (C). n= 1 infertile (control) patient.  
5.2.7 GIPC knockdown may attenuate hCG-mediated down regulation of decidual 
gene markers 
The above data suggests that GIPC may be important for the correct endosomal location of the 
LH/CGR in HESCs. Therefore, I next aimed to assess if GIPC knockdown could change the 
endogenous action of hCG in HESCs. Chapter 3 and prior reports [112, 113] demonstrated that 
hCG has the ability downregulate decidual gene markers in HESCs and I have also shown that it 
activates MAPK signalling in an internalisation-dependent manner (Chapter 4). Thus hCG and 
the endogenous LH/CGR in HESCS could be regulated at a spatial level via the VEE. To test this 
hypothesis, the effect of GIPC knockdown in HESCs on hCG downstream functions were 
assessed.  
Downstream gene expression of decidual markers in HESCs were analysed via RTQ-
PCR. I assessed if depletion of GIPC prior to the start of decidualisation in the presence of hCG 
could reverse hCG-induced downregulation of decidual gene markers, prolactin (PRL), 
prokineticin 1 (PROK1), and superoxidase dismutase 2 (SOD2) in HESC cultures from 3 control 
patients. To this end, undifferentiated HESCs were transfected with non-targeting siRNA-NT or 
siRNA-GIPC 3 days prior to treatment with cAMP and MPA in the presence or absence of hCG 
for 72 hours. siRNA-NT and siRNA-GIPC was re-transfected 24 hours following the start of 
decidualisation to ensure GIPC depletion was maintained throughout the decidual process. Total 
protein was collected following the initial siRNA-GIPC treatments prior to decidualisation as 
well at the end point of the experiment after 72 hours of decidualisation. Lysates were subject to 
analysis via Western blot to assess levels of GIPC protein. Cellular levels of GIPC were depleted 
by 75 ± 5.2% prior to decidualisation compared to siRNA-NT transfected cultures (Fig. 5.7A, left 
panel). This was maintained until the end of the decidualisation time course, where GIPC levels 
were diminished by 91.2 ± 4.5% of siRNA-NT treated samples (Fig. 5.6A, right panel). Total 
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RNA was also extracted at the end of decidualisation and samples were subjected to RTQ-PCR to 
assess levels of decidual gene markers. Interestingly and important to note, was that the levels of 
mRNA for each gene in decidualised cells in the absence of hCG were reduced in cells treated 
with siRNA-GIPC compared to siRNA-NT, with PRL being reduced by 58.9 ± 6.0%, PROK1 by 
64.0 ± 10.7% and SOD2 by 26 ± 7.1% (Fig. 5.7B). Therefore, the effect of hCG on decidual 
mRNA expression in siRNA-NT and siRNA-GIPC treated cultures was normalised to levels in 
cells decidualised without hCG with siRNA-NT or siRNA-GIPC respectively (Fig. 5.7C). I, and 
others [112, 113] have previously observed that hCG reduces levels of PRL and PROK1 in 
decidualised cells, in this sample set hCG treatment reduced the levels of PRL and PROK1 by 
40.0 ± 8.6% and 47.0 ± 10.6% respectively. Interestingly, in GIPC-depleted decidual cells, the 
amount of hCG-mediated PRL and PROK1 inhibition decreased to 23.2 ± 11.0% and 16.5 ± 
17.6%. I also observed a marked reduction of SOD2 in the presence of hCG in siRNA-NT treated 
samples by 70.7 ± 6.0%. Remarkably, this effect was partially but significantly reversed in cells 
transfected with siRNA-GIPC, where the reduction was 48.2% ± 7.8%. These results suggest that 
GIPC may be required for hCG-mediated downregulation of decidual genes and could suggest 
that that this change in endogenous hCG function is due to altered receptor location.  
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Figure 5.7. GIPC knockdown attenuates hCG-mediated downregulation of decidual gene 
markers. Undifferentiated HESCs were transfected with either non-targeting (NT) or GIPC siRNA 
oligos for 72 hours. Cells were then either lysed for Western blot analysis in order to assess GIPC 
knockdown efficiency prior to decidualisation (A, left panel, shows representative blots and 
knockdown quantitation) or remained in culture and were decidualised with cAMP and MPA (C+M) 
with or without hCG. Cells were re-transfected with siRNA oligos 24 hours after the start of 
decidualisation. After 72 hours of decidualisation cells were then either collected for Western blot 
analysis to assess GIPC levels (A, right panel, shows representative blots and knockdown 
quantitation) or for RNA extraction. RTQ-PCR was then used to measure the expression levels of 
PRL, PROK1 and SOD2 transcripts in HESCs treated with siRNA-NT or siRNA-GIPC as indicated 
and in the presence of hCG. The data is shown as the percentage change (± SEM) relative to cells 
decidualised transfected with siRNA-NT (for siRNA-NT treated samples) or siRNA-GIPC (for siRNA-
GIPC treated samples) in the absence of hCG (dotted lines) (B). mRNA levels of PRL, PROK1 and 
SOD2 in decidualised cells transfected with siRNA-GIPC but cultured in the absence of hCG is shown 
(C) relative to transcript levels in cells transfected with siRNA-NT (dotted lines). *, p<0.05 using the 
Student’s t-test, n.s= non-significant. n=3 infertile (control) patients.  
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 Discussion 5.3
In summary, this chapter provides evidence supporting the hypothesis that the VEE may be 
involved in the trafficking of the LH/CGR in HESCs. I demonstrate that the LH/CGR co-localises 
in endosomes with the components of the VEE pathway, APPL1 and GIPC, and that the 
LH/CGR-683T, which is unable to bind GIPC, re-routes more receptor to EEs. Additionally, 
preliminary data suggests that knockdown of GIPC changes receptor location and may reverse 
hCG-induced effects on gene expression in decidualising HESCs.  
The first observation that the VEE may play a role in LH/CGR action in the endometrium 
was the observation that GIPC and APPL1 were expressed throughout the cycle as well as in 
HESCs and that GFP-tagged constructs of these co-localise with the receptor. Importantly, the 
trafficking profile of the exogenously expressed LH/CGR is similar to prior published 
observations in HEK 293 cells in our laboratory [301]. Since only a subpopulation of the receptor 
endosomes co-localised with endogenous and GFP-tagged APPL1, this may suggest that this is 
not the only compartment that the receptor traffics through. Indeed there may be additional, and 
as yet unknown, markers of the VEE. Furthermore, APPL1 has known additional functions other 
than a marker of the VEE; APPL1 is known to be recruited by other pre-EE compartments, which 
are also positive for the GTPase Rab5, a known molecular tag of some endocytic compartments 
and has an important role in coordinating formation of effector complexes and as well as 
endosome maturation [304, 414]. It is possible that, although these Rab5 EE-precursor 
endosomes have been shown not to be implicated in LH/CGR trafficking or signalling in 
HEK293 cells [301], they could be involved in receptor trafficking in HESCs, but this has not yet 
been determined.  
The microarray data indicated that the tissue levels of GIPC and APPL1 are differentially 
regulated throughout the cycle. For both GIPC and APPL1, transcript levels dropped significantly 
between the mid-secretory and late secretory phases. Interestingly, this decrease is in synchrony 
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with the known increase of decidual marker genes, such as IGFBP-1, during these phases [413]. 
Although intriguing and suggestive of physiological role of these proteins in the endometrium, 
these proteins are both known for roles other than the VEE so it cannot be inferred that this 
change is purely related to VEE (or LH/CGR) function. 
Further support that LH/CGR was localising primarily to VEEs and not EEs was the 
small endosome size. This was supported by our knowledge of LH/CGR endosome size in 
HEK293 cells and also, since endosomes are known to become larger as they mature and fuse 
together through the endocytic pathway [415-417], the overall small endosome size of the 
LH/CGR indicates that the bulk of it is likely to be upstream of the EE. Corroborating this, the 
β2AR, which is a classical EE-localised GPCR, was mostly found in larger endosomes. However, 
I did observe that a small proportion of β2AR endosomes which were of the size of LH/CGR 
endosomes (300-400nm), therefore we cannot rule out the possibility that the β2AR localises or 
at least passes through the VEE or another smaller endosomal compartment before EE 
localisation, as shown for the transferrin receptor [301]. Of note, endosomal structures are not 
always maintained due to paraformaldehyde fixation methods which can cause a significant 
reduction in endosomal volume [418]. Future work may need to validate the endosome size data 
here in live-cells which would allow visualisation of endosomes in their natural morphology.  
In addition to the small endosome size, I provide data showing that a large proportion 
(~60%) of LH/CGR endosomes in HESCs are negative for EEA1, which also suggests the 
LH/CGR may be confined to the VEE. This trafficking to EEA1-negative endosomes is known to 
be lost when the LH/CGR receptor cannot bind GIPC in HEK293 cells and indeed I observed the 
same effect in HESCs using the truncated form of the receptor, LH/CGR-683T, both with and 
without the presence of hCG. This meant that localisation away from EEs is not dependent on 
binding of agonist to the receptor and that the constitutive mechanism of endocytic trafficking 
mimics agonist-dependent trafficking. It also showed that, as in HEK293 cells, the localisation of 
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the receptor to this compartment is sequence-dependent and thus regulated, likely via the 
interaction with GIPC. Sequence-dependent subcellular sorting of receptors is a well-established 
mechanism for GPCRs [419], many others carry C-terminally located PDZ ligands including the 
adrenergic, chemokine and cannabinoid GPCRs [388] and may interact with more than one PDZ 
proteins during their endocytic lifecycle [420]. They are known to be important to regulate the 
degradation of receptors [421], stabilisation of receptors in intracellular compartments [305] and 
sequence-dependent recycling pathways [200]. Indeed, it is known that trafficking of the 
LH/CGR to the EE prevented by truncation of the C-terminal tail blocks its recycling as measured 
by flow cytometry [301] so the VEE may be an intermediary station to allow regulated receptor 
resensitisation following internalisation. Due to the limited number of HESCs obtained from 
endometrial biopsies, as well as relatively low transfection rates of the exogenous receptors, 
recycling experiments could not be carried out via flow cytometry to assess if this was case in 
HESCs. However, it would be possible to assess if recycling levels are reduced with the 
LH/CGR-683T using TIRF microscopy as this requires a relatively small cell number and I have 
seen robust constitutive and ligand-induced recycling of the full-length receptor by which to 
compare these two receptors via this method (Chapter 3). In addition, it would be appropriate to 
investigate if the endogenous LH/CGR traffics in the same way that I have observed for the 
exogenous receptor. However, lack of specific and sensitive LH/CGR antibodies means that this 
is challenging. Attempts to fluorescently label hCG to visualise endogenous receptor were 
unsuccessful, rendering this sensitive hormone inactive during the labelling procedure. 
In line with the LH/CGR-683T data, my preliminary studies suggest that depletion of 
GIPC also re-routes the receptor to a larger proportion of EEA1 positive endosomes, indicating 
that it is involved in endocytic trafficking of the LH/CGR. In both cases, with the LH/CGR-683T 
and GIPC knockdown, there was still a proportion (~40%) of endosomes that were not positive 
for EEA1. This could be due to several reasons. Firstly, it may be that GIPC is not the only factor 
involved in routing the receptor away from the EE and there may be other as yet undefined 
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adaptor proteins which interact with the receptor upstream of the last 17-residues, either at the C-
terminal tail or on the intracellular loops of the receptor. For example, ADP-ribosylating factor 6 
(Arf6) small GTPase is known to be involved in the trafficking mechanisms of the LH/CGR 
(described in Chapter 1) [285] and, since Arf proteins are known to regulate key steps of 
vesicular transport [422] and Arf6 has been purported to interact with the intracellular loops 
GPCRs [423], it could be that this protein is involved in LH/CGR trafficking. Secondly, fixed cell 
imaging only provides a ‘snapshot’ of the receptor location at one particular point in time and 
although these experiments give a broad overview of receptor location, owing to the fast and 
highly dynamic nature of vesicular cargo trafficking the quantified number of EEA1-postive, as 
well as APPL1 and GIPC-GFP-positive endosomes may not necessarily be reflective of the 
number of receptors that have passed through the EE or the VEE. It is plausible that the LH/CGR 
could locate to the VEE or another compartment prior to the EE at earlier time points in receptor 
endocytosis and live-cell imaging or examining fixed cells stimulated with hCG different time-
points would help to ascertain if this was the case. Thirdly, although knockdown of GIPC was 
highly efficient, experiments using siRNA are subject to cell-by-cell variation in terms efficiency 
of knockdown and since cells are analysed here on a cell-by-cell basis, it may be that some cells 
have less efficient depletion of GIPC. To overcome this obstacle, either genome editing tools or 
tagged dominant-negative GIPC constructs could be used to block endogenous-GIPC-LH/CGR. 
In the final part of this chapter, I examined the functional consequences of GIPC 
knockdown on hCG-mediated inhibition of decidual gene markers. Notably, I observed that GIPC 
depletion has an inhibitory effect on the expression of decidual genes even in the absence of hCG. 
There may be a number of reasons for this. It may be that GIPC has as yet an undescribed role in 
the process of decidualisation, for example, by interacting with other receptors (such as the 
progesterone receptor) which are important for the triggering of decidual gene expression. To my 
knowledge there are no reports which have studied GIPC in the context of the endometrium 
however, GIPC is known to interact with many receptors, such as the tyrosine kinase receptor 
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(TrkA) [297] and the insulin growth factor receptor I (IGF-IR) [424]. Interestingly, IGF-I, the 
ligand for IGF-IR, has been reported to induce PRL expression in rat pituitary cells [425]. Thus, it 
is not inconceivable that, if GIPC modulates the IGF-IR and/or other receptors involved in the 
decidual response, lack of GIPC may dampen PRL, SOD2 and PROK1 expression. Another 
possibility for the downregulation of these decidual genes by GIPC could be that the siRNA is 
having off-target effects on the expression of another gene required for decidualisation or, that 
absence of GIPC is impacting another protein/s involved in decidualisation.  
Importantly, loss of GIPC impaired the ability of hCG to decrease the expression of the 
decidual gene marker SOD2, which is a free-radical scavenger known to render decidualising 
HESCs resistant to oxidative stress and cell death [92]. The observation that hCG was able to 
reduce the gene expression of SOD2 was unexpected since previous studies have shown that hCG 
prevents oxidative-stress induced apoptosis of decidualising cells by increasing protein levels of 
SOD2 [109]. Although my work shows the opposite effect whereby hCG downregulates SOD2 
transcripts, I still observed a reversal of this hCG-induced SOD2 downregulation when GIPC was 
depleted. In addition, the inhibitory effect of hCG on PRL and PROK1 levels in GIPC-depleted 
cells was partly reversed. This indicates that hCG could be mediating its effects through multiple 
pathways or endosomal compartments but only a proportion of these could rely on an interaction 
with GIPC. The preliminary data indicating that lack of GIPC re-routes the LH/CGR into a higher 
proportion (~60%) of EEs, but a proportion of the receptor (~40%) still remains EEA1-negative, 
may fit in with this notion and it may be that the VEE and the EE are not the only compartments 
that the LH/CGR localises to. In order to understand if GIPC truly has a role in LH/CGR 
compartmentalisation and hCG mediated downstream responses, these experiments will need to 
be carried out in a larger cohort of patients. Additionally, to characterise the role of GIPC further, 
GIPC knockdown could be carried out and more short-term signalling pathways of hCG could be 
investigated, for example MAPK signalling responses, which may substantiate the gene 
expression data and would be highly pertinent since FOXO transcription factors, which activate 
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SOD2 [426], are known to be regulated by the ERK1/2, JNK and p38 pathways [427]. 
Additionally, since decidualisation involves the activation of a number of cAMP dependent 
genes, further experiments could be carried out to investigate the effect of GIPC knockdown on 
levels of cAMP following hCG stimulation. Furthermore, this work has only explored the effect 
of GIPC knockdown on decidual transcript levels and this may not be reflective of levels of 
protein. Further work could assess if SOD2, PRL and PROK1 are altered at the protein level in 
the presence of GIPC knockdown.  
This chapter provides data in line with the developing appreciation of the significance of 
discrete subcellular compartments in GPCR function and signalling. I have unveiled some of the 
possible and until now unknown mechanisms of hCG action in HESCs and provided evidence 
that the VEE is involved in the action of hCG in the endometrium and, in a broader physiological 
sense, perhaps at the early stages of embryo implantation in humans. Whether these mechanisms 
are implicated or perturbed in reproductive disease phenotypes, such as recurrent IVF failure or 
recurrent miscarriage, is yet to be elucidated.  
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 Introduction  6.1
Recurrent miscarriage (RM) is defined as three or more consecutive miscarriages in the first 
trimester of pregnancy and is experienced by 1-2% of couples [320, 428]. Numerous factors have 
been invoked to explain the basis of RM and one major factor is thought to be the failure of 
embryo quality control at the feto-maternal interface [320, 321] and this is recognised to be in 
part mediated by the decidual compartment of the endometrium [76]. RM is characterised by lack 
of or abnormal responses to deciduogenic cues, which has been shown to be maintained in 
primary HESC cultures and is thought to significantly mitigate their embryo quality control 
capabilities [113]. This aberrant decidualisation is associated with abnormal responses to 
embryonic signals, including hCG. When decidualising HESCs are exposed to hCG this causes 
an induction of decidual gene markers PRL and PROK1 rather than a reduction as seen in control 
patient cultures [113]. The authors hypothesised that this induction prolongs the window of 
implantation which allows implantation of low-quality but highly invasive embryos at a sub-
optimal time, thus leading to pregnancy wastage.  
Dysregulation of GPCR function is known to occur in pathophysiological conditions and 
this can be due to over or under activation of cell signalling pathways as well perturbed receptor 
trafficking or a combination of both mechanisms [429, 430]. Therefore, it is possible that the 
perturbed hCG-mediated changes in expression of decidual genes observed in patients from RM 
could be a result of defective upstream signalling cascades in response to hCG and/or faulty 
LH/CGR trafficking mechanisms that alter LH/CGR activity. In this chapter, I determine whether 
the endogenous hCG signalling profiles are perturbed in HESCs from RM patients. Additionally, 
I delineate how receptor trafficking may be altered in these patients as a potential mechanism of 
altered hCG activity in RM.  
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 Results  6.2
6.2.1 RM patients are characterised by dampened ERK1/2 activation 
RM patients are known to have aberrant responses to hCG in downstream gene expression 
studies, but it is unknown whether short-term, upstream hCG signalling responses of these 
patients are altered. Chapter 3 demonstrated that control patients induce robust and sustained 
MAPK signalling responses with hCG in both undifferentiated and decidualised cells. In order to 
compare this signalling profile with that of RM patient samples, levels of phosphorylation of 
ERK1/2 was measured. HESCs from patients with a history of RM were either undifferentiated or 
decidualised and cells were then exposed to hCG for different time periods and ERK1/2 
phosphorylation was determined via Western blotting. For undifferentiated RM cells, weak or no 
ERK1/2 activation was seen and this was in contrast to control patients where activation was seen 
at all time points (Fig. 6.1A). The trend was similar when comparing responses in decidual cells, 
where in RM patients the ERK1/2 phosphorylation was also very weak, with some patient 
samples eliciting no response (Fig. 6.1B). Therefore this data demonstrates that the ERK1/2 
signalling induced by hCG is significantly blunted in RM patient samples. 
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Figure 6.1. The ERK1/2 signalling profile of RM patients is significantly blunted compared to 
control patients. HESCs from control patients (n=5) and RM patients (n=5) were decidualised for 72 
hours or left undifferentiated before being stimulated at the indicated time points with hCG (10nM). 
Lysates were collected and ERK1/2 phosphorylation was assessed via Western blotting using 
phospho-specific antibodies (A). Membranes were stripped and re-probed with total-ERK1/2 
antibodies. Levels of phosphorylation were quantitated using densitometry and normalised to total-
ERK1/2. Graphs show fold change for each target over basal phosphorylation levels (B). Students t-
test, * = P <0.05 and ** = P <0.01.  
 
 
0      5   10  15   30  45  0      5   10  15   30  45  
p-ERK 
t-ERK 
Control 
Undifferentiated 
p-ERK 
t-ERK 
Control 
Decidualised 
p-ERK 
t-ERK 
p-ERK 
t-ERK 
0      5   10  15   30  45  0    5   10   15   30   45  
RM 
Undifferentiated 
RM 
Decidualised 
A B 
Chapter 6: Results IV  
 
205 
 
6.2.2 A phospho-MAPK array reveals decidualisation reprograms the signalling 
profile in control but not RM HESCs  
ERK1/2 is only one of a multitude of protein kinases involved in signalling and since GPCRs and 
their ligands have the ability to activate many other MAPK signalling cascades, I questioned if a 
broader array of signalling pathways were activated by hCG in control HESCs and potentially 
altered in HESCs from RM patients. To address this question, HESCs from either a control 
patient (patient 14-196, see Appendix III) or an RM patient (patient 14-276, see Appendix III) 
were decidualised for 72 hours, or left undifferentiated. Cells were then stimulated at 0, 5 and 30 
minutes with hCG (10 nM). The resulting protein lysates were then used to probe phospho-
MAPK array membranes that detect 26 different phospho-MAPKs. Images of these for each 
patient are shown in Appendix I. Fold change over basal (0 minutes hCG) for each target at the 5 
and 30 minutes time points was calculated (Fig. 6.2A & 6.3A). In the undifferentiated control 
HESCs, 17 of the 26 phospho-MAPKs were upregulated after 5 or 30 minutes of hCG 
stimulation. Of these, AKT1 and 2, ERK1 and 2, JNK1 and 3, MKK6 and p38γ all elicited a 2-
fold or more increase compared to basal, p38γ showing the highest activation with a 4.9-fold 
change following 5 minutes of hCG stimulation. In comparison, decidualised HESCs from the 
control patient only activated 6 MAPKs in response to hCG, the strongest activation being AKT1, 
which had a 6.0-fold increase at 5 minutes compared to basal. Interestingly, in decidualised cells, 
16 of the phospho-MAPK targets were decreased with hCG treatment rather than activated, 
compared to only 4 of the targets in undifferentiated cells. These included the stress activated 
MAPKs JNK 1, 2 and 3 and p38β as well as CREB, RSK1 and 2 and TOR. The number of up and 
downregulated targets are summarised in the Venn diagram (Fig. 6.2B).  
In undifferentiated cells from the RM patient, nearly all (22 in total) of the phospho-
MAPKs were up-regulated by hCG (Fig. 6.3A). ERK1 and 2 were only weakly increased 
compared to the control patient, consistent with the previous ERK1/2 data in individual patients 
(Fig. 6.1). In contrast, some signal pathways were more strongly induced by hCG in the RM 
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sample; p38α gave the strongest activation with a 5.2-fold increase following 5 minutes of hCG 
stimulation, considerably higher compared to the control patient which did not activate p38α 
above basal. In the RM decidualised cells, 25 of the targets were up regulated after 5 or 30 
minutes, most striking was p38α and p70 S6 kinase, both displaying a 6.3-fold and 6.9-fold 
increases above basal respectively, compared to the control patient which down-regulated these 
below basal levels. In contrast to the control HESCs, AKT1 gave one of the weaker responses 
while GSK3β was not activated by hCG. The number of up and downregulated targets are 
depicted in the Venn diagram (Fig. 6.3B). Individual graphs of all of the MAPKs and changes in 
their relative expression (in A.U.) are provided in Appendix I. Collectively, the array data 
strongly suggests that control and RM patients have opposing signalling pathways. In control, 
many pathways activated by hCG in undifferentiated cells are decreased in decidualised cells and 
only a subset of pathways are activated. In RM, the same pathways are either not activated or not 
deactivated following decidualisation.  
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Figure 6.2. Phospho-MAPK array data from a control patient reveals opposing signalling 
profiles in undifferentiated and decidualised HESCs. (A) Undifferentiated and decidualised 
HESCs were stimulated with hCG (10nM) at 0, 5 and 30 min and subject to probing for activation of 
26 different targets with a phospho-MAPK array kit (RnD Systems). Bar graph shows fold changes 
over 0 min stimulation in levels of phosphorylation. (B) Venn diagram depicting the number or targets 
that went over or below basal phosphorylation levels in undifferentiated versus decidualised cells.  
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Figure 6.3. Phospho-MAPK array data shows HESCs from an RM patient do not reprogram 
hCG signalling upon decidualisation. (A) Undifferentiated and decidualised HESCs were 
stimulated with hCG (10nM) at 0, 5 and 30 min and subject to probing for activation of 26 different 
targets with a phospho-MAPK array kit (RnD systems). Bar graphs show fold changes over 0 min 
stimulation in levels of phosphorylation. (B) Venn diagram portraying the number or targets that went 
over or below basal phosphorylation levels in undifferentiated and decidualised cells.  
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6.2.3 Signalling of p38 and JNK switch upon decidualisation of HESCs from 
control patients and this may be altered in RM 
To corroborate the findings from the array, I examined the activation of some of the targets in a 
larger sample of control patients in more kinetic detail. I chose to explore p38γ and JNK1 and 3 
since these were highlighted in the array to be strongly activated in undifferentiated but 
dampened in decidual cells. HESCs from control patients were decidualised or left 
undifferentiated for 72 hours and cells were then treated with hCG (10 nM) at time points 
between 0-45 minutes. Lysates were immunoblotted with phospho-antibodies recognising either 
all four p38 isoforms (α,β, δ,γ) or all three p46/54 JNK isoforms (1, 2 and 3). Isoform specific 
antibodies were not used due to lack of availability of good quality antibodies to recognise these.  
In undifferentiated cells, p38 was activated following 5 minutes of hCG stimulation and 
this activation was sustained (Fig. 6.4A). Contrary to this, decidualised cells did not activate p38 
at any time point and decreased basal phosphorylation. Unexpectedly, I also observed an increase 
in levels of total-p38 in decidualised cells (Fig 6.4A), which to my knowledge has not been 
reported previously. Immunoblots for phospho-JNK displayed a sustained activation following 
hCG addition which peaked following 10 minutes (2-fold increase) of hCG stimulation in 
undifferentiated cells, whereas in decidualised cells no hCG-induced increase in phosphorylation 
was observed and basal phospho-JNK levels were decreased in some patient samples, similar to 
the p38 profile (Fig. 6.4B). It should be noted that p56 JNK was either not detected or very 
weakly detected and indicates activation may be preferential to the p46 isoform (data not shown). 
Preliminary validation of p38 activation has also been carried out in HESCs from RM 
patients. Cells were treated as control patients above. In contrast to control patients, p38 was not 
activated by hCG in undifferentiated cells yet decidualised cells exhibited robust activation 
following 15 minutes of hCG addition (Fig. 6.4C). Overall, this data is consistent with the signal 
profiles identified in the phospho-MAPK array and together suggests that decidualisation may 
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reprogram hCG-induced MAPK signalling in control HESCs and that a subset of pathways (i.e. 
p38), normally deactivated in decidualised control HESCs, are not in decidual RM HESCs.  
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Figure 6.4. hCG-mediated activation of p38 and JNK are altered during decidualisation in 
control patients but may not be in RM. HESCs from control or RM patients were decidualised or left 
undifferentiated before being stimulated at the indicated time points with hCG (10nM). Lysates were 
collected and p38 and JNK phosphorylation was assessed via Western blotting using phospho-
specific antibodies (A, B & C). Membranes were stripped and re-probed with respective total p38 and 
GAPDH antibodies as indicated. Levels of phosphorylation were quantitated using densitometry and 
normalised to total-p38 or GAPDH (for JNK normalisation). Graphs show fold change for each target 
over basal phosphorylation levels. (A) p38, infertile (control) patients, n=5 (B) JNK, infertile (control) 
patients, n=3. (C) p38, recurrent miscarriage, n=1. Students t-test, * = P <0.05 and ** = P <0.01. 
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6.2.4 Components of the VEE are expressed in RM patients  
Given the contrasting MAPK signalling pathways I have observed between control and RM 
patients, I speculated if this could be due to a change in the trafficking of the LH/CGR, as hCG-
induced signalling and trafficking are interlinked (Chapter 4-5). In Chapter 5, I have shown that 
the LH/CGR in control HESCs may compartmentalise to the VEE in both undifferentiated and 
decidualised cells. In HEK293 cells, APPL1 marks this compartment and knockdown of GIPC, 
which is essential to direct the LH/CGR to the VEE, weakens ERK1/2 signalling [301]. 
Therefore, since I observed a significantly blunted ERK1/2 response in RM patients, as well as 
other perturbed MAPK signalling responses as shown in the array, I hypothesised that this may 
be due to altered levels of APPL1 or GIPC. Previously published RNA-sequencing data was 
available from our collaborator (Prof. Jan Brosens, Warwick University) which had been carried 
out in 10 control and 10 RM mid-luteal endometrial biopsies and divided patients into two 
clusters by principal component analysis: cluster 1 was comprised of 7 control and 3 RM patients 
and cluster 2 comprised of 7 RM and 3 control patients [327]. Data on the level of APPL1 and 
GIPC gene expression levels was obtained from this data set (provided by Prof. Jan Brosens) and 
data from cluster 1 and 2 was compared (Fig. 6.5A). APPL1 and GIPC transcripts were present in 
both groups and there was no apparent change in the levels between the two groups. The levels of 
APPL1 and GIPC were also assessed at the protein level. HESCs from RM patients were 
undifferentiated or decidualised and APPL1 and GIPC protein levels were assessed by Western 
blotting (Fig. 6.5B). Both proteins were present in undifferentiated and decidualised cells and 
there were no changes in the levels between the two cell states. This indicates that although the 
signalling is altered in RM, this is not due to an absence of these proteins. 
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Figure 6.5. APPL1 and GIPC are expressed in HESCs from RM patients. (A) RNA-sequencing 
data showing the levels of APPL1 and GIPC in two patient groups: cluster 1, 7 control and 3 RM 
patients; cluster 2, 7 RM and 3 control patients. Data provided by Prof. Jan Brosens, Warwick 
University. (B) HESCs from RM patients (n=3) were decidualised with 8-Bromo-cAMP and MPA 
(+C+M) for 72 hours or left undifferentiated. Cells were then lysed and subject to Western blotting 
using APPL1 and GIPC antibodies. Membranes were then stripped and probed for GAPDH as the 
loading control. Bands were measured by densitometry and graphs show the levels of APPL1 and 
GIPC normalised to GAPDH and expressed as change from undifferentiated cells.  
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6.2.5 Endosomal compartmentalisation in the LH/CGR in RM patients  
Although GIPC and APPL1 were detected in RM patients, it was still plausible to speculate the 
possibility that the LH/CGR in RM patients could be adopting an altered trafficking behaviour. 
Change in the location of LH/CGR may explain the changes in signalling since this is tightly 
linked to receptor trafficking. I began with the following basic questions: (1) does the LH/CGR in 
RM patients undergo constitutive and agonist induced internalisation? (2) If so, what proportion 
of LH/CGR endosomes localise to early endosomes and are positive for EEA1? In order to test 
this, the LH/CGR was transfected in to undifferentiated and decidualised cells from 2 patients 
with a history of RM. Cell surface receptor was labelled with an anti-Flag antibody and cells were 
then stimulated for 20 minutes with hCG or left unstimulated. Fixed cells were then stained for 
EEA1 and imaged. Strikingly, for the first sample (RM-2), I could not observe any receptor 
localised in endosomes in undifferentiated unstimulated cells (Fig. 6.6A, upper panels). This is in 
stark contrast to that of samples from control patients, where I have consistently observed 
constitutive internalisation (Results Chapter 1). Internalisation was observed in all other 
conditions including that of unstimulated decidualised cells, which is in contrast to control 
patients where the LH/CGR was primarily on the surface (Chapter 3 and Fig. 6.6A, lower panels). 
When quantified, on average approximately 30% of endosomes co-localised with EEA1 and this 
did not differ significantly between conditions (Fig. 6.7A). Endosome size was also measured and 
these appeared to be between 380-420nm in diameter, which again did not change significantly 
between conditions (Fig. 6.7B). For the second sample (RM-3), the results were similar although 
I did observe a substantial amount of constitutive internalisation for the undifferentiated set of 
cells (Fig. 6.6B). In terms of EEA1 co-localisation, this was on average between 40-50% and did 
not vary between conditions (Fig. 6.7A). Endosome size was similar to RM-2, with endosomes 
on average having a diameter between 370-430nm across conditions (Fig. 6.7B). In sum, this 
preliminary data suggests that in terms of EEA1 co-localisation and endosome size, RM patients 
are comparable to that of control patients.  
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Figure 6.6. LH/CGR compartmentalisation in RM patient HESCs. Undifferentiated and 
decidualised HESCs from 2 RM patients were transfected with Flag-tagged LH/CGR 48 hours prior to 
treatments. Surface receptor was then labelled with an anti-Flag mouse antibody and cells were then 
stimulated for 20 minutes with 10nM hCG, or left unstimulated. Cells were washed and cell surface 
receptor removed via EDTA strip. Cells were stained for EEA1 and labelled with fluorescent mouse 
and rabbit secondary antibodies and imaged using confocal microscopy. Representative images are 
shown for each patient, RM Patient 2 (A) and RM Patient 3 (B). Scale bars: 10µm (main) and 5µm 
(insets).  
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Figure 6.7. Quantitation of the co-localisation of LH/CGR with EEA1 and LH/CGR endosome 
size in undifferentiated and decidualised cells from RM patients. Images from Fig.6.6 A and B 
were quantitated to assess the number of LH/CGR receptors which co-localised with endogenous 
EEA1 (n=8-10 cells/patient/condition) (A). Endosome size was also quantitated for each condition 
(n=5 cells/patient/condition) (B).  
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6.2.6 SEP-LH/CGR constitutive recycling is markedly reduced in RM patient 
samples 
The data above indicates that the compartmentalisation of the LH/CGR may not change in RM 
patients compared to control. However, I speculated that other post-endocytic trafficking 
pathways could differ in these patients and potentially offer an explanation as to the divided 
endogenous hCG responses. GPCR recycling is known to manipulate signalling mechanisms; 
even small changes in receptor recycling rates can influence cellular signal outputs and 
sensitivity. In Chapter 3, I investigated the recycling of the LH/CGR in control patients via TIRF-
M and I questioned if this pathway is altered in RM patients. To this end, I examined the ability 
of the LH/CGR to be sorted to the recycling pathway in undifferentiated and decidualised HESCs 
from 4 RM patients (including RM Patients 2 and 3, used in the above experiments). As 
previously, cells were imaged via TIRF-M for 60 seconds at 10 frames/second prior to and 
following hCG addition over a time period of 50 minutes. The number of SEP-LH/CGR recycling 
events were then counted from 1 min movies and normalised to cell surface area. Across all 
patients, SEP-LH/CGR-containing insertion events could be observed, but to a varying degree 
depending on the patient and condition. Receptor recycling rates from individual patients is 
shown in Figure 6.8A. For unstimulated undifferentiated cells, a small number of recycling 
events were observed (<6.5 events/cell/minute) which, for 3 patients (RM patients 1, 2 and 4) 
modestly increased upon hCG stimulation (<15.5 events/cell/minute). In one case (RM patient 3), 
recycling rate increased more substantially with hCG (36.5 events/cell/minute). When average 
event number per patient for each condition was plotted alongside control patient samples (Fig. 
6.8B), a significant decrease in the constitutive SEP-LH/CGR recycling in undifferentiated 
HESCs from RM patients compared to control patients can be observed, suggesting that the 
constitutive recycling in RM patients is greatly reduced. The rate of receptor recycling increased 
for both groups upon hCG addition, the control group to 39.9 ± 14.6 events/cell/min and the RM 
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group to 19.0 ± 5.7 events/cell/min which, although on average exhibited less recycling than 
control, was not significantly different.  
SEP-LH/CGR recycling was also observed in decidual HESCs from RM patients and 
although in some conditions this appeared less than in control patient samples this was not 
significantly different. This can be seen in individual patients (Fig. 6.8A) and in the pooled 
patient data as shown in the dot-plot (Fig. 6.8B). Constitutive recycling was moderate for both 
patient groups, with control patients having on average 7.0 ± 0.6 events/cell/min and RM patients 
on average 4.3 ± 1.3 events/cell/min. When the recycling number was quantitated following hCG 
addition, control patients showed a marked, significant increase in recycling event number with 
20.3 ± 2.7 events/cell/min, whereas RM patients showed only a small and non-significant 
increase above basal with 13.3 ± 5.0 events/cell/min. Given this reduction, as well as the reduced 
constitutive recycling in undifferentiated cells, it appears that these patients have either reduced 
receptor internalisation and/or a perturbed mechanism that slows or inhibits LH/CGR recycling. 
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Figure 6.8. SEP-LH/CGR receptor recycling rate changes in RM patients. (A) HESCs from 4 
patients with a history of RM were grown to confluency and either remained undifferentiated or 
decidualised for 72 hours with cAMP and MPA (+C+M). The SEP-LHCGR was transfected 48 hours 
prior to imaging using TIRF microscopy. Movies were taken for 60 sec at 10 frames per second (f.p.s) 
and recycling event number for each cell was quantified using ImageJ software. Unstimulated cells 
n=5-8 cells per patient, for hCG-stimulated cells n=10-12 cells per patient. Error bars represent SEM 
(B) Pooled patient data shown as dot plots comparing control (n=4) and RM (n=4) recycling event 
number/min for undifferentiated and decidualised HESCs, with and without hCG. Students t-test, * = P 
<0.05 and ** = P <0.01. All events are normalised to cell surface area of 1500µm. Error bars: standard 
error of the mean (SEM). 
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6.2.7 hCG-induced SEP-LH/CGR recycling changes over time  
Recycling events were also measured in a time-dependent manner following hCG addition for 
control and RM patient samples (Fig. 6.9A&B). Control patient 4 and RM patient 3 and 4 showed 
a noticeable trend of increased recycling events with increase in time after hCG addition. In the 
other patient samples, recycling rate appeared to peak at certain time points, for example, in 
control patient 3 undifferentiated cells had a peak of 51 events/min at 25 minutes of hCG 
exposure and at later time points recycling rate was reduced to ≤22.9 events/min. Similarly, for 
decidualised cells of the same patient, recycling event rate peaked at 28 minutes with 38.9 
events/min, but then dropped to ≤30.6 events/min for cells following this. Other patients showed 
events peaking at earlier time points, for example control patient 1 where 145 events/min were 
measured at 11 minutes of hCG stimulation in undifferentiated cells but this then dropped to ≤49 
events or less for later time points. Some RM patient samples also showed a similar trend, for 
example in undifferentiated cells in RM patient 2, recycling rate reached its highest point at 19 
min of hCG exposure with 39.3 events/min. Due to the relatively small patient sample number, 
the pattern of recycling is still ambiguous. However, overall it appears that agonist exposure time 
manipulates recycling rate of SEP-LH/CGR in HESCs and the onset of events following hCG 
exposure in control patients may be faster than in RM patients. 
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Figure 6.9 SEP-LH/CGR hCG-induced recycling events may increase in a time-dependent 
manner. SEP-LH/CGR recycling events from undifferentiated and decidualised HESCs from 4 control 
patients (A) and 4 RM patients (B) (same patients as shown in Fig. 6.8) plotted on a cell-by-cell basis 
over time of hCG addition (0-50 min). All events are normalised to cell surface area of 1500µm. Linear 
regression is shown by lines.  
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 Discussion  6.3
In this chapter, I have demonstrated four main findings: (1) decidualisation reprograms hCG-
induced MAPK signalling in control patients; (2) this reprogramming may be altered in RM 
patients; (3) endosomal compartmentalisation of the LH/CGR in RM patients appears comparable 
to control patients; and (4) ability of LH/CGR to recycle differ in RM patients compared to 
control.  
The reprogramming of hCG signalling in control HESCs upon decidualisation is 
intriguing as previously studied signalling pathways (i.e. ERK1/2 and cAMP, see Chapter 3) had 
suggested that undifferentiated and decidual cells gave similar responses. Of course, this may not 
be surprising given the vast cellular changes at the proteome and transcriptome level that 
underpin decidualisation which allows, for example, cellular resistance to oxidative stress and the 
ability to survive inflammatory-like events that take place during implantation [8]. Indeed, two of 
the targets from the array I highlighted, p38 and JNK, are known to be silenced at decidualisation 
[431, 432]. Decidualisation causes inhibition of numerous factors upstream of JNK, such a 
MEKK1, but induces MKP1 expression which is known to dephosphorylate JNK and p38. 
Therefore, undifferentiated HESCs are able to activate JNK in response to oxidative stress signals 
whereas decidualising HESCs are incapable of doing so [431]. The findings here mirror this data 
as hCG was unable to elicit activation of JNKs 1, 2 or 3 in decidualised HESCs as shown in the 
array. This was supported by data from 3 additional patients, where only undifferentiated cells 
could activate p46 JNK and decidualised cells either did not respond or reduced phosphorylation 
levels from basal. JNK is associated with many physiological processes including cell 
proliferation, survival and apoptosis [433]. Since hCG has been shown to be involved in the latter 
processes in the endometrium it may be that these reported effects are mediated by JNK [328]. 
For example, hCG is known to prevent apoptosis in luteal phase endometrium [124] and since 
activation of JNK can induce apoptosis [434], it is possible that hCG acts on decidual 
endometrium via JNK to prevent apoptotic cell death and promote survival. However, JNK has 
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antagonistic actions on the one hand to promote cell survival and on the other to induce apoptosis 
and the final outcome is known to be determined by the intensity and duration of the stimulus 
[435]. Therefore, in further studies it may be appropriate to examine downstream genes involved 
in these processes following long-term treatments of hCG and if these can be modulated by 
inhibitors of the JNK pathway.  
In decidual HESCs, I have shown unambiguously that hCG does not activate p38 and 
instead reduces phospho-p38 basal levels, whereas undifferentiated cells activate this pathway. 
Since p38 signalling is known to be associated with inflammation, hCG may be mediating 
inflammatory effects here. The relationship between p38 activation and inflammation has been 
established in a number of systems and can regulate multiple responses such as expression of pro-
inflammatory mediators, chemotaxis and leukocyte function [436]. hCG has previously been 
shown to activate the p38 pathway in other cell types including human placental 
syncytiotrophoblasts [437, 438] as well as in luteal cells [439] although hCG has not been 
directly related to inflammatory outcomes in these studies. To my knowledge, this is the first 
report that hCG directly induces p38 signalling in HESCs. The role of hCG in inflammation 
during the time of implantation seems to be limited and sometimes conflicting. Anti-
inflammatory effects of hCG have been shown via its ability to stimulate lipoxin A4 release 
which, via its cognate receptor (the formyl peptide receptor 2 (FPR2)) has been shown to initiate 
anti-inflammatory events in decidual tissue during early pregnancy [440]. Another example is the 
ability of hCG to inhibit pro-inflammatory interleukin-6 (IL-6) production in endometrial 
epithelial cells [142]. Contrastingly, pro-inflammatory effects of hCG has been demonstrated by 
its ability to down-regulate gene expression of apolipoprotein A-I (ApoA-I) in decidualising cells, 
which is a powerful anti-inflammatory molecule [141]. Since the successful initiation of 
pregnancy involves a dynamic balance between pro- and anti-inflammatory events, it may well be 
that hCG contributes to both.  
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Recurrent miscarriage is known to be associated with an extended and powerful pro-
inflammatory response via a disordered activation of interleukin-33 (IL-33) and its receptor, ST2 
[326] and is also associated with an increase of other pro-inflammatory molecules such as tumor 
necrosis factor alpha (TNFα) and inflammatory leukocytes [441, 442]. The kinase array data from 
the RM patient indicated that, unlike control patients, p38 (particularly p38α) continues to be 
activated upon decidualisation and, since p38 can regulate the biosynthesis of pro-inflammatory 
cytokines [443], this data seems to be in line with the aforementioned studies. Further studies 
could directly assess the role of hCG-mediated p38 signalling in pro-inflammatory gene 
expression in control versus RM patients. 
The array also highlighted other pathways that were switched on in undifferentiated but 
dampened in decidualised cells such as p53 and CREB in control, but remained activated in RM. 
P53 is known to be increased during decidualisation [444], as is CREB activation [15, 445] thus 
they could also be considered markers of decidualisation among the typical genes such as PRL. 
Deactivation of these proteins via hCG in decidual cells echoes the known ability of hCG to 
downregulate decidual markers PRL and PROK1. It is also in line with my previous data, which 
shows that hCG may act to reduce levels of cAMP in control HESCs and since CREB is activated 
by cAMP/PKA, lower levels of cAMP will therefore reduce activation of CREB. Furthermore, 
the PRL promotor region contains the cAMP response element (CRE) and expression of PRL is 
partly dependent on binding of CREB and elevated cAMP levels [15]. In RM, I observed an 
hCG-dependent increase in activated CREB and p53 in decidual cells and this again aligns with 
evidence that RM patients show increased PRL and PROK1 expression in the presence of hCG 
[113].  
In addition to the array data, the ERK1/2 profiles between individual control and RM 
patients differed significantly, with RM eliciting a strongly blunted response to hCG. Sustained 
ERK1/2 signalling is known to be important for cell proliferation [446]. Since in control cells I 
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observe a sustained ERK1/2 profile and in RM patients a transient and weak profile, it may be 
that hCG is bestowing proliferative abilities on HESCs in control but not in RM. It has recently 
been shown that ERK1/2 activation is required for decidualisation of HESCs and that inhibiting 
this pathway leads to decreased expression of decidual markers IGFBP-1 and PRL [447]. 
According to these reports, if hCG activates rather than inhibits this pathway then this may lead 
to enhanced decidualisation, but this is conflicting with previous knowledge that it inhibits 
decidualisation [112, 113]. It is likely that ERK1/2-dependent activation by hCG may have 
multiple, distinct roles prior to and during decidualisation. Together, the ERK1/2 signalling and 
the array data strongly suggest that control and RM patients have distinct and bifurcated 
signalling pathways, both in undifferentiated and decidualised cell states. Clearly, there must be 
some as yet undefined gene or protein expression changes relating to hCG signalling in control 
cells which allows for this ‘switch’ that is perturbed in RM HESCs. Preliminary experiments 
have shown a decrease in LH/CGR mRNA levels in decidualised HESCs from RM patients 
compared to undifferentiated cells (data not shown) which may offer an explanation to the change 
in signalling in this patient group, however, some pathways in RM were even more strongly 
activated by hCG. Another explanation could relate to our knowledge that RM patients are known 
to undergo abnormal decidualisation [113] and therefore this could affect hCG signalling profiles.  
In view of the divergent signalling mechanisms, I wanted to determine if the trafficking 
of the LH/CGR also changed in RM patients given the integral role this plays in LH/CGR 
signalling [301]. However, preliminary data indicates that endosome size and receptor 
compartmentalisation was comparable to control samples. These results must be interpreted with 
caution as this experiment was carried out in only 2 patients but, if the LH/CGR is still localising 
to VEEs in RM patients, another mechanism likely underlies the change in signalling. For 
example, adaptor proteins which do not modulate receptor trafficking but modify receptor 
signalling, could be failing to associate with the receptor in the RM group or vice versa thus 
changing the signalling profile. Alternatively, it could be that the majority of the LH/CGR in RM 
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patients are not localising to the EE or the VEE but another distinct endosome population that 
may explain the signalling changes in these patients.  
I also investigated the recycling of the LH/CGR in RM patients via TIRF and compared 
this to data previously obtained in control patient samples. Most striking was that the constitutive 
recycling I saw in undifferentiated cells from control patients was lost and this was consistent 
across all patient samples. It is also consistent with data I had observed in patient RM-2, where 
constitutive internalisation was not observed via confocal microscopy. Intriguingly, RM-3 did 
show robust constitutive internalisation via confocal microscopy, but also exhibited minimal 
constitutive recycling when imaged in TIRF. This suggests that, for this patient, constitutive 
recycling, rather than internalisation, is inhibited. Constitutive internalisation without recycling 
could point towards receptor degradation and down-regulation [448], although this patient did 
have an increased recycling rate following agonist addition suggesting a pool of receptors did still 
remain on the surface. In decidualised cells, I found that hCG-induced recycling was impaired in 
patients with RM. My data showed no significant increase in recycling of the SEP-LH/CGR in 
RM following ligand addition, whereas in control patients a significant elevation above basal 
levels was seen. This was an interesting finding and defects in receptor recycling are known in 
other disease phenotypes, for example central precocious puberty is known to be caused by a 
mutation in the kisspeptin GPCR which inhibits receptor downregulation and increases receptor 
recycling [449]. Since signalling of RM patients is dramatically altered, it is tempting to speculate 
that this could be due to the lack of recycling. Indeed, as with other trafficking pathways, 
recycling can also modulate receptor signalling and vice versa. Recent studies have shown that 
transient recycling events can be modulated by cAMP-PKA and inhibiting PKA can increase 
receptor recycling frequency [211, 212]. Modulation of recycling of the LH/CGR in HEK293 
cells by cAMP-PKA that phosphorylates APPL1 is also known (unpublished data from 
Hanyaloglu lab). Taken in the context of the data on LH/CGR recycling in HESCs, it is possible 
that recycling in these cells could also be modulated by cAMP-PKA or potentially MAPKs, thus 
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if such signalling pathways are altered, as in RM, then the post-endocytic fate of the receptor 
could be re-routed possibly as a result of altered spatial localisation within endosomes, but more 
samples are required to determine this.  
In summary, this chapter has provided novel insights into the how hCG signalling and 
LH/CGR trafficking may be altered in RM, indicating that overall hCG/LH/CGR activity is 
disrupted in RM patients. It is possible that the failure of RM HESCs to reprogram their hCG 
signalling and the LH/CGR to undergo rapid recycling upon decidualisation could both be 
important defects which contribute to erroneous embryo selection at the time of implantation that 
can lead to pregnancy loss.  
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 General Discussion 7.1
This thesis has investigated the mechanism of action of hCG in the endometrium and I have 
provided novel insights into how this hormone may be exerting its function in vivo at the time of 
blastocyst implantation by using primary HESCs to model LH/CGR actions and hCG signalling 
pathways. Maternal inability to respond appropriately to embryonic cues can lead to delayed 
implantation or implantation of chromosomally or developmentally compromised embryos which 
ultimately results in pregnancy loss. Although hCG has been implicated in paracrine signalling 
resulting in impacts on processes during the time of implantation, including decidualisation and 
immunomodulation, there has been no documentation of how LH/CGR mediates these signalling 
outcomes or, critically, how perturbation of its action may underpin conditions such as RM. My 
data presented here has outlined how this receptor might function in control patient HESCs and 
how its action may undergo fundamental changes during decidualisation, both in terms of its 
trafficking and signalling profiles. Additionally, I have shown that a distinct endosomal 
compartment, the VEE, is involved in receptor post-endocytic trafficking and may have 
repercussions on hCG downstream signalling. Most importantly, the data here provides novel 
evidence that LH/CGR trafficking and hCG signalling pathways are disordered in patients with 
RM, thereby giving support towards a model whereby erroneous embryo implantation is caused 
by miscommunication of key embryonic factors at the feto-maternal interface.  
 
 The LH/CGR ‘Reprogramming’ hypothesis 7.2
My data presented here sheds new light on unanticipated modes of trafficking and signalling of 
the LH/CGR in HESCs. Firstly, I have shown that that LH/CGR exhibits atypical constitutive 
internalisation and recycling which is predominantly seen in undifferentiated HESCs and 
decreased upon decidualisation. Secondly, I provide compelling evidence corroborating this data 
by observations showing that a subset of hCG-induced MAPK signalling pathways is 
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dramatically changed in a decidualisation-dependent manner. Together, these changes in 
trafficking and signalling support the hypothesis that the receptor and hCG responses are 
‘reprogrammed’ in decidual cells.  
Data presented in Chapter 2 gave the first evidence of this receptor reprogramming 
phenomenon. Therein, I aimed to characterise the basic trafficking mechanisms of the LH/CGR 
and unexpectedly found that the majority of undifferentiated cells exhibit robust constitutive 
internalisation, while in decidualised cells only a small subset displayed this characteristic and the 
receptor is largely distributed on the cell surface. Internalisation is seen after hCG addition in 
decidualised cells, but this was reduced compared with undifferentiated cells. This was an 
LH/CGR specific reprogramming event, since the β2AR did not show such a switch. Quantitative 
assessment of LH/CGR recycling via TIRF-M underscored both the constitutive ability of the 
receptor and its ‘reprogramming’ behaviour; undifferentiated cells have the ability to 
constitutively recycle the LH/CGR but this is significantly reduced upon decidualisation. 
Combined, two main conclusions may be inferred from this data. That I observe increased 
constitutive internalisation in concert with constitutive recycling in undifferentiated cells suggests 
that the plasma membrane receptor must be replenished, at least partially, with endocytosed 
receptor and thus the unliganded LH/CGR undergoes continual cyclic rounds of endocytosis and 
exocytosis from and to the plasma membrane. Then there is the switch: decidualised cells retain a 
more stable pool of receptor on the plasma membrane and, accordingly, a smaller amount of 
receptors are constitutively recycled.  
To my knowledge, no other GPCR has been reported to have the ability to undergo such 
dramatic change in its trafficking or signalling within the same cell type, but cell-type-dependent 
changes in GPCR activity are known. Undifferentiated and decidualised HESCs could be 
considered separate cell types of their own, owing to the vast differences they have in terms of 
gene and protein transcription [14, 413]. As highlighted in earlier sections, this reprogramming 
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could therefore be due to differential expression of proteins required for maintaining the receptor 
at the surface and/or for constitutive internalisation. In Chapter 3, I investigated the latter 
hypothesis by measuring protein levels of βARRs, key proteins involved in receptor 
desensitisation and internalisation, but no change in levels of βARR1 were seen. βARR1 
localised with the receptor before and after agonist addition in undifferentiated cells and in the 
subset of decidualised cells that exhibited internalisation. Taken together, it is probable that 
expression of βARR1 alone is not sufficient to cause constitutive internalisation, since in 
decidualised cells expressing βARR1 surface LH/CGR expression could be seen and βARR1 was 
not recruited. Rather, it is likely that another mechanism is in place in undifferentiated cells that 
is absent, or altered, in decidualised cells, such as phosphorylation by GPCR kinases (GRKs) 
and/or second messenger kinases (PKA/PKC) which facilitate βARR recruitment by 
phosphorylating the receptor. Indeed, GRKs are known to phosphorylate receptors in both their 
inactive and active states and it is also known that the complement of GRKs within cells can 
dictate engagement of βARR with GPCRs [450, 451]. To speculate, the reprogramming could be 
due to change in levels or activities of specific GRKs, for example PKA can alter GRK2 activity 
[452] which may alter the ability of decidualised cells to phosphorylate the LH/CGR, thus it is 
unable to internalise efficiently. 
Reprogramming could also be due to a change in function of other proteins/pathways 
during decidualisation, for instance at the level of the CIE or CME machinery. That dynamin 
inhibition unequivocally demonstrates that the receptor in undifferentiated cells can be 
manipulated to mimic receptor distribution in decidual cells, where in the majority of cells the 
receptor does not internalise. This puts into question of the ability of the receptor to utilise CIE or 
CME pathways of internalisation in decidualised cells. My data showed that the β2AR could be 
robustly internalised following agonist in decidualised cells and, since β2AR is known to undergo 
dynamin-dependent CME [224, 453, 454], this suggests that decidualised cells are unlikely to be 
deficient in the core machinery involved in receptor CME. Instead, this may relate to a more 
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receptor-specific occurrence, either relating to βARR1, GRKs and/or the impairment of receptor 
phosphorylation.  
Differences in receptor trafficking, although intriguing, would be inconsequential if they 
did not amount to a change in signalling and downstream cellular outcomes. Reprogramming of 
LH/CGR trafficking was indeed echoed in a subset of signalling pathways as I described in 
Chapter 5, where p38 and JNK were shown to be activated in undifferentiated cells and unable to 
be activated or silenced in decidualised cells in response to hCG. Interestingly, a subset of 
pathways had similar profiles to undifferentiated cells, namely ERK1/2 activation and cAMP 
inhibition, as well as others highlighted in the MAPK-array. Thus, this points towards a specific 
remodelling of hCG responses in decidualised cells, where on the one hand they still respond in a 
similar manner to undifferentiated cells but on the other their hCG signalling becomes modified 
and they respond in an opposing manner. In the context of the known cellular model that 
trafficking and signalling are closely coordinated [330], this simultaneous reprogramming I see 
for both hCG signalling and LH/CGR trafficking is highly suggestive of a link between these 
mechanisms. Indeed, I showed a link between signalling and trafficking via dynamin inhibition, 
which caused both increased LH/CGR surface expression and abolishment of ERK1/2 signalling. 
Interestingly, this resembles the effect that decidualisation has on inhibition of p38 and JNK 
activation. It is possible that the increased surface expression and reduced internalisation and 
recycling in decidualised cells limits activation of p38 and JNK pathways but not ERK1/2 
pathways. The latter could result from the small amount of agonist induced internalisation I 
observe in decidual cells and thus occurs from a pool of endosome localised receptors that can 
only couple to ERK1/2 but not p38 or JNK.  
Alternatively, if these differential signalling traits are indeed related to receptor 
trafficking and/or docking of adaptor proteins needed for signalling, then it is possible that 
reprogramming of hCG signalling is due to distinct protein complexes with which the LH/CGR 
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interacts at the surface and/or along its endocytic cycle. The LH/CGR recruited βARR1 which, 
alongside βARR2, is not only important for receptor desensitisation but acts as a scaffold for G-
protein-independent MAPK signalling [399]. Intuitively, this seems to suggest that βARR1 may 
be involved in MAPK signalling in HESCs, and therefore, if the LH/CGR cannot interact with 
βARR1 as postulated earlier, then it is possible that MAPK signalling will be dampened, although 
that does not occur in decidual cells. Indeed it has been shown that βARR1 depletion can result in 
a decrease of JNK phosphorylation [455]. It might be that βARR1 scaffolds activation of 
ERK1/2, p38 and JNK in undifferentiated cells, but only ERK1/2 in decidualised cells hence p38 
and JNK are not activated. However, it is also possible that this may not be a switch in the 
LH/CGR trafficking/associating scaffolds but rather a change in the signalling machinery 
available to all receptors as a whole in decidualised cells. As described in Chapter 6, 
decidualisation is known to cause inhibition of MEKK1, which is upstream of JNK, and an 
increase in MKP1, which dephosphorylates both JNK and p38, thus limiting the activation of 
these kinases [431, 432]. Therefore it is possible that any stimulus, not just hCG, would be 
incapable of eliciting JNK or p38 phosphorylation in decidualised cells. In contest to this 
however, preliminary data from the array showed that there are other pathways that are 
downregulated by hCG in decidualised cells which are known to be able to be activated by other 
stimuli. For example, CREB was silenced by hCG in decidual cells, but it is known that another 
GPCR ligand relaxin can cause significant activation of CREB in decidualised cells [456]. The 
latter supports a receptor-specific rather than a global reprogramming event.  
Reprogramming of the LH/CGR is a novel mechanism for a GPCR not just in endometrial 
stromal cells, but for any cell type, that has never been documented elsewhere. The switching 
ability is consistent with our knowledge that decidualisation is coupled with not only a vast 
change in levels of a plethora of genes and proteins, but that other cellular components can be re-
localised following cell stimulation with deciduogenic cues. To my knowledge, no other types of 
receptors have been reported to change their localisation but other non-receptor examples of this 
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include the subcellular redistribution of c-Src tyrosine kinase (known to play key functions in 
signal transduction) which translocates from a perinuclear region to the cytoplasm during 
decidualisation [457] and the small ubiquitin-like modifier 1 (SUMO1) which is redistributed 
upon cAMP and MPA co-treatment to punctate nuclear regions and this is known to be important 
to for progesterone signalling [62]. I propose that the capacity to spatially organise and 
redistribute cellular components such as these and the LH/CGR is likely to be an evolved 
mechanism to prepare cells so that they are pre-sensitised and equipped to respond in a timely 
manner to embryonic cues.  
 
 hCG: A hormone with multiple signalling capabilities in HESCs 7.3
hCG is well-known for its ability to maintain progesterone production from the corpus luteum 
during early pregnancy. A significant body of evidence has now established that it is also 
important at the embryo-endometrial interface and may be involved in events such as 
inflammation, angiogenesis, decidualisation as well as sensitising the endometrium to other 
secreted embryonic factors. Knowledge of the way in which these diverse events are orchestrated 
by hCG, via the LH/CGR, is still lacking and this thesis has delineated some of the signalling 
pathways that may be involved. I have found that one prevailing aspect of hCG signalling appears 
to be that it does not have the ability to signal via Gαs and, in many cases, it can instead couple to 
Gαi. I have also observed that another overriding feature of hCG is the multiplicity it has in 
regard to its signalling effectors, namely MAPKs, and vitally, how activation of these are 
dependent on cell status, i.e. decidualisation. These signalling patterns are likely to represent an 
important mechanism that bestows hCG with the ability to co-ordinate events which facilitate 
appropriate implantation.  
Initial studies outlined in Chapter 3 aimed to elucidate the basic signalling pathways in 
HESCs triggered by hCG. In terms of G-protein mediated signalling, I found that in a subset of 
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patients hCG has the ability to cause a decrease in intracellular cAMP levels, which can be 
reversed with the Gαi inhibitor Ptx. This signalling is paradoxical to what is known of the 
signalling of the LH/CGR, which is dependent on signalling to Gαs in other cell types. However, 
the finding was consistent with previous data documenting that hCG has the ability to 
downregulate expression of cAMP-dependent genes PRL and PROK1 [112, 113]. I confirmed 
this ability of hCG to modulate decidual PRL and PROK1 mRNA expression where in the 
majority of, but not all, patients it was downregulated following hCG treatment and I also 
established that PRL expression, like cAMP-downregulation, can be reversed by Ptx. In addition, 
I showed that hCG can inhibit levels of SOD2, which is another marker of decidualisation. 
Together, this indicates a direct role for hCG in the decidualisation process and also highlights an 
importance for Gαi-coupling in order for hCG to exert these downstream effects. 
PRL, PROK1 and SOD2 have various functions in the endometrium. PRL is a 
polypeptide hormone that increases throughout pregnancy and in addition to cAMP, its secretion 
is also increased by progesterone, IGF-1 and insulin [42, 458]. In early pregnancy, it has been 
suggested to enhance embryo growth and invasion, stimulate angiogenesis and modulate uNK 
survival [459]. PROK1 is known to trigger vascular remodelling, increase vascular permeability 
and to induce important genes known for the establishment of pregnancy such as cyclooxygenase 
2 (COX2) [460]. SOD2 is increased by the transcription factor FOXO1 during decidualisation 
and is a reactive oxygen species scavenger known to be important to protect against oxidative cell 
death [92]. Therefore, the hCG-dependent downregulation of these genes, either by Gαi, or via 
another mechanism, will ultimately lead to a uterine environment that is not favourable for an 
implanting blastocyst. This returns to the concept that hCG may be a mechanism by which the 
embryo can modulate its own window of implantation. The implanting embryo produces high 
local concentrations of hCG which increases through the early stages of pregnancy so if it acted 
continually to enhance factors that promote implantation such as PRL, PROK1 and SOD2, then 
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this window of implantation could be much more prolonged and allow either embryos to implant 
at an inappropriate time or incompetent embryos to implant which otherwise would be rejected.  
In addition to attenuating cAMP and PRL, PROK1 and SOD2 gene expression levels, I 
also found that hCG was able to evoke activation of a number of MAPK signalling pathways as 
shown by the array (Chapter 6). Not only did I find that the signalling pathways between 
undifferentiated and decidualised cells are distinct, as described previously, but knowledge of 
such targets activated by hCG has given valuable insight into how this hormone may exert its 
function. Initial studies demonstrated that hCG is able to robustly activate the ERK1/2 signalling 
cascade in both undifferentiated and decidualised cells. ERK1/2 is one of the most widely 
expressed members of the MAPK family, is classically known for its pro-survival and 
proliferative effects and is a prototypical downstream effector of many GPCRs, including the 
LH/CGR [461-463]. Indeed, hCG can induce proliferation of other cell types, for example, theca-
interstitial cells, which depends on the ERK1/2 as well as Akt activation [331]. Therefore, one 
possible purpose of hCG-induced activation of ERK1/2 could be to induce stromal cell survival 
and proliferation. ERK1/2 signalling in the endometrium by other factors is known to increase 
cell survival as well as enhance the invasiveness of endometrial stromal cells; examples of these 
factors include 17β-estradiol, growth factors and the chemokine CCL2 [464, 465]. hCG could 
therefore be working in synergy with these and other factors to also promote invasiveness and 
this would be in line with knowledge that hCG facilitates invasion by increasing levels of MMPs 
and decreasing MMP inhibitors (TIMPs) in endometrial biopsies taken at the mid-secretory phase 
[119]. To verify if hCG ERK1/2 signalling is involved in trophoblast invasion, a co-culture model 
of HESCs with trophoblast spheroids could be used [72] and coupled with inhibition of hCG-
induced ERK1/2 signalling, for example by blockade of dynamin.  
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Although ERK1/2 signalling was consistent in both cell states, at decidualisation there 
was a distinct switch in the ability of hCG to activate other signalling pathways as shown by the 
MAPK array. This was confirmed in a larger group of patients where p38 and JNK were only 
activated in undifferentiated cells. In some cases, hCG actively antagonised these pathways, as 
well as others as shown in the array, such as CREB. JNK and p38 signalling pathways are usually 
activated by pro-inflammatory cytokines, or following exposure to cellular stress signals such as 
genotoxic, hypoxic or oxidative stress [466]. The JNK pathway is involved in apoptosis and 
therefore downregulation of this pathway by hCG may aid in preventing apoptosis which would 
be in line with knowledge that hCG induces anti-apoptotic factors such as Bcl-2 [109]. In regard 
to p38, silencing of this pathway could relate to an anti-inflammatory effect of hCG. As discussed 
in Chapter 6, hCG is known to have both inflammatory and anti-inflammatory effects in HESCs, 
so although my data may point towards the latter, the role of hCG in inflammation is not clear-
cut.  
These signalling profiles highlight that hCG can signal via multiple mechanisms in HESCs 
which may ultimately lead to the various biological outcomes that hCG is known to evoke. The 
non-canonical Gαi signalling I have described is an unusual mechanism of signalling via the 
LH/CGR. Although it is not uncommon for GPCR to adapt their G-protein coupling depending 
on cell type and desired cellular outcome, this does not mean that it can be assumed that this Gαi 
signalling is via the LH/CGR. As described in Chapter 3, hCG is known to signal via other 
receptors, namely the TGFβ and mannose-6-phosphate receptors. Owing to this promiscuity, it is 
possible therefore that the signalling pathways mediated by hCG are via these or possibly even 
other receptors. Interestingly, TGFβ1, the ligand for the TGFβR, is also known to act like hCG to 
downregulate expression of decidual gene markers [467]. One way to investigate the possibility 
that hCG is acting via other receptors would be to deplete cellular LH/CGR levels, or 
alternatively, block known components of TGFβR signalling pathway, such as SMAD proteins 
[468] and test if hCG can still induce signalling. Genome editing tools, namely the Crispr/Cas9 
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system, could also be used to label the endogenous receptor with a Flag epitope or GFP to 
ascertain localisation and trafficking of the endogenous receptor [469].  
 
 The VEE: A signalling hub for hCG in the endometrium?  7.4
Correct endosomal compartmentalisation of GPCRs is known to be critical to evoke appropriate 
signalling outcomes in response to extracellular stimuli. In this thesis, I have documented the 
presence of a distinct endocytic compartment, the VEE, in HESCs and, importantly, preliminary 
data has shown that this may be a site of signalling for hCG. My experiments showed that the 
LH/CGR co-localised to the components of the VEE, GIPC and APPL1, enriched in small, VEE-
like endosomes and that truncation of the C-terminal tail or depletion of GIPC forced the receptor 
into a higher proportion of endosomes positive for EEA1. Additionally, absence of GIPC partially 
but significantly blocked hCG inhibition of the decidual gene marker SOD2 and also had an 
effect on levels of PRL and PROK1 expression. This signifies that this compartment may play an 
important role for hCG to control the levels of these decidual markers. As described, receptor 
recycling can play a significant role in receptor sensitivity and, since preliminary data showed 
that the LH/CGR may alter its compartmentalisation upon GIPC knockdown, it would be 
pertinent to explore if in addition this alters the post-endocytic fate of this receptor.  
 
 Mechanism of Recurrent Miscarriage: a potential role of hCG and LH/CGR 7.5
Here, I have shown that hCG signalling and LH/CGR trafficking may both be disordered in 
patients with RM. This was seen strikingly in the MAPK array, where a number of targets in both 
undifferentiated and decidualised cells were differentially regulated by hCG compared to the 
MAPK array carried out in the control patient. Preliminary data suggested that p38 signalling is 
opposite to control patients in that it is not silenced upon decidualisation. Additionally, the 
ERK1/2 signalling profiles in RM patients were significantly blunted or even absent in both 
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undifferentiated and decidualised cells. Alongside published data that PRL and PROK1 are also 
oppositely regulated by hCG, this further highlights that RM patients have perturbed rather than a 
lack of response to hCG.  
This disordered signalling may be coupled to abnormal LH/CGR modes of trafficking. 
Additionally, there was lack of evidence for a receptor reprogramming event as in control 
patients; the recycling profiles of the receptor appeared to be the same between undifferentiated 
and decidualised cells and preliminary data suggested that there was constitutive internalisation in 
both cell states. The reasons behind the disrupted trafficking in RM patients remain to be defined. 
It could be caused by a number of reasons, but at this point I can only speculate what these may 
be. Since I saw low levels of constitutive recycling, but high levels of internalisation was evident, 
this could suggest a degradative pathway for this receptor in RM patients. This desensitisation of 
the receptor followed by lack of resensitisation in the absence of agonist could overall mean a 
lower level of receptor cell surface expression, which may explain the weak and transient 
ERK1/2 and signalling profiles. The LH/CGR683T is known not to be able to recycle or to bind 
GIPC and evokes a more transitory ERK1/2 signalling pathway [301], so it could be that there is 
a disruption in binding to GIPC in RM patients, for example by an inhibitory protein which 
blocks the binding site of GIPC. However, my preliminary data did suggest that, like the 
LH/CGR in control patients, the majority did not localise to the EE. Whether the receptor could 
be localising to another distinct non-VEE and non-EE compartment in these patients which 
allows transduction of different signalling profiles and pathways, is a possibility but remains to be 
determined. Additional mechanistic explanations for the abnormal hCG responses and receptor 
trafficking could be due to altered post-translational modifications of the receptor in RM patients. 
GPCRs are subject to multiple post-translational modifications including phosphorylation, 
palmitoylation and glycosylation. Ubiquitination is also a common post-translational 
modification required for sorting to a lysosomal pathway [470]. Interestingly, ubiquitination has 
also recently shown to be a novel mechanism for p38 activation on endosomes, thus this might 
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also explain the activation of this pathway in decidualised cells in RM patients but not in control 
patients [471].  
Another factor to be determined is the G-protein coupling of the receptor in RM patients. 
Data described in Chapter 3 showed that in a subset of control patients Gαi inihibition could 
reverse hCG-inhibition of the decidual marker PRL and in some cases increase this above basal 
levels. This profile mimics the known gene expression profiles of RM patients exhibiting an 
increase, rather than a decrease, in hCG-regulated PRL levels [113]. This raises the possibility 
that the LH/CGR in RM patients could be coupling to Gαs, possibly via changes in cross-talk 
with other GPCRs such as CB1R that may underlie the Gi-coupling ability of LH/CGR in 
control HESCs. Changes in signalling, resulting in higher levels in cAMP for example, may also 
in turn feedback to alter the trafficking fate of the receptor, as is known for other GPCRs.  
The molecular details underpinning hCG actions in control versus recurrent miscarriage 
patient samples that I have presented here are derived only from ex-vivo tissue samples. For 
obvious reasons, these experiments can not be carried out in humans, but our knowledge could be 
greatly improved by the use of animal models. Unfortunately, there are no current primate or 
mice models for RM. There are primate models of other disorders, such as endometriosis, that 
have been developed and this has helped greatly to facilitate further insight into this condition 
[472]. The development of an RM primate model would be very beneficial, but owing to the 
complexity of this condition such a model could be difficult to generate. 
 
 Concluding Remarks 7.6
Our knowledge of embryo quality control by the endometrium has developed extensively over the 
past decades and is still rapidly increasing. Although we now have vastly increased knowledge of 
mechanisms mediating feto-maternal communication and decidualisation, the complex and 
dynamic nature of these processes has hampered efforts to translate this knowledge into useful 
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interventions and predictive tests to avoid poor pregnancy outcomes. In addition, we do not yet 
have a full understanding of RM and therefore management of this condition is still challenging. 
Many patients are treated with immunomodulatory drugs on the unproven basis that RM is 
caused by maternal immune rejection of the semi-allogenic fetus [8]. hCG has also been tested in 
clinical trials as a treatment for miscarriage, but this has been shown not to be effective [473]. 
The only treatment that has shown some signs of success is progesterone, although this is still 
awaiting confirmation in larger clinical trials [474]. Other treatments such as drug interventions 
during pregnancy are tightly restricted due to unknown birth defects that these could cause. In 
view of this, a lot of research has now worked instead towards finding biomarkers which may be 
predictive of endometrial receptivity and/or pregnancy complications and could be used prior to 
pregnancy in a clinical setting [475]. If a biomarker to predict pregnancy outcome could be 
developed this could have great advantages in the management of RM as well as other obstetric 
complications such as pre-term birth and pre-eclampsia, and could be combined with strategies 
which would help patient outcome. 
Our understanding of the role hCG has during pregnancy has been dramatically rebuilt 
and it is now clear that it contributes to much more than progesterone production from the corpus 
luteum during pregnancy. Here, I have provided an extra layer to our understanding of the 
workings of this hormone and its receptor at the embryo-endometrial interface, both in a 
physiological and pathological setting, and opened up some promising avenues for further 
research. With further knowledge on the pathways involved and how hCG signalling outcomes 
differ between control and RM patients, drug targeting of the LH/CGR could be eventually 
become a possibility. Indeed, GPCRs are the targets of a number of successful drugs and novel 
therapeutic targets are now being driven towards not simply inducing or blocking receptor 
activity, but more refined modulation of receptor signalling pathways. Prevalent in the field at the 
moment is the development of biased ligands which, by targeting orthosteric or allosteric receptor 
binding sites, can stabilise the receptor in particular conformations and ultimately tailor its 
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signalling as well as reducing off-target effects [476, 477]. For the LH/CGR, as well as other 
receptors involved in reproduction such as the FSHR, small allosteric compounds are in 
development [478, 479]. It is tempting to suggest then, that if a signalling pathway can be found 
that is activated by hCG in RM patients but not control patients or vice versa, then this could 
provide a basis for specifically targeting that pathway with biased compounds to the LH/CGR. 
Use of such a compound could be combined with predictive biomarkers and provide a means to 
re-establish patient fertility and prevent pregnancy loss.  
 
 Future work 7.7
Aim 1: Further examine the role of the VEE in the endometrium in control patient samples. 
Hypothesis: My current data suggests that the LH/CGR is targeted to the VEE in both 
undifferentiated and decidualised cells. Routing to this compartment may also have functional 
implications for this receptor as cellular depletion of GIPC, an essential component of the VEE, 
reverses hCG-induced downregulation of decidual genes. The upstream signalling pathways by 
which this occurs or the involvement of other cellular components however has not been 
explored. I hypothesise that the VEE acts as a signalling hub for the LH/CGR and that this may 
implicate subsequent gene expression profiles. 
Experimental Approach: To identify the upstream signalling pathways which may occur from 
the VEE, various approaches could be adopted. My previous data has shown that hCG induces 
robust MAPK signalling responses and also has the ability to decrease intracellular levels of 
cAMP. To assess if this is governed at the level of the VEE, RNA interference to deplete cellular 
levels of GIPC could be combined with hCG stimulation and assessing MAPK activation via 
Western blot compared to control cells. A phospho-MAPK array could also be utilised to identify 
other pathways which may be altered in the absence of GIPC. cAMP signalling could also be 
examined via ELISA to compare signalling profiles in cells with and without GIPC knockdown. 
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To assess if the MAPK signalling is truly coming from a VEE rather than an EE compartment, 
knockdown of Rab5 (a classic EE component) using siRNA could be carried out. MAPK 
activation following hCG treatments could then be assessed. 
To determine if the MAPK pathway is involved in the downstream gene expression changes, 
MAPK selective inhibitors (for example U0126, an inhibitor of MEK1/2) could be utilised during 
a decidual time-course to assess if this reverses the hCG-inhibition of decidual gene markers.  
The trafficking of the LH/CGR to the VEE and the involvement of GIPC also requires further 
exploration. Preliminary data showed that in cells depleted for GIPC, a higher receptor number 
localises to an EEA1-positive compartment. This experiment would be repeated in further patient 
samples. In addition, HESCs could be co-stained with Rab5 to compare the percentage of the 
LH/CGR localising with this marker GIPC depleted vs. control cells.  
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Aim 2: Identify the mechanisms underlying the perturbed signalling and trafficking shown in 
RM patients vs. control patients 
Hypothesis: Data in this thesis has provided preliminary data showing that the MAPK 
signalling profile in RM patients is perturbed compared to control patient samples. In addition, 
the recycling of the LH/CGR is significantly reduced in RM patients. The mechanisms 
underlying these differences have not been defined in the data presented here. I hypothesise that 
the blunted MAPK signalling and the altered recycling may be due to the receptor re-routing to a 
separate endosomal compartment and/or being targeted to a degradation pathway.  
Experimental approach: The endosomal location of the receptor in RM patient samples needs 
to be determined in a larger set of patient samples. This would be done by co-staining receptor-
transfected cells with EEA1 and imaging with confocal microscopy. In addition, the localisation 
of the LH/CGR could be compared with the classic EEA1-localised receptor the B2AR.  
To determine if the reduced recycling observed in RM patient samples is due to the receptor 
being targeted to a default degradation pathway, HESCs could be stained for the lysosome (for 
example by using Lysotracker or staining with LAMP1) and localisation of the receptor to the 
lysosome upon hCG treatment could be assessed. In order to assess if lack of recycling is due to 
lack of receptor internalisation, radiolabelled hCG could be used to assess the extent of receptor 
internalisation in RM patient vs. control patient samples.  
The blunted MAPK activation observed could be due to lack of localisation to the VEE. This 
could be due to lower levels of GIPC in RM patients. Rescue of the MAPK activation could be 
tested using GIPC overexpression.  
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Figure. AI-1. Phospho-MAPK array blots from Control and Recurrent miscarriage patients. 
HESCs from a Control patient (A) and a Recurrent Miscarriage patient (B) were left undifferentiated or 
decidualised for 72 hours and then stimulated with hCG (10nM) for 0, 5 and 30 min time points. 
Lysates were then probed using the phospho-MAPK array kit from RnD systems. Each array 
membrane contained 26 different capture antibodies in duplicate. Reference spots (upper left hand 
corner of each membrane) were also included for normalisation. [The co-ordinates for each target can 
be found at www.rndsystems.com/products/human-phospho-mapk-array-kit].  
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Figure. AI-2. Phospho-MAPK array data from Control patient 
Legend overleaf. 
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Figure. AI-2. Phospho-MAPK array data from Control patient. Pixel intensities of each spot shown 
from the array (Fig.AI-1, A) were quantified using ImageJ and normalised to reference spots. Each 
bar represents pool values from duplicate spots. Graphs show changes in levels of phosphorylation 
for each target as arbitrary units (A.U.).  
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Fig. AI-3. Phospho-MAPK array data from RM patient 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure. AI-3. Phospho-MAPK array data from RM patient. Pixel intensities of each spot shown 
from the array (Fig.AI-1, B) were quantified using ImageJ and normalised to reference spots. Each 
bar represents pool values from duplicate spots. Graphs show changes in levels of phosphorylation 
for each target as arbitrary units (A.U.). 
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Table AII-1. Primer sequences for cloning 
 
 
Fwd/Rev Sequence 
LH/CGR-B Fwd Fwd AfeI 
GTAGCGCTGCGCGAGG  
CGCTCTGCC 
LH/CGR-B Rev Rev ApaI 
CAGGGCCCCAGTTAACACT  
CTGTGTAGCGAG 
LH/CGR-644 T Fwd Fwd 
GCAAATTTGGCTGCTGTA 
AACGTCGGGCTGAACTT 
LG/CGR-644 T Rev Rev 
GCAAATTTGGCTGCTGTTA 
ACGTCGGGCTGAACTT 
 
Table AII-2. LH/CGR variants primers for RTQ-PCR 
 
Gene  
Primer Locations 
(exons) 
Primer sequence 5'-3' 
LH/CGR-A 
(Fwd) 9 ATTTGTCAATCTCCTGGAGGC 
(Rev) 11 CACTCAGTTCACTCTCAGCA 
LH/CGR-B 
(Fwd) 8 & 10 AGGGCCGAAAACCTTACAGAA 
(Rev) 11 CACTCAGTTCACTCTCAGCA 
LH/CGR-C 
(Fwd) 9 ATTTGTCAATCTCCTGGAGGC 
(Rev) 10 & 11 CCCCATGCAAAAAGTGTTTTG 
LH/CGR-D 
(Fwd) 8 & 10 AGGGCCGAAAACCTTACAGAA 
(Rev) 10 & 11 CCCCATGCAAAAAGTGTTTTG 
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Table AII-3. Housekeeping and Decidual Gene primers for RTQ-PCR 
 
Gene  Fwd/Rev Primer sequence 5'-3' 
GAPDH 
Fwd CGGAAACGGTCGTACACTTC 
Rev CCGACTGATGGAAGGCATC 
L19 
Fwd GCGGAAGGGTACAGCCAA 
Rev GCAGCCGGCGCAAA 
PRL 
Fwd AAGCTGTAGAGATTGAGGAGCAAAC 
Rev TCAGGATGAACCTGGCTGACTA 
PROK1 
Fwd GTGCCACCCGGGCAG 
Rev AGCAAGGACAACAGGTGTGGTGC 
SOD2 
Fwd AATTGCTGCTTGTCCAAATCAG 
Rev TCCCAGCAGTGGAATAAGG 
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Table AIII-1. Patient details. 
 
  
Identifier Age 
Live 
Births 
1st 
Trimester 
Losses 
BMI Biopsy LMP 
Day of 
cycle 
Notes 
INF1 26 0 0   21/01/2013 07/01/2013 d14 
Primary Infertility, uterine filling 
defect 
INF2 30 0 0   21/01/2013 03/01/2013 d18 Primary Infertility, unexplained 
INF3 30 0 0 30 28/01/2013     Primary Infertility, unexplained 
INF4 34 0 0 24 28/01/2013 15/01/2013 d13 Primary infertility (5yrs) 
INF5 34 0 0   25/02/2013 18/02/2013 d7 Primary Infertility, unexplained 
INF6 39 0 0   25/02/2013 28/01/2013 d28 Primary Infertility, unexplained 
INF7 38 0 3   25/02/2013 25/02/2013 d0 RM 
INF8 34 0 0   04/03/2013 26/02/2013 d7 
Primary infertility, reduced 
ovarian reserve, tubal factor 
INF9 33 0 0   04/03/2013     Primary Infertility, unexplained 
INF10 37 0 0   04/03/2013 28/02/2013 d5 Primary Infertility, unexplained 
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Identifier Age 
Live 
Births 
1st 
Trimester 
Losses 
BMI Biopsy LMP 
Day of 
cycle 
Notes 
INF11 39 0 0   04/03/2013 21/02/2013 d11 Primary Infertility, unexplained 
INF12 36 0 0   08/04/2013 20/03/2013 d29 Primary Infertility, unexplained 
INF13 36 0 0   08/04/2013 Reg cycles   Male factor infertility 
INF14 31 0 0   15/04/2013 09/04/2013 d6 Infertility  
INF17 
 
0 0   22/04/2013 10/04/2013 d12 Primary Infertility, unexplained 
INF18 36 0 0   22/04/2013 
 
    
INF19 
 
0 0   22/04/2013 20/03/2013 d32 Primary Infertility, unexplained 
INF20 38 0 0   29/04/2013 12/04/2013 d17 Infertility 
INF21 
 
0 0   29/04/2013 
 
  Primary Infertility, unexplained 
INF22 37 0 0   20/05/2013 12/04/2013   Primary Infertility, unexplained 
INF23 
 
0 0   03/06/2013     Primary Infertility, unexplained 
INF24   0 0   03/06/2013     Primary Infertility, unexplained 
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Identifier Age 
Live 
Births 
1st 
Trimester 
Losses 
BMI Biopsy LMP 
Day of 
cycle 
Notes 
INF25 30 0 0   17/06/2013       
INF26 32 0 1 25 17/06/2013     Male factor infertility 
INF27 31 0 0   15/07/2013 14/06/2013 d30 Tubal factor infertility, primary 
INF28 36 0 0   22/07/2013     Primary Infertility, unexplained 
INF29 31 0 0   22/07/2013     Primary Infertility, unexplained 
NP2 37 0 0   28/08/2013     
Unknown- patient was not trying 
to get pregnanct (NP clinic) 
NP3 40 2 0   28/08/2013 10/07/2013   Fertile. Patient having Essure. 
INF44 33 0 0   21/10/2013 26/09/2013 d25 
Primary infertility. Patient had 
intermenstrual bleeding 
INF145 35 0 0 27 21/10/2013 17/10/2013 d4 Primary Infertility, unexplained 
INF49 37 0 0   04/11/2013 17/10/2013 d18 Primary Infertility, unexplained 
INF50 31 0 0 21 11/11/2013     PCOS, infertility, filling defect 
INF51 32 0 0 20 11/11/2013 12/10/2013 d31 PCOS, infertility 
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Identifier Age 
Live 
Births 
1st 
Trimester 
Losses 
BMI Biopsy LMP 
Day of 
cycle 
Notes 
INF52 25 0 0   18/11/2013     Primary infertility 
INF56 39 0 0   13/01/2014 07/01/2014 d6 Primary Infertility, filling defect 
INF57 39 0 0   20/01/2013 11/01/2014 d9 
Primary Infertility, unexplained, 
Ashermann's syndrome 
INF58 37 0 1   27/01/2013 11/01/2014 d16 Primary Infertility, unexplained 
INF59 34 0 0 30 27/01/2013 19/01/2014 d8 
 
INF73 39       07/04/2014       
INF74 39 0 0   07/04/2014 31/03/2014 d7 Primary infertility 
NP5 33 4 0   09/04/2014 03/04/2014 d6 Fertile 
INF77   0 1   14/04/2014 02/04/2014 d12 Infertile. Miscarriage at 10weeks.  
INF78   0 0   14/04/2014 24/03/2014 d21 Primary Infertility, unexplained 
INF79 37 0 0   27/08/2014     Primary Infertility, unexplained 
INF80 33 0 0   01/09/2014 11/08/2014 d21 Primary Infertility, unexplained 
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Identifier Age 
Live 
Births 
1st 
Trimester 
Losses 
BMI Biopsy LMP 
Day of 
cycle 
Notes 
INF81   0 0   01/09/2014 23/08/2014 d9   
INF90 39 0 0   22/09/2014 Reg cycles   Male factor infertility 
INF91 30 0 0   22/09/2014 05/09/2014 d17 
Primary infertility, history of 
PCOS 
INF92 28 0 0   06/10/2014     
Possible male factor infertility 
(azoospermia) 
INF93 33 0 1   06/10/2014       
INF96 38 1 0   06/10/2014     Live birth via IVF 
INF97   0 0   06/10/2014     Primary Infertility, unexplained 
INF98   0 0   13/10/2014     Primary infertility, PCOS  
INF99   0 2   13/10/2014     Primary Infertility, unexplained 
INF100   0 0   13/10/2014 04/10/2014 d9 
Primary infertility, 
endometriosis 
INF101 33 0 1 30 20/10/2014 20/09/2014 d30 
Primary Infertility, 
unexplained, 2xTOP, irregular 
cycles 
INF102 23 0 0   20/10/2014 20/09/2014 d30 Primary Infertility, unexplained 
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Identifier Age 
Live 
Births 
1st 
Trimester 
Losses 
BMI Biopsy LMP 
Day of 
cycle 
Notes 
INF103 34 0 0   27/10/2014     Male factor infertility 
INF104   0 0   27/10/2014     
Primary Infertility, unexplained, 
Ashermann's syndrome 
INF105 35 0 0   27/10/2014     Tubal factor infertility, primary 
INF106 36 0 1   27/10/2014 04/10/2014 d23 Primary Infertility, unexplained 
INF107 32 0 0   03/11/2014 09/10/2014 d24 Tubal factor infertility, primary. 
INF108   0 0   03/11/2014 01/10/2014 d33 Primary Infertility, unexplained 
INF109 20 0 1   03/11/2014     Primary Infertility, unexplained 
INF110 35 0 0   10/11/2014     
Primary Infertility, unexplained. 
Poss endometriosis 
FERT111 36 1 0   05/11/2014     Fertile patient.  
INF112 34 0 1   10/11/2014 28/10/2014 d13 Primary Infertility, unexplained 
INF113 33 0 2   10/11/2014 15/10/2014 d26 Primary Infertility, unexplained 
INF114 37 1 0   17/11/2014 07/11/2014 d10 Secondary infertility.  
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Identifier Age 
Live 
Births 
1st 
Trimester 
Losses 
BMI Biopsy LMP 
Day of 
cycle 
Notes 
INF115 35 0 2   17/11/2014 08/11/2014 d19 Primary Infertility, unexplained 
INF116 42 0 0   18/11/2014       
INF117 33 0 2   01/12/2014 19/11/2014 d13 
Infertility. One miscarriage 1st 
trimester, one at 28 weeks.  
INF118 38 1 1   01/12/2014 22/11/2014 d9 Primary Infertility, unexplained 
INF119 32 0 0   01/12/2014 20/11/2014 d11 Primary Infertility, unexplained 
INF120 35 0 0   08/12/2014 03/12/2014 d5 Tubal factor infertility, primary. 
INF121 35 0 0   08/12/2014     Primary Infertility, unexplained 
INF122 37 0 0   08/12/2014 Reg cycles   
Submotile sperm, tubal factor 
infertility. 
INF123 41 0 0   15/12/2014 20/11/2014 d25 
1XTOP @ age 18. PCO 
morphology on 1 ovary 
INF124 36 0 0   15/12/2014     Primary Infertility, unexplained 
INF125 37 0 0   05/01/2015     Primary Infertility, unexplained 
INF126 44 0 0   05/01/2015     Primary Infertility, unexplained 
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Identifier Age 
Live 
Births 
1st 
Trimester 
Losses 
BMI Biopsy LMP 
Day of 
cycle 
Notes 
INF127 34 0 0   12/01/2015 20/12/2015 d23 Primary Infertility, unexplained 
INF128 34 0 0   12/01/2015 23/12/2015 d20 poss endometriosis/PCOS 
INF129 38 0 1   12/01/2015 06/01/2015 d6 
3XIVF failure. Unexplained 
infertility. 
INF130 27 0 0   13/01/2015 
Cycle 
every 6 
weeks 
  
Intermenstrual bleeding (not 
attending infertility clinic) 
INF131 39 0 0   16/02/2015     Primary Infertility, unexplained 
INF132 34 0 0   16/02/2015     Primary Infertility, unexplained 
INF133 39 0 0   23/02/2015 13/02/2015 d10 Primary Infertility, unexplained 
INF134   0 0   23/02/2015     Primary Infertility, unexplained 
INF135 36 0 0   23/02/2015     Primary Infertility, unexplained 
FERT136 37 1 0   25/02/2015 
28-32day 
cycles 
  Fertile 
INF137   0 0   16/02/2015     Primary Infertility, unexplained 
INF138 31 0 0   16/02/2015 Reg cycles   Primary Infertility, unexplained 
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Identifier Age 
Live 
Births 
1st 
Trimester 
Losses 
BMI Biopsy LMP 
Day of 
cycle 
Notes 
INF139   0 0   09/03/2015 Reg cycles   Primary Infertility, unexplained 
INF140 34 0 0   09/03/2015 
20-40day 
cycles 
  
Primary Infertility, unexplained. 
1Xectopic pregnancy 
INF141 32 0 0   23/03/2015     
Low sperm count/uterine filling 
defect 
INF142 32 0 0   30/03/2015     Endometriosis/primary infertility.  
INF143 26 0 0   30/03/2015     1XTOP. Primary infertility. 
INF144   1 0   01/04/2015     
Fertile patient (not attending 
infertility clinic) 
INF145   3 0   01/04/2015 Reg cycles   
Fertile patient (not attending 
infertility clinic) 
INF146 36 0 2   13/04/2015     Primary Infertility, unexplained 
INF147 36 0 0   13/04/2015     
Primary Infertility (7yrs), 
unexplained 
INF148 42 0 0   20/04/2015     Primary Infertility, unexplained 
FERT150 34 2 0   29/04/2015     
Fertile patient (not attending 
infertility clinic) 
INF151 36 0 0   29/04/2015     Not attending infertility clinic 
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Identifier Age 
Live 
Births 
1st 
Trimester 
Losses 
BMI Biopsy LMP 
Day of 
cycle 
Notes 
INF152 22 0 0   27/04/2015     Male factor infertility 
INF153   0 0   27/04/2015 Reg cycles   poss PCOS 
FERT154 39 3 0   05/05/2015     
Fertile patient (not attending 
infertility clinic) 
INF155 33 0 0   18/05/2015 Reg cycles   Infertility/PCOS 
INF156 38 0 0   18/05/2015 Reg cycles     
INF157 29 0 0   01/06/2015     poss PCOS 
INF158 39 0 0   01/06/2015 Reg cycles     
INF159 36 1 0   01/06/2015     Endometriosis? 
INF160 36 0 0   08/06/2015       
INF161   1 0   08/06/2015     
Live birth via IVF. Male factor 
infertility.  
INF162 24 0 0   09/06/2015     Primary Infertility, unexplained 
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Identifier Age 
Live 
Births 
1st 
Trimester 
Losses 
BMI Biopsy LMP 
Day of 
cycle 
Notes 
INF163 42 0 0   22/06/2015     Primary Infertility, unexplained 
INF164 35 0 0   22/06/2015     Primary Infertility, unexplained 
INF165 42 0 0   22/06/2015     3xTOP 
INF167   0 0   26/06/2015     Primary Infertility, unexplained 
INF168   0 0   06/07/2015     Primary Infertility, unexplained 
INF170 30 0 1   13/07/2015     Primary Infertility, unexplained 
INF171 38 0 0   28/07/2015 07/07/2015 d21 
Patient attending IVF clinic. 
3xIVF failures 
INF172   0 0   27/07/2015 06/07/2015 d21 
Patient attending IVF clinic. 
2xIVF failures 
INF175 39 0 0   19/08/2015     Primary Infertility, unexplained 
INF176 35 0 0   09/11/2015 19/10/2015 d21 
IVF clinic. 1xIVF failure. Tubal 
factor infertility.  
INF177   0 0   11/11/2015 21/10/2015 d20 Possible male factor infertility  
14-60 32 0 0 21 26/02/2014   LH+8 none, prim tubal infert 
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Identifier Age 
Live 
Births 
1st 
Trimester 
Losses 
BMI Biopsy LMP 
Day of 
cycle 
Notes 
13-249 33 0 0   25/11/2013   LH+10 Recurrent IVF failure 
13-233 42 0 1 32 12/11/2013     x1 IVF 
14-66 32 0 1 28 03/03/2014   LH+10 RIVF 
14-61 38 0 4 24 24/02/2014   LH+7 RM 
13.-85 32 0 5   24/06/2013   D21   
14-57 40 0 5 25 27/02/2014   LH+10 RM 
14-69 28 0 6 24 03/03/2014   LH+10 RM 
14-119 38 0 8 26     LH+8 RM, X7 MISC, X1 ECTOPIC 
14-120 31 0 5 -     LH+8 RM 
14-194 42 1 6 29.9 02/06/2014   LH+7 Recurrent Miscarriage, Sec misc. 
14-195 25 0 5 28 02/06/2014   LH+8 x1 ectopic, x4 biochemical loss 
14-196 42 1 1 24 02/06/2014   LH+7 normal 
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Identifier Age 
Live 
Births 
1st 
Trimester 
Losses 
BMI Biopsy LMP 
Day of 
cycle 
Notes 
14-198       19.6 06/06/2014   LH+5 Recurrent Miscarriage 
14-201 40 1 6 36 09/06/2014   LH+10 Recurrent Miscarriage 
14-202 37 0 0 25 09/06/2014   LH+9   
14-203 44 1 3 27 09/06/2014   LH+9 Recurrent Miscarriage 
14-269 38 0 3   15/08/2014   LH+6 RIVF, RM 
14-272 35 0 5   18/08/2014   LH+7 Endometriosis, missed misc. 
14-273 28 0 2 23 18/08/2014   LH+8 haemophiliac carrier 
14-274 39 1 5   18/08/2014   LH+8   
14-275 24 0 6 30 18/08/2014   D25 No CH 
14-276 32 0 6   18/08/2014   LH+8 RM, Missed misc. 
14-277 42 1 5   18/08/2014   LH+ x1 Top, x4 misc 
14-287 41 1 1 30 01/08/2014   LH+7 Repeat, endometriosis, RIVF 
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Identifier Age 
Live 
Births 
1st 
Trimester 
Losses 
BMI Biopsy LMP 
Day of 
cycle 
Notes 
14-288 36 0 1 23 01/08/2014   LH+9 RIVF 
14-289 29 0 0 19 01/08/2014   LH+9 RIVF 
14-291 45 0 1 35 05/08/2014   Day 21 TOP 
14-295 35 0 1 24 05/08/2014   Day 20 x2 RIVF, Scratch 
14-350 32 0 1 34 31/10/2014   LH+8 RIVF, Male + tubal 
14-351 30 0 0   31/10/2014   LH+9   
14-361 30 2 7   07/11/2014   LH+10   
14-363 38 0 2 25 10/11/2014   LH+8 Endometriosis, RIVF & RM 
15-075 41 1 4 33 23/02/2015   LH+9 sec misc. / superfertile 
15-076 35 0 4 30 23/02/2015   LH+11 x2 TOP, X2 misc (sec trim) 
15-087 32 0 7 28.2 02/03/2015   LH+10 
balanced translocation, x4 misc + 
x3 IVF / PGD failure 
15-088 37 2 2   02/03/2015   LH+8   
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Identifier Age 
Live 
Births 
1st 
Trimester 
Losses 
BMI Biopsy LMP 
Day of 
cycle 
Notes 
15-089 41 1 5   02/03/2015   LH+8 superfertile 
15-090 42 0 3   02/03/2015   LH+7 RM & RIVF 
15-173   2 2   May-15   LH+10 RM 
15-175 39 0 3   May-15   LH+10   
15-176         May-15   LH+10 RIVF, scratch 
15-177 31 0 4   May-15   LH+6 RM 
15-178 35 0 8   May-15   LH+11 RM 
15-238 35 1 2 18 05/06/2015   LH+7 IVF failure 
15-255 40 0 1 27 12/06/2015   LH+8 TOP, RIVF 
15-257 31       12/06/2015       
15-258 28 0 2 23 12/06/2015   LH+8 'normal' 
15-345 40 1 3 29 27/07/2015   LH+8 mid-trim loss 
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Identifier Age 
Live 
Births 
1st 
Trimester 
Losses 
BMI Biopsy LMP 
Day of 
cycle 
Notes 
15-346 29 0 3 26 27/07/2015   LH+8 RM, 2 misc, 1 ectopic 
15-343 37 0 4 22 27/07/2015   LH+6   
15-322 39 1 6 26 17/07/2015   LH+7 RM 
15-290 36 0 6 30 29/06/2015   LH+10 RM 
15-488 35 0 0 26 18/12/2015     d22, type 1 diabetes, scratch 
15-490 43 0 5 24 18/12/2015     misc ? Donor oocyte 
15-596 30 0 2 22 22/12/2015   LH+10 3x IVF failure, male factor 
16-031 38 1 3   22/01/2016   LH+9 RM 
 
